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Abstract
Gaps between treatment guidelines and medical decisions persist despite interventions
with physicians, which are mostly atheoretical. The purpose of this retrospective crosssectional study was to compare atheoretical and theory-based logistic regression models
of a binary outcome: potentially unsafe prescribing of attention-deficit hyperactivity
disorder (ADHD) medications to adults. Social cognitive theory and self-determination
theory provided the framework for the study. Predictors were framed as social cognitive
theoretical constructs: knowledge (e.g., physician specialty) and environmental influence
(e.g., interventions). Atheoretical hypotheses were based on legislation mandating
meaningful use of electronic health records and computerized decision support (CDS).
Theory-based hypotheses were derived from literature on cognition in medicine and on
the controlled motivation construct in self-determination theory. Research questions
addressed associations of CDS and meaningful use with the outcome and fit of competing
models. The sample included office-based physician visits made by patients aged > 17
years with ADHD (n = 810) or potentially unsafe medical conditions (n = 9,101),
recorded in a U.S. database in 2014–2016. Findings for the atheoretical model were
reduced odds of the outcome with CDS, and nonsignificant improvement in model fit
using theory. Supporting the self-determination theory-based hypothesis, odds were
increased with meaningful use. This study adds to research suggesting autonomy as a
core issue in medicine. Positive social change may result from psychology-based
strategies to empower physicians through participation in developing clinically relevant
information systems.
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Chapter 1: Introduction to the Study
Evidence-based medicine, broadly defined as the consideration of findings from
high-quality research in medical decision-making (Sackett & Rosenberg, 1995), has
produced life-saving improvements in medical treatment protocols (Djulbegovic &
Guyatt, 2017); is widely supported in concept by physicians and medical associations
(Chan et al., 2017; Institute of Medicine [IOM], 2011); and is incorporated in the
curricula of most U.S. medical schools (Blanco, Capello, Dorsch, Perry, & Zanetti,
2014). However, inconsistencies between evidence-based treatment guidelines and
decisions made in clinical practice have been documented for more than two decades
(Cabana et al., 1999; R. Lau et al., 2016). This “evidence to practice gap” has persisted
despite many initiatives intended to improve the medical decision-making process (Baker
et al., 2015; Jäger et al., 2016; R. Lau et al., 2016, para. 1).
To address this gap, health policy analysts advanced the idea that providing
physicians with automated guidance during their encounters with patients would increase
adherence to evidence-based practice, thereby improving quality of care and patient
safety (Bates & Gawande, 2003; Bates et al., 2003; IOM, 2000, 2001). Meaningful use
provisions of the Health Information Technology for Economic and Clinical Health
(HITECH) Act of 2009 codified this concept in federal law (Blumenthal & Tavenner,
2010), providing a system of financial incentives and penalties to encourage use of
computerized decision support (CDS) and electronic health record (E-HR) technology in
medical decision-making (U.S. Centers for Disease Control and Prevention [CDC],
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2019a), including the prescribing of medications (U.S. Centers for Medicare & Medicaid
Services [CMS], 2012a).
As intended, HITECH Act implementation was soon followed by expanded use of
electronic technologies in physician offices nationwide (Hsiao, Hing, & Ashman, 2014).
However, the few evaluations of meaningful use performed prior to this study indicated
negligible effects on quality of care for a variety of disease states and samples (Afonso,
Alfonso, & Morgan, 2017; Grinspan et al., 2017; Jung et al., 2017; Kern, Edwards,
Kaushal, & HITEC Investigators, 2015; Levine et al., 2017; Samal, Wright, Healey,
Linder, & Bates, 2014; Unruh et al., 2017). Additionally, the expanded use of CDS and
E-HRs in medical practice has been associated with new safety problems (Brown et al.,
2017; Carling, Kirkehei, Dalsbø, & Paulsen, 2013; Howe, Adams, Hettinger, & Ratwani,
2018) and increased occupational dissatisfaction among physicians (Colligan, Sinsky,
Goeders, Schmidt-Bowman, & Tutty, 2016; Friedberg et al., 2013; Shanafelt et al., 2016).
These results may have occurred because psychological theory and evidence,
particularly from human factors study of human-device-environment interaction, were
not considered in designing CDS or E-HR systems (Ratwani et al., 2016; Savage,
Fairbanks, & Ratwani, 2017). More broadly, the core strategy underlying the HITECH
Act, paying physicians to meet externally determined metrics, may be inconsistent with
psychological theory about the effects of extrinsic financial incentives on human
motivation (Himmelstein, Ariely, & Woolhandler, 2014; Kao, 2015). Consistent with
these views, one early proponent of electronic technologies in health care recently noted
that the exploratory application of behavioral science to CDS began in 2015 or 2016 (Cho
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& Bates, 2018). Therefore, meaningful use and CDS may be described as atheoretical,
meaning they were developed without regard to psychological theory (Prestwich,
Kenworthy, & Conner, 2018). This atheoretical approach is typical of health-system
interventions on physician behavior (Jäger et al., 2016; R. Lau et al., 2016; L. Liang et
al., 2017).
Whether theory-based approaches to changing medical decision-making might
produce better outcomes than atheoretical approaches is an important but understudied
question. No comparisons of theory-based and atheoretical interventions to promote
evidence-based medical practice were identified in the literature review for the current
study. To address this gap in the literature, I compared two approaches—theory based
and atheoretical—to predicting a non-evidence-based medical decision that negatively
affects U.S. population health (see Compton, Han, Blanco, Johnson, & Jones, 2018; Seth,
Scholl, Rudd, & Bacon, 2018): the prescribing of attention-deficit hyperactivity disorder
(ADHD) medications to adult patients for whom they may be unsafe (see Fairman, Davis,
Peckham, & Sclar, 2018). Results may be used to inform health psychology-based
interventions to improve medical decision-making, including but not limited to those for
ADHD medications, potentially facilitating positive social change.
In this chapter, I introduce the need for theory-based approaches, explain the
safety risks associated with some ADHD-medication prescribing decisions, present
difficulties in evidence-based practice promotion and potentially unsafe ADHDmedication prescribing as research problems, and describe the purpose of this study. In
the remainder of the chapter, I provide an overview of the nature of the study, including
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quantitative methods and definitions of key variables, and present research questions,
definitions and assumptions, study scope, and study limitations.
Background
Theory-based assessments of physician decision-making are uncommon (R. Lau
et al., 2016), identified in only two of 178 surveys on barriers to guideline-based medical
practice in one systematic 10-year review (Willson, Vernooij, & Gagliardi, 2017), and
totals of six studies of clinical practice behaviors and 29 studies of behavioral intentions
in a 40-year systematic review of cognitive theory-based research in health care (Godin,
Bélanger-Gravel, Eccles, & Grimshaw, 2008). In a 10-year scoping review of guidelineimplementation interventions described as theory based, only 42 studies were found, of
which only 10 included a theoretical basis for design or evaluation (L. Liang et al., 2017).
Moreover, most guideline-implementation studies that were purportedly theory based did
not include a map (link) of specific intervention components to any theoretical construct
(L. Liang et al., 2017), a common problem in studies of physician decision-making (R.
Lau et al., 2016) and other health behavior-change initiatives (Prestwich et al., 2014;
Prestwich, Webb, & Conner, 2015). Related to this problem is a lack of theory-based
health care research on objective behavioral measures (Conner & Norman, 2017;
Prestwich et al., 2015) or on broad policy interventions with potential population health
impact (Conner & Norman, 2017; Prestwich et al., 2018).
These deficits represent inconsistencies between currently available health
psychology research and American Psychological Association (APA, 2014) guidelines
for the development of preventive interventions. These guidelines recommend a basis in

5
theory, empirical support, consideration of system-wide factors, and advocacy for
population-health promotion. Summarizing these needs, theory-based research including
objective behavioral measures is needed to study health-related behaviors, including nonevidence-based medical decisions, with potential population health effects (APA, 2014;
Conner & Norman, 2017; L. Liang et al., 2017).
One such non-evidence-based medical decision recently identified using an
objective behavioral measure (Fairman et al., 2018) is ADHD-medication prescribing that
is potentially unsafe according to evidence-based federal guidelines (U.S. Food and Drug
Administration [FDA], 2002, 2007a). Specifically, patients with substance use disorder
(SUD) who receive a stimulant medication may be put at risk of increased misuse
(Compton et al., 2018; FDA, 2007a; McCabe et al., 2019) or of an overdose that leads to
emergency care (L. Y. Chen et al., 2016; Fulde & Forster, 2015) or death (Seth et al.,
2018). Additionally, those with cardiovascular disease (CVD) who receive either a
stimulant or the most commonly used nonstimulant alternative, atomoxetine (Fairman,
Peckham, & Sclar, 2017), may be put at risk of a cardiac event, such as a myocardial
infarction (heart attack) or cerebrovascular event (stroke; FDA, 2002, 2007a). However,
in a national sample of adults who were newly prescribed medications for ADHD,
Fairman et al. (2018) found that 11–19% of stimulant-treated patients had SUD, and 16%
of patients aged 55–64 years who were prescribed stimulants or atomoxetine had CVD.
In accordance with APA (2014) recommendations, a theory-based assessment of this
prescribing problem, which represents an important population health issue, was needed
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to address the lack of research on psychology-informed promotion of evidence-based
prescribing.
Problem Statement
Two problems were addressed in this study. Each of the two social problems was
associated with a research problem. These research problems represented gaps between
APA (2014) guidance and available published information.
The first social problem was persistent failure to achieve the goal of promoting
evidence-based medical practice (Baker et al., 2015; R. Lau et al., 2016). A related
research problem was the paucity of studies in which researchers applied psychological
theory to medical decision-making (Godin et al., 2008; Jäger et al., 2016; R. Lau et al.,
2016; L. Liang et al., 2017). By mapping potential predictors of medical decisions,
including CDS and meaningful use interventions, to theoretical constructs, this research
comported with APA (2014) recommendations for use of theory and evidence.
The second social problem was the prescribing of ADHD medications to adults
for whom they may be unsafe. As a recently identified issue in the literature on evidencebased medicine (Fairman et al., 2018), potentially unsafe ADHD-medication prescribing
was also a research problem because known predictors were limited to a few patient
characteristics, such as age or medical conditions (Compton et al., 2018; Fairman et al.,
2018; McCabe et al., 2019). Increasing rates of diagnosis and medication treatment for
ADHD among U.S. adults (Fairman et al., 2017; Olfson, Blanco, Wang, & Greenhill,
2013) have been accompanied by growth in rates of stimulant misuse, overdose, and
death (Seth et al., 2018; U.S. Substance Abuse and Mental Health Services
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Administration, 2013). Through use of a national sample (CDC, 2015a) to study this
problem, this research comported with APA (2014) recommendations for system-wide
assessments to promote population health.
Purpose of Study
The purpose of this quantitative study was to assess the relative strengths of
atheoretical and theory-based approaches to promotion of evidence-based medicine by
comparing alternative logistic regression models of an objective behavioral measure of
potentially unsafe ADHD-medication prescribing: one model based on the rationales
underlying two atheoretical interventions (CDS and meaningful use) and the other based
on theory-derived predictors. To provide U.S. population-level findings, I chose a sample
that was nationally representative (see CDC, 2015a). To provide theory-based research, I
mapped hypotheses for predictors of interest, including CDS and meaningful use, to
theoretical constructs based on qualitative and quantitative evidence about the
psychology of medical practice, and about cognitive and emotional response to CDS and
E-HRs (see Holden, 2011; Shanafelt et al., 2016; Slight et al., 2016). Because the term
atheoretical refers to the way that interventions are developed, not to the way that they
are studied (Prestwich et al., 2018), both atheoretical interventions and theory-based
predictors were mapped to theoretical constructs in this research.
Theoretical Framework
Prescribing is a cognitive activity in which physicians weigh the benefits against
the risks of a given medication based on clinical situation, medical knowledge, and
influences present in the medical practice environment (Djulbegovic & Elqayam, 2017).
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The interventions examined in this study included CDS, which was intended to improve
the knowledge available to physicians in the decision-making process (see Bates et al.,
2003), and meaningful use, which was intended to motivate physicians to use electronic
technology (see Buntin, Jain, & Blumenthal, 2010; Heisey-Grove & Patel, 2014). To
frame these cognitive and environmental influences in competing statistical models for
this study, I chose two theories: social cognitive theory (Bandura, 1989), which served as
the general theoretical framework, and self-determination theory (Deci & Ryan, 2008a),
which informed hypotheses about incentives in the practice environment, including
meaningful use. These theories are described briefly here and in more detail in Chapter 2.
Social Cognitive Theory
Social cognitive theory depicts decision-making as a function of cognitive
processes performed by human actors who actively and reciprocally engage with the
environments in which they operate, basing intentions and behaviors on forethought and
self-regulation, and influenced by knowledge, social norms, and environmental
conditions (Bandura, 1989, 2001; Kelder, Hoelscher, & Perry, 2015). In addition to its
appropriateness to describe prescribing as a cognitive activity influenced by
environmental factors (Djulbegovic & Elqayam, 2017), the theory facilitates
understanding of the transmission of occupational norms in medical training. The
professional values inculcated in medical education, which are reflected in medical
practice (Colligan et al., 2016), may be described in the theoretical framework as norms
developed through training and observational learning (Bandura, 1999) that influence
self-regulated cognition and behaviors in occupational settings (Bandura, 2001). In
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medicine, these norms include a commitment to meeting patients’ needs (Colligan et al.,
2016; Cooke, Irby, Sullivan, & Ludmerer, 2006) and a personal identity as a biomedical
expert who is trained for autonomous, complex decision-making (Accreditation Council
for Graduate Medical Education [ACGME], 2019; Berkhout, Helmich, Teunissen, van
der Vleutin, & Jaarsma, 2018). Additionally, the theoretical construct of emergent
interactive agency (Bandura, 1989), referring to mutual human-environmental influence,
facilitates understanding of physicians’ adaptations to the introduction of CDS and E-HR
systems in the practice environment, sometimes with responses not intended by system
developers (Nanji et al., 2014; Slight et al., 2016; Wright et al., 2018).
Knowledge constructs, including characteristics of the patient, such as diagnoses,
and of the prescriber, such as specialty, were common to the theory-based and
atheoretical models. The environmental-influence constructs differed. Theory-based
hypotheses for the use of CDS in the practice environment were derived from research
evidence on cognition in medical practice. Hypotheses for the remaining environmentalinfluence predictors were derived from self-determination theory (see Deci & Ryan,
2008a).
Self-Determination Theory
Self-determination theory is a framework for understanding the ways in which
types of motivating factors affect task performance and psychological well-being (Deci &
Ryan, 2008a). According to the theory, the more autonomous (i.e., internal to self) a
motivating factor is for a given task, the more an individual will persist with the task,
execute it well, and derive psychological satisfaction from it. Autonomous motivation
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results, in varying degrees, either from intrinsic enjoyment of the task, which is fully
autonomous, or from extrinsic rewards tied to the performance of tasks that a person
would have valued regardless of reward, which is partially autonomous (Deci & Ryan,
2008b; Prestwich et al., 2018). In contrast, incentives linked to tasks that an individual
does not value are more likely to be perceived as external to self, leading to a sense of
controlled motivation and to diminished task persistence and performance (Deci & Ryan,
2008a). Environmental incentives mapped to these two constructs of self-determination
theory, and hypotheses for these incentives, were based on literature describing
professional values in medicine. These incentives included meaningful use in both the
atheoretical and theory-based models (see Emani et al., 2017; Shanafelt et al., 2016;
Weeks, Keeney, Evans, Moore, & Conrad, 2015) and additional incentives, patientderived revenue, and nature of professional relationship with the patient (see Colligan et
al., 2016; Friedberg et al., 2013; Tak, Curlin, & Yoon, 2017) in the theory-based model
only.
Nature of Study
This quantitative study was a retrospective and cross-sectional analysis of a
sample of U.S. office-based physician visits recorded in the publicly available National
Ambulatory Medical Care Survey (NAMCS) archival data set (CDC, 2015a, 2019b). The
NAMCS, which is based on a probability, cluster-randomized, stratified, multistage
sampling design (CDC, 2015a), is conducted annually by the National Center for Health
Statistics (NCHS) and represents services provided by U.S. office-based physicians,
excluding those employed in federal facilities (e.g., Indian Health Service, Department of
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Veterans Affairs [VA]) or those who do not provide direct patient care (e.g., radiologists,
pathologists; CDC, 2019b). Weights provided in the data set are used to adjust for the
sampling design and for nonresponse, producing nationally representative estimates.
NAMCS data are widely used in research on U.S. health care (CDC, 2019c). During the
time period for this study, 2014–2016 NAMCS data were collected for a total of 87,207
visits across all ages and diagnoses (see CDC, 2017, 2018, 2019b).
NAMCS procedures and variables are discussed in detail in Chapter 3. Data for
sampled physicians and visits are collected by U.S. Bureau of the Census representatives
from medical records using an automated, laptop-based tool and standard definitions
(CDC, 2019b). Data relevant to the current study included patient characteristics (e.g.,
diagnoses, demographics), prescribed medications and therapies, characteristics of the
office (e.g., CDS use, meaningful use status) and provider (e.g., specialty, revenue
sources), and nature of physician-patient relationship (e.g., whether physician is the
primary care provider).
Outcome (Dependent) Variable
The study outcome (dependent variable), potentially unsafe prescribing of an
ADHD medication, was measured as a binomial. Two clinical scenarios were tested. The
first scenario (A) represented patients diagnosed with ADHD and prescribed any
treatment: a medication, psychotherapy, or both. The binomial outcome in Scenario A
was a potentially unsafe medication versus an alternative treatment, including either a
safer medication or psychotherapy. The second scenario (B) represented patients who
have a medical condition, either CVD or SUD, that would make some ADHD
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medications potentially unsafe. The binomial outcome in Scenario B was a potentially
unsafe prescribed medication versus no potentially unsafe prescription. Only Scenario A
was restricted to patients with an ADHD diagnosis, for reasons explained in the
descriptions of study assumptions and definitions derived from federal guidance on
medication use (see FDA, 2018) and misuse (see Compton et al., 2018). The binomial
outcomes, described in Chapter 2 and operationalized in Chapter 3, were based on
treatment guidelines current during the study period (see Bolea-Alamañac et al., 2014;
Post & Kurlansik, 2012) and on federal prescribing information (see FDA 2002, 2007a).
Predictor (Independent) Variables
In both scenarios, predictor (independent) variables were mapped to constructs
from each of the two theoretical frameworks. Knowledge construct predictors, reflecting
both expertise and information needed to perform a behavior (see Kelder et al., 2015),
were included and hypothesized to act in the same way in both the atheoretical and
theory-based models because they were exogenous (i.e., not affected by the
environmental variables of interest during the visit; see Pedhazur, 1982). These variables
included characteristics of the patient, including demographics (see Fairman et al., 2017;
Grinspan et al., 2017; McCabe et al., 2019; Rigg & Monnat, 2015), medical and
psychiatric comorbidities (see Q. Chen et al., 2018; D. D. Jeffery, May, Luckey, Balison,
& Klette, 2014; Mao & Findling, 2014; Rigg & Monnat, 2015), and whether the patient
had a medical condition associated with a black-box status, which in federal guidance
indicates the highest risk level for a medication (see FDA, 2012). Physician
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characteristics included specialty and urban versus rural location (see Leslie et al., 2012;
Rigg & Monnat, 2015).
Environmental construct predictors differed in the atheoretical and theory-based
models. Both models included CDS and meaningful use, with competing hypotheses.
Additional theory-based predictors were patient-derived revenue and nature of
professional relationship with the patient. Hypotheses for these predictors are described
below and in more detail in Chapter 3.
Hypotheses for Environmental Predictors
Hypotheses for CDS and meaningful use in the atheoretical model were based on
the rationales described by their proponents. These included provision of easily
accessible, evidence-based knowledge (see Bates et al., 2003), incentives to motivate use
of that knowledge (see Buntin et al., 2010; Heisey-Grove & Patel, 2014), and prevention
of unsafe prescriptions (see Bates & Gawande, 2003), especially those that are highest
severity as indicated by black-box warning status (FDA, 2012). Hypothesized
associations of CDS with prescribing behavior in the theory-based model were based on
the following: (a) literature on cognitive barriers to evidence-based medical practice (see
Arts, Voncken, Medlock, Abu-Hanna, & van Weert, 2016; Baatiema et al., 2017; Chan et
al., 2017; F. Fischer, Lange, Klose, Greiner, & Kraemer, 2016), (b) a comparison of the
cognitive norms for which physicians are trained (see Berkhout et al., 2018; Cooke et al.,
2006) with the cognitive demands of CDS and E-HRs (see Ratwani et al., 2016; Ratwani,
Reider, & Singh, 2019; Stead, Searle, Fessler, Smith, & Shortliffe, 2011), and (c)
evidence about CDS and E-HRs that was available when meaningful use policies were
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developed (see Linder, Ma, Bates, Middleton, & Stafford, 2007; Romano & Stafford,
2011).
Hypothesized associations of environmental incentives with prescribing behavior
in the theory-based model were based on self-determination theory (see Deci & Ryan,
2008a). Meaningful use incentives were hypothesized as a controlled motivator
associated with mandated use of a technology that is not valued (see Emani et al., 2017;
Shanafelt et al., 2016; Weeks et al., 2015). Patient-derived revenue and nature of
professional relationship with the patient were hypothesized as autonomous motivators
associated with the valued outcome of maintaining patient relationships (see Anderson,
Stowasser, Freeman, & Scott, 2014; Colligan et al., 2016; Friedberg et al., 2013; Sinsky
et al., 2013; Tak et al., 2017), compared with other sources of revenue, such as salary.
Key to the study hypotheses in the theory-based model was an understanding of positive
task performance as the physician is trained to define it: maintaining the therapeutic
relationship with, and meeting the needs of, the patient (see Cooke et al., 2006). As
discussed in more detail in Chapter 2, the physician’s definition of positive task
performance for ADHD-medication prescribing may differ from that of evidence-based
guidelines or of the FDA.
Statistical Analyses
Logistic regression analysis of office visits was chosen as the analytic approach to
facilitate statistically controlled, quantitative assessments of the theoretical constructs and
comparisons of the theory-based and atheoretical models using standard measures of
model quality: whether odds ratios were in the predicted direction (see Warner, 2013);
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the concordance or “c” statistic, a measure of predictive accuracy (see Austin &
Steyerberg, 2012); and model fit (see Pampel, 2000). Differences in model fit, comparing
the atheoretical and theoretical models, were tested for statistical significance using the
standard χ2 difference test based on change in –2 log-likelihood (–2LL), accounting for
between-model differences in degrees of freedom (see Pampel, 2000). In accordance with
NCHS guidance (CDC, 2019b), all analyses were performed using the IBM SPSS
Complex Samples module (V25.0), which adjusts for the design effect (i.e., homogeneity
of variance) associated with the multistage sampling process (see Groves et al., 2009).
Because of the multistage sampling process, assessment of sample size adequacy was
made based on NCHS guidance for post hoc analyses of statistical reliability (see CDC,
2019b; Parker et al., 2017), which is described in Chapter 3.
Definitions
The following definitions were used in the development of the rationale, methods,
and research questions for this study:
ADHD medication: An ADHD medication is a product approved by the FDA to
treat ADHD. The definition applies regardless of whether the treated patient has been
diagnosed with ADHD because there is no prohibition in the United States against
prescribing an approved medication for an unapproved purpose, known as off-label use
(FDA, 2018). FDA prescribing guidelines do not describe off-label use of ADHD
medications, such as for cognitive enhancement (Compton et al., 2018), as potentially
unsafe (Novartis, 2019).
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Adult: According to the American Psychiatric Association (2013), diagnostic
criteria for adult ADHD apply to patients who are aged 17 years or older.
Atheoretical intervention: An intervention on health-related behavior or outcomes
is considered atheoretical when it is developed “without reference to, or use of, theory”
(Prestwich et al., 2018, p. 95).
Behavior-change technique: In health care, a behavior-change technique is a
method used to attempt to influence the health-related behaviors of individuals or groups,
sometimes through manipulation of environmental features to change motivating factors
or other influences on behavior (Prestwich et al., 2018).
Clinical or computerized decision support system: A clinical or computerized
decision support (CDS) system is an electronic device or interface that provides
informational support and guidance to clinicians at the point of care, as they make
medical decisions or order treatments, including medications (Korb-Savoldelli, Boussadi,
Durieux, & Sabatier, 2018).
Computerized prescription order entry: Computerized prescription order entry,
also known as e-prescribing, is the use of an electronic system or device to generate a
prescription, which is transmitted to the entity responsible for executing the order, such
as a pharmacy that dispenses medication (Korb-Savoldelli et al., 2018).
Evidence-based medicine: Although the concept of evidence-based medicine has
evolved over an approximately 50-year period (Djulbegovic & Guyatt, 2017), the
currently accepted definition (Blanco et al., 2014) is “the conscientious, explicit, and
judicious use of current best evidence in making decisions about the care of individual
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patients” based on the integration of clinical observation and expertise with high-quality
research evidence (Sackett, Rosenberg, Gray, Haynes, & Richardson, 1996, p. 71).
Incentives: Rewards to encourage certain behaviors and discourage alternatives
are commonly used in behavior-change techniques (Prestwich et al., 2018). In the
HITECH Act of 2009, which was intended to encourage use of electronic technologies in
medical decision-making, incentives included payment increases for expanded use of,
and payment decreases for failure to use, these technologies (Kibbe, 2010).
Intention-to-treat: In this approach to assessment of the effects of an intervention,
data are analyzed based on the treatment to which an individual is assigned instead of the
treatment received (Prestwich et al., 2018). This approach is distinguished from per
protocol analysis, which is limited to those who receive or complete a course of treatment
(Ranganathan, Pramesh, & Aggarwal, 2016).
Intervention mapping: In the development of behavior-change interventions that
are both theory based and evidence based, an intervention mapping approach links
constructs from psychological theory to problems, strategies, or interventions, relying on
available research evidence (Prestwich et al., 2018).
Medication-relevant CDS: Medication-relevant CDS, as operationalized in this
study, includes use of computerized prescription order entry and warnings of drug safety
issues (see CDC, 2019b).
Misuse: Misuse of a prescribed medication is use other than that directed by a
physician (Compton et al., 2018). By definition, off-label use as prescribed is not misuse.
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Patient-derived revenue: As operationalized in this study, this term refers to
receipt of income based on patient volume, such as from practice ownership, or
satisfaction, such as from patient satisfaction surveys (CDC, 2019b).
Potentially unsafe prescribing: This term is used by health care organizations to
indicate a medication treatment recommendation that has an elevated potential to result in
harm or death (M. M. Jeffery, 2018; Williamson, 2018). For patients with CVD or SUD
who are treated with some ADHD medications, potential safety risks occur because of
neurochemical side effects (Faraone, 2018; Nissen, 2006).
Theory-based intervention: In contrast to an atheoretical intervention on health
behavior, which is developed without consideration of psychological theory, a theorybased intervention relies on one or more psychological theories to identify behavioral
determinants, target populations, or behavior-change techniques (Prestwich et al., 2018).
Usability: The usability of a technological device is defined as the degree to
which people using the device in a particular environment or context are able to achieve
their goals for use (Ratwani et al., 2016).
Research Questions
The first two research questions (RQs) addressed the associations of CDS and
meaningful use, respectively, with the outcome measure. RQ3 addressed the comparison
of the theory-based versus atheoretical models overall.
RQ1: What is the quantitative association of medication-related CDS in the
practice environment with potentially unsafe prescribing of ADHD medications,
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measured as a binomial, in a logistic regression model that accounts for knowledge
construct variables?
Ho1: (theory-based). Medication-related CDS is not significantly associated with
potentially unsafe prescribing of ADHD medications.
Ha1: (atheoretical). Medication-related CDS is associated with decreased odds of
potentially unsafe prescribing of ADHD medications, particularly for patients who have a
medical condition with a black-box warning.
RQ2: What is the quantitative association of meaningful use in the practice
environment with potentially unsafe prescribing of ADHD medications, measured as a
binomial, in a logistic regression model that accounts for knowledge construct variables?
Ho2: (atheoretical). Meaningful use is associated with decreased odds of
potentially unsafe prescribing of ADHD medications.
Ha2: (theory-based). Meaningful use is associated with increased odds of
potentially unsafe prescribing of ADHD medications.
RQ3: Which model—that based on atheoretical interventions or that based on
theory-derived predictors—better explains the binomial measure of potentially unsafe
ADHD-medication prescribing, where better explanation is defined as coefficients in the
expected direction, predictive accuracy measured with the c-statistic, and model fit
measured with the –2LL statistic?
Ho3: The atheoretical model better explains potentially unsafe prescribing of
ADHD medications.
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Ha3: The theory-based model better explains potentially unsafe prescribing of
ADHD medications.
Assumptions
A key assumption of this study was that the prescribing of a medication to a
patient for whom it is potentially unsafe, according to federal guidelines (see FDA, 2002,
2007a), is suboptimal. This assumption does not indicate that all such prescriptions are
unsafe, as the term potentially unsafe confers increased but not absolute risk. The
assumption, which was necessary because not every evidence-based suggestion is
appropriate for every patient (see Sackett et al., 1996), rests on the increased risk
associated with some medications and on the availability of safer alternatives (see BoleaAlamañac et al., 2014; Post & Kurlansik, 2012).
A second assumption was that intention-to-treat analysis is appropriate to measure
the outcomes of CDS as an intervention that represents an expenditure of monetary and
human resources. Consistent with an intention-to-treat approach, which has been used to
study the association of CDS with quality of care in physician office visits (see M. J.
Miller, Burns, Kapusnik-Uner, Carreno, & Matuszewski, 2017), no attempt was made to
determine whether the CDS guidance was actually delivered to the physician or whether
the physician read it (see Nanji et al., 2014). Instead, the intervention was defined as the
presence of a CDS system with a feature intended to warn the physician of drug safety
issues. This assumption was necessary because it is not feasible to measure every
interaction between a physician and a medical device.
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Finally, I assumed that the medical risks associated with ADHD-medication use
in patients with CVD and SUD occur regardless of whether the patient has ADHD. This
assumption was reasonable because these risks are caused by neurochemical side effects,
specifically the transmission of dopamine to a brain region associated with addiction and
norepinephrine-triggered increases in heart rate and blood pressure (see Faraone, 2018;
Nissen, 2006), which would logically be expected to occur regardless of the reason for
medication usage. Moreover, the literature review for this study indicated no increase or
decrease in ADHD-medication risk associated with off-label prescribing. This
assumption was necessary because of increased prescribing of ADHD medications to
adults who do not have a formal diagnosis of ADHD (see Olfson et al., 2014; Safer,
2016).
Delimitations and Scope
The scope of this study was national, representing adults who visited a U.S.
office-based practice and received direct patient care from a medical doctor or doctor of
osteopathy (see CDC, 2015a). For Scenario A, the scope included adults diagnosed with
ADHD. For Scenario B, the scope included adults at risk of potentially unsafe prescribing
because they had CVD or SUD (see CDC, 2002, 2007a). The scope of the outcome
(dependent) variable was prescribing decisions made by physicians in those visits, not
choices made by patients after they left the office (e.g., to overuse medication, give it to a
third party, or obtain it elsewhere; see Compton et al., 2018).
The scope of the knowledge-based predictor (independent) variables in this study
represented information that was known to the physician and included in the medical
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record. The scope did not represent information not available to the physician during the
visit, or not recorded for another reason. Moreover, the study outcome represented
potentially unsafe prescribing, not all types of potentially inappropriate prescribing. No
attempt was made to determine whether a patient’s symptoms warranted a prescription,
which is a medical judgment that may rely on unobservable information. Additionally,
because the potential benefits of E-HRs for patient care are widely accepted despite
challenges that physicians face in using them (Schiff, Hickman, Volk, Bates, & Wright,
2016), no attempt was made to address the hypothetical question of whether E-HRs
represent an improvement over paper record systems.
Finally, I assessed outcomes associated with interventions and environmental
features currently present in the medical practice environment, not theory-based
interventions that were suggested from the literature review but that have not yet been
designed or implemented. As described in Chapter 5, findings of the literature review,
coupled with results of the current study, suggested a need for additional theory-based
assessments of practice-ownership and physician-employment structures, which were not
directly studied in this research. Because the topic of using psychology-based strategies
to promote evidence-based practice is relatively unexplored (Godin et al., 2008; R. Lau et
al., 2016; L. Liang et al., 2017), the comparison of theory-based with atheoretical
approaches in this study should be considered a first step.
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Study Limitations
Internal Validity
One important potential limitation of this study, similar to that of any quantitative
research with an objective behavioral outcome measure, was a lack of direct information
about psychological mediators, such as physician knowledge, cognition, or emotion, that
a researcher might measure in a qualitative study or in a survey in which physician
opinion constitutes the outcome. Similarly, results represent intention-to-treat estimated
associations of interventions with the outcomes. Whether physicians received or read
CDS-delivered guidance is unknown. Although this approach may have resulted in some
loss of internal validity in characterizing the reasons for a potentially unsafe prescription,
the approach enhanced external validity by making it feasible to study nationally
representative data (see CDC, 2015a). In this respect, the methods of this study improved
on those of physician surveys that included self-reported measures, which may be
unreliable or biased (see Conner & Norman, 2017); that had low response rates without
statistical adjustments for nonresponse (see Leslie et al., 2012; Shanafelt et al., 2016;
Weeks et al., 2015); or that were based on convenience samples (see Goodman, Surman,
Scherer, Salinas, & Brown, 2012).
An additional possibility was confounding by unmeasured factors, such as
symptom severity, patient demands, or features of the practice office not included in
study measures (see Warner, 2013). Providers who chose to participate in the meaningful
use program may have systematically differed from nonparticipants (Grinspan et al.,
2017), particularly on attitudinal factors such as agreement with guidelines (Cloutier et
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al., 2018; F. Fischer et al., 2016) or with their application to individual patient
circumstances (Arts et al., 2016). This bias could have affected the associations of CDS
and meaningful use with the outcome in this study. Although the measures of model
quality used in this research provided information about the degree to which results were
affected by this problem, the absence of confounding cannot be guaranteed with this or
any nonexperimental design (see Warner, 2013).
An additional potential limitation on internal validity was the possibility of
misclassification of exposure because of omissions of relevant data from the medical
record (see Madden, Oakoma, Rusinak, Lu, & Soumerai, 2016). Examples include the
provision of substance abuse counseling without a recorded diagnosis of SUD and the
lack of a code for psychotherapy in visits made to mental health professionals. Although
data transformations and sensitivity analyses were used to address these situations, the
possibility remains that errors or omissions affected study results.
Potential limitations also arose because of small sample sizes for subgroups,
particularly in Scenario A, which included only patients with ADHD. This situation was
assessed using standard NCHS tests for statistical reliability estimation (see CDC, 2019b;
Parker et al., 2017). Descriptions of quantitative findings include statistical precision of
all estimates based on results of these tests.
External Validity
One potential limitation on external validity was caused by an NCHS decision to
allow participants in the 2016 NAMCS to submit E-HRs in lieu of on-site data collection,
in partial fulfilment of two federal incentive payment systems, including meaningful use
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(CDC, 2019b). For reasons not fully described by the NCHS, these data, which
“presented many processing challenges,” were not included in the 2016 data set (CDC,
2019b, p. 2). Because the technological capabilities or practice patterns of physicians
who chose E-HR data collection may have systematically differed from those of other
participants, I performed sensitivity analyses excluding 2016. Although results suggested
that findings were robust to this issue, the possibility remains that findings do not
generalize to providers with more sophisticated E-HR systems, or to those who opted
against on-site data collection for some other reason. Findings also do not generalize to
surgical visits, which were excluded from this research, or to patients who were sent
directly from the physician office to emergency care.
Additionally, it is possible that NAMCS participants systematically differed from
nonparticipants despite previous research evidence of minimal nonresponse bias in
physician surveys with low response rates (see McFarlane, Olmsted, Murphy, & Hill,
2007; Willis, Smith, & Lee, 2013; Ziegenfuss et al., 2012). During the study period, the
NAMCS participation rate, defined as the percentage of sampled physicians who
contributed at least one patient record, ranged from 29.5–39.3% (CDC, 2017, 2018,
2019b). An extensive validation study, conducted by the NCHS and described in Chapter
3, suggested minimal bias after weighting (Hing, Shimizu, & Talwalkar, 2016).
Additionally, comparisons of study results with national data, described in Chapter 4,
suggested good external validity. Nonetheless, the possibility of nonresponse bias cannot
be completely ruled out.
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Significance of the Study
The medical literature has implicated the incorporation of electronic technologies
into the practice environment as a major or partial contributor to numerous outcomes that
have the potential for negative impact on the health care system and the health of
individuals: disengagement from patients (J. Levinson, Price, & Saini, 2017),
professional burnout (Shanafelt et al., 2016), departure from the practice of medicine
(Sinsky et al., 2017; Wright & Katz, 2018), and potential or actual medical harms (Howe
et al., 2018; Schiff et al., 2015; Korb-Savoldelli et al., 2018). These concerns are
supported by a substantial body of research evidence. The current study investigation of
whether theory-based interventions on medical decision-making might represent an
improvement over current approaches has the potential to benefit physicians and the
health care system. More broadly, positive social change could result from encouraging a
multidisciplinary approach to the study of medical decision-making and evidence-based
practice promotion (see Djulbegovic & Guyatt, 2017) by engaging the unique capabilities
of professionals working in the fields of psychology, health policy, and medicine (see
Holden, Binkheder, Patel, & Viernes, 2018; Ray et al., 2019). Study findings suggested
several potential roles for health psychologists in these endeavors, which are described in
Chapter 5.
Additionally, the medical decision examined in this research, potentially unsafe
ADHD-medication prescribing, may be understudied relative to its population-health
implications. Although psychostimulants other than cocaine caused only 12% of U.S.
drug-overdose deaths in 2016, the rate of increase from 2015 to 2016 in overdose deaths
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from these substances (33%) was triple that of prescribed opioids (11%; Seth et al.,
2018). Recognizing these risks, the CDC recently added stimulants to its drug
surveillance protocols (Kariisa, Scholl, Wilson, Seth, & Hoots, 2019). By providing
information about predictors of potentially unsafe ADHD-medication prescribing, this
study may inform efforts to mitigate the problem, thereby benefiting patients treated in
U.S. medical practice.
Summary
In this quantitative study, I compared theory-based with atheoretical approaches
to explaining a non-evidence-based medical decision with potentially substantial effects
on population health. The theory-based approach reflected physician training,
professional norms, and cognitive demands of CDS and E-HRs, as recorded in a large
body of qualitative and quantitative research. The theory-based approach also reflected an
assessment of whether physicians value E-HRs and the guidance provided by CDS, an
important determinant of the effects of meaningful use incentives, according to selfdetermination theory. All statistical models accounted for physician specialty and patient
characteristics that may affect ADHD-medication prescribing decisions.
In Chapter 2, I describe the study’s theoretical frameworks in more detail and
assess potential linkages between those frameworks and medical decision-making. The
remainder of Chapter 2 addresses research relevant to three key constructs of social
cognitive theory: knowledge, cognition, and environmental influence. The review of
knowledge covers the specific treatment choices made during an ADHD-medication
prescribing decision and the limitations on information available during the decision-
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making process. The review of cognition includes a description of medical training and
professional norms. At the intersection of cognition and the environment are evidencebased decision-making and barriers to it. Environmental factors reviewed include CDS,
meaningful use, and other incentives. The chapter concludes with summaries of gaps in
the literature and of theory-based and atheoretical perspectives on environmental
influences affecting medical practice.
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Chapter 2: Literature Review
Despite widespread support for principles of evidence-based medicine among
U.S. physicians (Blanco et al., 2014; Chan et al., 2017), treatments prescribed in routine
practice commonly differ from those recommended in evidence-based guidelines (Baker
et al., 2015; R. Lau et al., 2016). The widespread adoption of E-HRs in U.S. medical
practices that resulted from implementation of the HITECH Act (Gabriel & Swain,
2014), although intended to improve patient health by aligning routine care with research
evidence (Bates et al., 2003), produced unintended consequences (Brown et al., 2017;
Colligan et al., 2016; Ratwani et al., 2019; Shanafelt et al., 2016). These outcomes have
been attributed by some observers to failure to consider psychological theory or evidence,
particularly from human-factors research (Ratwani et al., 2016; Savage et al., 2017), in
developing E-HR systems. Similar concerns have been expressed about the psychological
effects of strategies that pay physicians to perform according to externally determined
metrics (Himmelstein et al., 2014; Kao, 2015), such as meaningful use incentives.
As atheoretical behavior-change interventions (Cho & Bates, 2018), CDS and the
HITECH Act were typical of policies intended to improve medical decision-making
(Jäger et al., 2016; R. Lau et al., 2016; L. Liang et al., 2017). Whether use of a theoretical
basis in designing these interventions might represent an improvement over current
approaches is an understudied question. As a preliminary step in addressing that question,
this quantitative study was conducted to compare atheoretical and theory-based models of
potentially unsafe ADHD-medication prescribing (see Fairman et al., 2018). Study results
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may effect positive social change both for physicians who are affected by interventions
on their medical decisions and for adults who are prescribed ADHD medications.
The order of sections in this chapter was based on three core tenets of the study’s
primary theoretical framework, social cognitive theory: knowledge, cognition, and
environmental influence (see Bandura, 1989, 1999; Kelder et al., 2015). After explaining
the literature search strategy, theoretical framework, and evidence regarding the study
dependent variable (DV, outcome) measure, I discuss knowledge available to physicians
about ADHD medications and safety issues. Then I consider cognition: how physicians
are trained to make decisions and the occupational values and norms that influence their
decision-making. I discuss evidence-based medical practice as an interaction of cognition
and environment, describing barriers to evidence-based practice and evaluating whether
the provision of knowledge, the core function of CDS, might reasonably be expected to
mitigate those barriers. I then discuss two key environmental influences on the medical
practice environment, CDS and meaningful use provisions, explaining the rationale for
these policies and describing physician experiences with them. Because study hypotheses
about CDS were based in part on evidence available at the time the HITECH Act was
developed, I distinguish early (pre-2012) from postimplementation experiences. The
chapter concludes with summaries of the literature on CDS and meaningful use, set
within the current study’s theoretical frameworks, and of gaps in the literature addressed
by this research.
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Literature Search Strategy
As shown in Figure 1, the systematic strategy used to search the literature
encompassed the following topics and sources: (a) theoretical frameworks
(PsycARTICLES); (b) medical information about ADHD, ADHD medications, and
outcomes of CDS and E-HRs (PubMed); (c) physician cognition and decision-making
(PsycARTICLES, PsycINFO, Academic Search Complete); (d) key policy documents
and position white papers (Google); and (e) purposive searching for works by key
opinion leaders (varied sources).

Figure 1. Literature search strategy. ADHD = attention-deficit hyperactivity disorder;
CDS = computerized decision support; CPOE = computerized prescription order entry;
E-HR = electronic health record.
Most searches were limited to 2010 or later. Exceptions included the following:
(a) searches on the rationales for CDS and meaningful use policies, which covered
approximately 10 years prior to HITECH Act passage (see U.S. Congressional Budget
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Office [CBO], 2008); (b) information about adult ADHD and inappropriate use of
stimulants, which covered primarily the past 3 years because research attention to these
topics is recent (see Compton et al. 2018; Fields, Johnson, & Hassig, 2017; Kooij et al.,
2019; McCabe et al., 2019); and (c) theoretical texts. Literature regarding features of EHR technologies was limited to the United States to reflect state of practice for U.S.
settings.
Theoretical Frameworks
Prescribing is a cognitive activity that is intended to be information based and
rational but may be context dependent and constrained by environmental influences
(Djulbegovic & Elqayam, 2017). A theoretical framework for prescribing decisions
should encompass (a) informational inputs, (b) the way those inputs are processed
cognitively, and (c) environmental influences on the cognitive process. The theories
chosen were social cognitive theory and self-determination theory.
Social Cognitive Theory
Social cognitive theory is grounded in a core assumption that human action is
characterized by emergent interactive agency, neither completely independent of, nor
completely determined by, environmental influence (Bandura, 1989). The framework
presents individuals as constantly engaging with their environments, both acting on them
and being acted upon by them, in a process of triadic reciprocal causation that
encompasses mutual interactions among individual (emotional or cognitive), behavioral,
and environmental events. Although the theory acknowledges environmental constraints
that may be “thrust upon people whether they like it or not,” the theory also suggests that
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humans respond to these constraints with personal agency in an ongoing process of
adaptation (Bandura, 1999, p. 23). Humans engage in forethought about various courses
of action; form intentions, which are plans and strategies; act in a way that is expected to
provide satisfaction; and monitor the outcomes of those actions, adjusting future
cognition and behavior accordingly (Bandura, 1989; Bandura & Locke, 2003).
Outcome expectations, knowledge, and the environment. According to social
cognitive theory, human actions are based on outcome expectations, a theoretical
construct that refers to the anticipated effects of decisions (Bandura, 1989; Kelder et al.,
2015). These expectations are derived from a cognitive process that accounts for
knowledge, which includes both the expertise and the information necessary to perform a
behavior, and environmental influences. In prescribing, relevant knowledge includes
proficiency in medical practice derived from medical training (Mowery, 2015) and
information about the patient, such as symptoms, clinical complexity, or other factors that
affect the potential benefits or risks of the prescription (Anderson et al., 2014; Gupta &
Cahill, 2016; Pérez de los Cobos, Siñol, Pérez, & Trujols, 2014). Environmental
influences, which are facilitators and barriers to various actions (Kelder et al., 2015), may
in the medical practice office include tools that provide information, such as CDS (Cho &
Bates, 2018); input from other providers or from patients (Donohue et al., 2018; Sirota,
Round, Samaranayaka, & Kostopoulou, 2017); or financial or nonfinancial rewards for
specific behaviors (Heisey-Grove & Patel, 2014; Tak et al., 2017).
Application of social cognitive theory to study topic. As noted in Chapter 1,
cognitive theories have seldom been applied to the study of medical decision-making
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(Godin et al., 2008). Nonetheless, as will be shown throughout this chapter, four
constructs of social cognitive theory are helpful in explaining physician behavioral
response, this study’s outcome (DV), to E-HR-delivered CDS, the independent variable
(IV, predictor) in RQ1. The first two constructs are occupational self-regulation
(Bandura, 2001) and moral agency (Bandura, 1999). These constructs represent the ways
that human beings regulate their behavior in accordance with occupational norms,
forming what Bandura (2001) described as a “personal identity” (p. 15) around work.
Application of these constructs to this study derived from an inconsistency between the
ways that physicians are trained to think, as a part of their occupational identity, and the
changes to the practice environment brought about by CDS and E-HRs (see Berkhout et
al., 2018; Colligan et al., 2016; Friedberg et al., 2013; Shanafelt et al., 2016).
The third construct is self-efficacy, referring to the degree to which humans
perceive themselves as capable of executing certain behaviors (Bandura & Locke, 2003).
Self-efficacy for medical practice is developed in physicians through a rigorous training
process (Mowery, 2015) that is discussed in the section on medical training. Application
of this construct to this study derived from an inconsistency between the tasks for which
physicians are trained to have self-efficacy (see Berkhout et al., 2018) and the cognitive
demands introduced by CDS and E-HRs (see Ratwani et al., 2016).
The fourth construct is emergent interactive agency (Bandura, 1989). The
literature review for this study indicated inconsistencies between the expectations of EHR system proponents (see Bates et al., 2003; Blumenthal & Tavenner, 2010) and the
sometimes unexpected ways in which physicians have responded to these systems (see
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Nanji et al., 2014; Slight et al., 2016; Wright et al., 2018). In theoretical terms, physicians
adapted to E-HR-related environmental changes with the human agency described by
Bandura.
Potential limitation of theory to explain prescribing. Social cognitive theory
does not alone indicate whether a given environmental influence is a facilitator or barrier.
Rather, social cognitive theory provides a structure of constructs to which various
environmental features may be mapped (i.e., linked) in a theory-based model (see
Prestwich et al., 2018). A potential limitation of social cognitive theory for a model of
prescribing decisions, the outcome (DV) in this study, is that it does not address
competition among the various types of environmental incentives that may influence the
outcome expectations of physicians. Different incentives—such as financial rewards for
using CDS (Heisey-Grove & Patel, 2014), satisfied patients (Tak et al., 2017), or revenue
derived from volume of patient business (Kao, 2015)—could produce different choices.
Therefore, theory-based hypotheses about prescribing must address not only whether
incentives affect behavior, but also the expected direction of influence. Selfdetermination theory helps resolve this dilemma by pointing to the importance of type of
motivation in determining the effects of incentives on psychological well-being and task
performance (Deci & Ryan, 2008a).
Self-Determination Theory
Self-determination theory is built on a foundational assumption that human beings
have universal needs for competence, autonomy, and relatedness with others (Deci &
Ryan, 2008a). Motivators that meet these needs will improve task persistency, task
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performance, and psychological health. A key consideration in determining these
outcomes is whether motivation is autonomous or controlled.
Autonomous motivation, which improves task performance and psychological
health, is associated with rewards that are intrinsic, that is, inherent to an activity, such as
enjoyment of a task (Deci & Ryan, 2008b). In contrast, controlled motivation, which
damages task performance and psychological health, is associated with rewards that are
extrinsic, that is, both tangible (e.g., money, grades in school) and contingent on criteria
determined by others. However, the theory does not suggest a simple motivational
dichotomy. Instead, subtypes of motivation lie on a continuum from more to less selfdetermined, based on the degree to which a reward structure is consistent with an
individual’s values (Deci & Ryan, 2008b; Prestwich et al., 2018).
Autonomous motivation may result not only from intrinsic rewards, but also from
extrinsic reward systems that reflect values with which an individual identifies as a core
aspect of self, a subtype of autonomous motivation known as integrated motivation, or
from rewards that reflect a valued outcome, a subtype known as identified motivation
(Deci & Ryan, 2008b; Prestwich et al., 2018). In work contexts, environmental inputs
that are viewed as informational, meaning they foster a perception of “choice and
personal initiative,” increase the sense of self-determination and thereby autonomous
motivation (Deci & Ryan, 1985; Deci, Connell, & Ryan, 1989, p. 580). In contrast, workenvironment inputs that signify externally determined pressure, such as threats of
penalties or behavioral surveillance, foster a sense of controlled motivation (Deci &
Ryan, 2008b).
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Consistent with the concept of a motivation continuum, occupational or scholastic
rewards linked to level of task performance, such as exceeding standards achieved by
peers, may have neutral or positive effects on motivation and performance (Cameron,
Banko, & Pierce, 2001; Deci, Koestner, & Ryan, 1999). Only rewards that communicate
“task triviality” produce negative outcomes (Eisenberger, Pierce, & Cameron, 1999, p.
677). In a study conducted in one corporation, allowing workers opportunities for choice
and initiative was associated with improved occupational satisfaction if basic working
conditions (e.g., pay, benefits) were satisfactory (Deci et al., 1989). Despite these
applications to work settings, no studies in which researchers applied self-determination
theory to the promotion of evidence-based practice were identified in the current
literature review, although the theory has been applied to suggest that extrinsically
determined financial incentives may diminish intrinsic motivation for medical practice
(Himmelstein et al., 2014; Kao, 2014).
Considered together, these findings suggest that the more an individual identifies
with the values and outcomes associated with a reward system, the more that system is
likely to meet the needs for competence and autonomy. The key question in determining
type of motivation is not so much whether rewards exist, but the degree to which those
rewards represent values with which the “true or integrated self” would have identified
regardless of the reward (Deci & Ryan, 2008b, p. 16). Applying this question to the
current study topic, the theory suggests that prescribing-behavior response, the study
outcome (DV), to the extrinsic rewards offered in meaningful use incentives, the study
predictor (IV) in RQ2, would depend on physician assessments of the value of
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meaningful use. For physicians to see meaningful use as valuable would require that the
standards they use to assess their task performance match those implicit in the technology
promoted by meaningful use. This question is addressed in this chapter with assessments
of how physicians are trained for decision-making, which is the primary task in the
medical practice environment, and with evidence about their experiences in performing
that task using the electronic tools promoted by the HITECH Act. Before turning to those
topics, I describe literature on the specific task that is this study’s outcome measure
(DV): the decision of whether to prescribe a potentially unsafe ADHD medication to an
adult.
Adult ADHD Symptoms and Treatments
ADHD is a chronic condition characterized by symptoms that fall into two broad
domains: (a) inattention (e.g., forgetfulness, carelessness) and (b) hyperactivity or
impulsivity (e.g., fidgeting, impatience; Kooij et al., 2019). Among those aged 17 years
or older, a formal diagnosis of ADHD requires at least five symptoms, which may present
in a combined type across both domains, of which “several” must have been present
before aged 12 years (American Psychiatric Association, 2013, p. 33). Symptoms should
impair functioning in more than one setting, such as both home and work, and should not
be better explained by a different diagnosis, such as a mood disorder or psychosis.
Although classified in treatment guidelines as neurodevelopmental and
genetically inheritable, ADHD is associated with few consistent neurobiological
characteristics or symptoms (Kooij et al., 2019; Mahone & Denckla, 2017). Complicating
diagnosis, ADHD symptoms often overlap with those of other disorders (Asherson,
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Buitelaar, Faraone, & Rohde, 2016). For example, ADHD shares with anxiety disorders,
symptoms of restlessness and mind-wandering; with depression, symptoms of irritability,
diminished concentration, and lowered self-esteem; and with bipolar disorder, symptoms
of restlessness, mood lability, and lack of mental focus. One guideline describes ADHD
as “an umbrella term for a range of different but related pathophysiological entities”
(Bolea-Alamañac et al., 2014, p. 183) for which no reliable physiological test exists
(Kooij et al., 2019). In patients with SUD, the diagnostic process is even more
complicated because symptoms of both disorders, such as poor impulse control, overlap
(Fatseas, Debrabant, & Auriacombe, 2012; Mao & Findling, 2014) and because patients
may feign symptoms to obtain stimulants (Clemow & Walker, 2014).
Treatment Options for Dependent Variable: ADHD Medications and Therapies
Medications currently approved by the FDA to treat ADHD are summarized in
Table 1. These options informed the outcome (DV) measure in this study, potentially
unsafe versus safer treatments. As shown in the table, all ADHD medications work by
increasing the availability in the brain of one or both of two neurotransmitters, dopamine
and norepinephrine, that are thought to play key roles in ADHD symptoms (BoleaAlamañac et al., 2014). The two types of potentially unsafe prescribing, the outcome
(DV) in this study, arise from side effects of these neurotransmitters. As explained in
Chapter 1, these neurotransmitter-related side effects would be expected to occur
regardless of whether the patient has been diagnosed with ADHD, although only
anecdotal evidence about off-label use is available (Lakhan & Kirchgessner, 2012).
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Table 1
Medications Approved for Attention-Deficit Hyperactivity Disorder
Name
Amphetamines

Mechanism of action
• Increases availability of
dopamine and norepinephrine
by blocking reuptake and
decreasing breakdown in
neuronal synapsesa
• Increases release of dopamine
from neuronsa

Treatment considerations
• Black-box warning for abuse and dependenceb
• Extended-release formulations may have
reduced abuse potentialc
• Should not be used in serious CVDb

Atomoxetine

• Increases norepinephrine
availability by blocking
reuptakec

• No known abuse potentiald
• Preferred for those with abuse riskc,d,e
• May be somewhat less effective than stimulants
(mixed evidence)c,f
• Slower onset of action than stimulantsc
• Should not be used in serious CVDd

Clonidine as brand
Kapvayg,h

• Agonist (stimulating) effect at
α-2A adrenergic receptorsi

• No known abuse potentialh
• Use with caution: hypotension, bradycardia,
heart block, severe CVD, or kidney failureh

Guanfacine as
brand Intunivg,j

• Agonist (stimulating) effect at
α-2A adrenergic receptorsg

• No known abuse potentialj
• Use with caution: hypotension, bradycardia,
syncopej
• No other known cardiovascular considerationsj

Lisdexamfetaminek

• Increases availability of
dopamine and norepinephrine
by blocking reuptake,
decreasing breakdown in
neuronal synapses, and
increasing releasek

• Black-box warning for abuse and dependencek
• Prodrug formulation thought to make it less
abusable than other stimulantsc,f
• Should not be used in serious CVDk
• Unlike other ADHD medications, has a dual
indication for binge-eating disorderk

Methylphenidatel

• Increases availability of
dopamine and norepinephrine
by blocking reuptakea
• Activates α-2 adrenergic
receptorsa

• Black-box warning for abuse and dependencel
• Extended-release formulations may have
reduced abuse potentialc
• Should not be used in serious CVDl

Note. ADHD = attention-deficit hyperactivity disorder; CVD = cardiovascular disease; FDA = Food and Drug
Administration.
aFaraone (2018). bTeva Pharmaceuticals (2017); FDA (2007a). cBolea-Alamañac et al. (2014). dFDA (2002). ePost and
Kurlansik (2012). fKooij et al. (2019). gFor clonidine and guanfacine, brand names are shown because these
formulations are approved for ADHD, and other brands are for hypertension (Jain, Hiremath, Michael, Ryan, &
McMahon, 1985). hFDA (2010). iBidwell, Dew, and Kollins (2010). jFDA (2013). kFDA (2007b). lNovartis (2019).
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Types of potentially unsafe prescribing measured in study DV. The first safety
concern with ADHD medications arises because stimulant-produced increases in
dopamine availability in the central nervous system take place not only in target brain
regions, such as the prefrontal cortex, but also in the nucleus accumbens, a brain region
commonly implicated in addictive behaviors (Faraone, 2018). For this reason, stimulants
are controlled substances (Clemow & Walker, 2014). All FDA product labels for
stimulants (FDA, 2007a; Novartis, 2019) contain black-box warnings, so named because
they appear surrounded by a prominent black rectangle to indicate “serious or lifethreatening risks” (FDA, 2012, p. 1), for SUD. These risks are considered greater for
immediate- than extended-release formulations (Bolea-Alamañac et al., 2014; Fields et
al., 2017), although even an extended-release action may be bypassed by parenteral
abuse, such as crushing or dissolving a tablet to sniff or inject the active ingredient
(Morton & Stockton, 2000; Novartis, 2019). One stimulant product with reduced abuse
potential (Kooij et al., 2019) is lisdexamfetamine, which is a prodrug (FDA, 2007b),
meaning it does not become pharmacologically active until after it is digested and
metabolized (Advokat, Comaty, & Julien, 2014).
The second safety concern arises because increases in norepinephrine availability
resulting from use of either stimulants or atomoxetine increase blood pressure and heart
rate (Kooij et al., 2019). Although small and clinically unimportant on average, at a
population level, these changes are potentially clinically significant for patients at
elevated risk of cardiovascular events, such as those with CVD (E. F. Liang et al., 2018;
Martinez-Raga, Ferreros, Knecht, Alvaro, & Carabal, 2017), particularly among the
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estimated 5–15% of treated patients who experience unusually large increases in heart
rate or blood pressure (Hammerness, Karampahtsis, Babalola, & Alexander, 2015).
Accordingly, product labels for stimulants warn that because serious cardiovascular
events, including sudden death, heart attack, and stroke, have been reported in adults
taking “recommended doses” of these medications, they should be avoided in those with
“known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm
abnormalities, coronary artery disease, and other serious heart problems” (Novartis, 2019,
p. 3). The warning for atomoxetine is similar (FDA, 2002).
Evidence-based recommendations for patients with risk factors. The
operationalized outcome (DV) measures in this study, which are described in Chapter 3,
reflected evidence-based guidelines for treatment options in patients with CVD or SUD.
These guidelines suggest that for patients with medical conditions that would make one
ADHD treatment potentially unsafe, similarly effective alternatives are available,
including safer medications and behavioral therapies. These alternatives are presented
below for each type of risk.
SUD. Although the topic of ADHD-medication treatment for patients with SUD is
somewhat controversial (Carpentier & Levin, 2017; Pérez de los Cobos et al., 2014;
Faraone, 2018), treatment guidelines available during the study period were consistent
with FDA prescribing guidance in recommending against use of stimulants in patients at
risk of medication abuse (FDA, 2007a, 2007b). Three guidelines in effect during or
immediately after the current study period all recommended atomoxetine for these
patients (Bolea-Alamañac et al., 2014; Fields et al., 2017; Post & Kurlansik, 2012). One
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also mentioned the nonstimulants clonidine and guanfacine as treatment options without
specifically recommending them for patients with SUD (Bolea-Alamañac et al., 2014).
Evidence on potential use of the stimulant prodrug, lisdexamfetamine, for patients with
SUD was emerging during the study period (Bolea-Alamañac et al., 2014) and was
eventually incorporated into one recent European guideline (Kooij et al., 2019) but not
into FDA (2007b) prescribing information.
CVD. Guidance about CVD risks was somewhat equivocal during the study
period. Like FDA-approved product labels (FDA, 2002, 2007a), one guideline published
during the first year of the current study period (Bolea-Alamañac et al., 2014)
recommended a thorough history and physical examination, cardiovascular testing if
initial screenings indicate potential disease, and monitoring during treatment for
symptoms of cardiac problems. However, guidance from the American Academy of
Family Physicians did not recommend CVD risk assessment (Post & Kurlansik, 2012).
Medication options for patients with CVD include guanfacine (Bolea-Alamañac et al.,
2014) and clonidine, but neither should be used in patients with certain serious
cardiovascular or kidney conditions (FDA, 2010, 2013).
Either CVD or SUD. An additional treatment option for patients with CVD or
SUD is cognitive behavioral therapy, such as mindfulness or skills training (Jensen,
Amdisen, Jørgensen, & Arnfred, 2016; Knouse, Teller, & Brooks, 2017). Although
behavioral treatments are generally recommended for use with medication, rather than as
a substitute for it (Bolea-Alamañac et al., 2014; Fields et al., 2017; Post & Kurlansik,
2012), the authors of one recent guideline noted that for patients who do not “desire or
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tolerate” medication, behavioral therapy may be optimal (Kooij et al., 2019, p. 25).
Published results for behavioral strategies are consistent with these recommendations,
suggesting positive outcomes (Arnold, Hodgkins, Caci, Kahle, & Young, 2015), with
treatment effect sizes comparable to those of amphetamines (Castells, Blanco-Silvente, &
Cunill, 2018; Knouse et al., 2017; Lopez et al., 2018).
ADHD-Medication Knowledge Gaps and Safety Problems
A few studies have suggested that prescriptions for ADHD medications do not
consistently comport with evidence-based safety guidelines, perhaps because of gaps in
knowledge. One survey, conducted with a Web-based convenience sample of physicians,
suggested a lack of confidence in diagnosing and treating ADHD, with 8% of primary
care physicians and 27–28% of psychiatrists rating themselves as “extremely confident”
in these activities (Goodman et al., 2012). In vignette-based knowledge tests, rates of
recognition of SUD were generally high at 76% of primary care physicians and 82% of
psychiatrists. However, only 33% of primary care physicians and 44% of psychiatrists
recognized the need for a cardiovascular assessment or treatment change when a patient
develops symptoms suggesting CVD. Confidence in managing a patient with CVD was
generally low, at 5% of primary care physicians and 13% of psychiatrists. Another selfreport survey, based on a national probability sample of psychiatrists with a response rate
of 40%, measured cardiac assessments prior to stimulant prescribing for pediatric ADHD
(Leslie et al., 2012). Although nearly all respondents reported obtaining a medical history
(96%), and most (71%) obtained vital signs, 26% reported no physical examination, by
themselves or by another physician, prior to writing the prescription.
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A limitation of both physician surveys was their reliance on self-reported
behavior. Stronger evidence was provided by two studies of objective behavioral
measures. Gerhard et al. (2010) examined the association of cardiovascular risk with
prescribing choice, using a retrospective analysis of a claims (medical and pharmacy
billing) database, in a large (n = 8,752) sample of commercially insured patients aged 21–
64 years diagnosed with ADHD in 2006 or 2007. The investigators found that stimulant
prescriptions were filled by 41% of patients with and 53% of those without CVD,
suggesting some risk awareness. However, this effect was observed only in younger
adults, not in those aged 46–64 years, and was not observed for atomoxetine.
Fairman et al. (2018) used the same database but a different design, examining
prevalence of SUD, CVD, and serious CVD—defined as pacemaker-controlled
arrhythmia, cardiomegaly, cardiomyopathy, cerebrovascular disease, congestive heart
failure, myocardial infarction, or a heart valve disorder—in patients aged 18–64 years (n
= 91,588) newly treated for ADHD with either atomoxetine or a stimulant in 2014–2015.
These investigators found that in the one year prior to the first prescription, the
prevalence of SUD in the subgroup of stimulant-treated patients was 11–19%, depending
on how SUD was defined. Although rates of CVD were generally low for the sample
overall, only 6% for all CVD and 2% for serious CVD, these rates increased with older
age, reaching 16% for any CVD and 7% for serious CVD among those aged 55–64 years.
An important limitation of the studies by Fairman et al. (2018) and by Gerhard et
al. (2010) is that neither included the growing population of patients prescribed ADHD
medications without an ADHD diagnosis (Olfson et al., 2013; Safer, 2016). Mitigating
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this limitation, similar findings were produced by an analysis of National Survey on Drug
Use and Health (NSDUH) household-interview data for 2015–2016 (Compton et al.,
2018). In the NSDUH, 5% of adult respondents who reported heart disease indicated
past-year use of prescribed stimulants; and use rates were high among persons with SUD:
18% among those with alcohol use disorder; 26% and 34% with misuse of prescribed
opioids and sedatives, respectively; and 33–34% with use of cocaine or heroin. In
addition to these rates, which indicated any prescribed stimulant use, rates of misuse,
expressed as a proportion of all prescribed stimulant use, were considerably elevated in
adults with SUD, ranging from 58–66% among those with use disorders for alcohol,
prescribed opioids or sedatives, or cannabis. NSDUH findings also suggested that the
likelihood of obtaining medication from a physician, rather than from a family member or
friend, increased with degree of misuse (ranging from 7% of those with 1–2 days of pastmonth misuse to 25% with > 7 past-month misuse days) and was highest (38%) in those
with SUD. These findings, together with those of the database studies, suggest that
patients for whom an ADHD medication is potentially unsafe are nonetheless commonly
able to obtain that medication from a physician.
Because physicians are trained to seek and use scientific evidence in making
medical decisions (Berkhout et al., 2018), a key question in ADHD-medication
prescribing is the degree to which the consequences of potentially unsafe prescribing are
reported in the research literature. Like the evidence-based guidelines described
previously, the research literature contains more definitive information for SUD than for
CVD. Specifically, public health alerts documented a 3.5-fold increase in the number of
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U.S. emergency visits made by adults aged 18 years or older for nonmedical use of
ADHD medications from 2005 to 2010 (U.S. Substance Abuse and Mental Health
Services Administration, 2013), and a 32% increase in the rate of overdose from
stimulants excluding cocaine for those aged 24 years or older from 2015 to 2016 (Seth et
al., 2018). The medical literature also reported challenges in medical management of
stimulant overdose because no antidote agent exists (Fulde & Forster, 2015; Spiller et al.,
2013). Despite the availability of this knowledge, its salience may have been offset by
competing risk information. Some researchers have suggested that attention to opioid
misuse has diverted public health focus away from the also-substantial risks of abusing
stimulants and sedatives (McCabe et al., 2019). For this reason, awareness of SUDassociated ADHD-medication risks may have been limited during the study period.
For CVD-associated ADHD-medication risks, the base of published research
evidence is even more limited. Based on studies demonstrating no increased populationlevel cardiovascular event risk from ADHD-medication treatment of adults (MartinezRaga et al., 2017), the medications are generally perceived as safe (Kooij et al., 2019;
Kratochvil, 2012). However, this population-level base of evidence provides limited
information about event rates in higher-risk patients (Jackson, 2016; Mick, McManus, &
Goldberg, 2013). The only study of that question identified in this study’s literature
review was conducted in a sample of children who developed a new heart rhythm
disorder during treatment with methylphenidate (Shin, Roughead, Park, & Pratt, 2016).
Consistent with warnings against use in patients with CVD (Jackson, 2016), a temporal
association between arrhythmia onset and treatment initiation (incidence rate ratio [IRR]
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= 1.61 for the first 2 months of use), was particularly pronounced in children with
congenital CVD (IRR = 3.49).
Several patterns in use of stimulants by adults—rapidly growing prevalence, ageassociated elevations in cardiovascular risk, and evidence that fatalities had occurred in
patients with CVD not identified until autopsy—led the Drug Safety and Risk
Management Advisory Committee of the FDA to recommend black-box warning status
for cardiovascular event risks on stimulant product labels (Nissen, 2006). However, the
FDA overrode the recommendation. Other than a black-box warning for cardiovascular
events in amphetamine overdose (Teva Pharmaceuticals, 2017), these risks are currently
given only a standard warning, not the more salient black-box caution. Despite this
decision, a recent draft of proposed FDA (2019) guidance for pharmaceutical
manufacturers would, if implemented, require studies of cardiac safety during the
stimulant drug-development process, to include evaluations of heart-rhythm changes and
dose-response assessments of heart rate and blood pressure.
Summary: Uncertainty in the Prescribing of ADHD Medications to Adults
As a disorder that shares symptoms with other prevalent psychiatric conditions,
ADHD is difficult to diagnose and treat, especially in patients with SUD. Moreover,
concerns about medication-associated risks, although based in evidence, may not be fully
understood. Heightening these challenges, use of ADHD medications by adults has
increased rapidly in the past 20 years (Fairman et al., 2017; Olfson et al., 2013). From the
perspective of the treating physician, these patterns may represent an important source of
uncertainty about which evidence-based prescribing guidance is available but not readily
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synthesized—exactly the circumstance that CDS is intended to address (Bates et al.,
2003). However, the degree to which CDS can improve decision-making may depend on
its alignment, as an environmental strategy, with the way that physicians are trained to
think and make decisions. This topic is discussed in the next section.
Medical Education and Occupational Identity
Medical education, and the occupational norms and values resulting from it,
reflect three core themes that have remained consistent since 1910, the date of a pivotal
curriculum-development document, the Flexner report (Cooke et al., 2006; Schrewe,
2013). The foremost theme is professional autonomy. In 1915, Flexner noted that the
primary characteristic of a profession, such as medicine or law, was a “free, resourceful,
and unhampered intelligence applied to problems and seeking to understand and master
them” (Flexner, 1915, para. 7). This theme repeats throughout training, which lasts for 7
to 11 years after college graduation (Mowery, 2015). A core objective of medical-school
education is the promotion of lifelong, self-regulated patterns of learning that will
translate across clinical circumstances (Berkhout et al., 2018). The foremost goal
described by the accrediting body for postgraduate training is that physicians should be
able to make high-quality decisions about patient care with “autonomy and
independence” (ACGME, 2019, para. 5). Final training outcomes include a licensing
examination that assesses capability for “unsupervised” practice (U.S. Medical Licensing
Examination [MLE], 2019, para. 1) and assessment of entrustable professional activities,
which are tasks to be performed without direct supervision (ten Cate, 2013).
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The second and third goals of medical education, biomedical expertise (Schrewe,
2013) and devotion to patients (Cooke et al., 2006), are linked. In the vision espoused by
Flexner, expertise, to be acquired in programs characterized by rigorous empiricism
(Schrewe, 2013), was intended to be applied to the well-being of patients and the public
(Flexner, 1915). Consistent with this goal, an editorial published in a high-impact
medical journal to commemorate the Flexner centennial noted that medical education
should inculcate “a crucial set of professional values and qualities, at the heart of which is
the willingness to put the needs of the patient first” (Cooke et al., 2006, p. 1341).
Accordingly, the second accreditation goal is that a demanding training program should
enable physicians to “take life-saving actions” for patients (ACGME, 2019, para. 6).
The centrality and persistence of these values suggests that, consistent with
Bandura’s (2001) concept of personal identity in occupational settings, medical training
consists of much more than developing biomedical knowledge. It is intended to be a
process in which physicians develop professionally normative patterns of thought,
confidence in information seeking and decision-making (Berkhout et al., 2018), and
devotion to patient care (Cooke et al., 2006) that reflect what Bandura (1999) described
as moral agency. Additionally, physicians are trained for, and therefore would be
expected to have self-efficacy for, a self-directed cognitive flexibility that Bandura
(2001) described as occupational self-regulation. These training outcomes are reflected in
the ways that physicians make decisions, discussed next.
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Occupational Identity and Cognition in the Medical Practice Environment
Information about the occupational identity and cognitive processes that
physicians use in medical decision-making comes from two bodies of evidence, the first
on physician occupational satisfaction and the second on predictors of medical decisions,
including prescribing. As shown in the literature presented in this section, these two
bodies of evidence are linked because, as social cognitive theory would suggest, humans
act in ways that they believe will provide them with satisfaction (Bandura & Locke,
2003). Specific applications of these predictors to the theory-based model are
summarized at the end of this section.
The physician-patient relationship and patient preference. Consistent with the
training emphasis on applying biomedical knowledge to promote the well-being of
patients (Cooke et al., 2006), physicians characterize good patient relationships as an
indicator of high-quality care, place value on meeting the needs of individual patients
(Friedberg et al., 2013), and derive satisfaction from patient relationships (Colligan et al.,
2016; Tak et al., 2017) and from resolving intellectually challenging clinical problems to
benefit patients (Colligan et al., 2016). Conversely, physicians experience loss and
dissatisfaction from organizational changes, such as increases in administrative tasks and
reductions in time allotted for visits, that diminish opportunities for patient care (Colligan
et al., 2016; Friedberg et al., 2013; Sinsky et al., 2013). Corresponding to these values,
extensive evidence suggests that patient preferences influence prescribing decisions
(Becker & Midoun, 2016; Dempsey, Businger, Whaley, Gagne, & Linder, 2014;
Hawkins et al., 2017; Moloney, 2017; Sirdifield et al., 2013; Wallis, Andrews, &
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Henderson, 2017). In several studies, physicians cited patient expectations and concerns
about loss of patient relationships as key determinants of potentially inappropriate
prescribing (Anderson et al., 2014; Sirdifield et al., 2013; Wallis et al., 2017).
The role of the patient-physician relationship in prescribing decisions
encompasses both clinical and business considerations. Because physicians view
alleviation of patient suffering as a critically important aspect of their role as clinical
providers, they may write prescriptions for medication they believe will alleviate physical
or emotional distress (e.g., insomnia, anxiety, pain), even knowing that the root cause of
the problem is biologically unclear or represents a difficult life circumstance rather than a
biomedical issue (Moloney, 2017; Sirdifield et al., 2013). For the same reason, they may
choose to give patients “the benefit of the doubt” even when misuse is suspected (M. A.
Fischer et al., 2017, p. 7). At the same time, physicians may acquiesce to clearly
inappropriate requests because they know that a patient who is denied medication may
provide a negative rating on a satisfaction survey, potentially reducing physician
compensation (Zgierska, Miller, & Rabago, 2014), or may choose another physician, who
will prescribe the requested medication (Moloney, 2017; Sirdifield et al., 2013).
Professionalism. Related to desires to make decisions that benefit individual
patients, and consistent with the occupational norms of autonomy and self-directed
learning, are considerations of professionalism. These include autonomous decisionmaking (Friedberg et al., 2013; Wright & Katz, 2018); work content and provision of
high-quality care consistent with professional expertise (Colligan et al., 2016; Friedberg
et al., 2013; Shanafelt et al. 2016); and the perception of medicine as a calling (Tak et al.,
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2017). In a mixed-methods study of a geographically diverse sample of U.S. physicians,
odds of occupational satisfaction were approximately tripled by opportunities to provide
high-quality care and to initiate quality-improvement efforts (Friedberg et al., 2013).
Personal experience and cognitive salience. Consistent with a training
environment that encourages physicians to develop and rely on their own biomedical
expertise in making decisions (Berkhout et al., 2018; Stead et al., 2011), physicians
commonly rely on personal experience, including familiarity with histories of individual
patients, medications, and salient events (Bell, Steinsbekk, & Granas, 2015; Doctor et al.,
2018; Ebbert et al., 2018). For example, in a small-sample (N = 26), single-institution
study, psychiatrists who were asked about the most important sources of information in
prescribing decisions commonly gave “more than average” ratings to the patient’s (96%)
and physician’s (85%) experiences with the medication, although the patient’s diagnosis
and symptoms were foremost (100%; Rajendran, Sajbel, & Hartman, 2012, p. 274).
Similarly, Hawkins et al. (2017) found that among primary care physicians in the VA, a
commonly cited reason for benzodiazepine-opioid coprescription was that the patient was
already successfully taking the combination without adverse effects. Conversely, adverse
experience may play a role in the decision not to prescribe a medication. For example,
knowledge of a patient’s overdose reduced opioid prescribing by 10% in one randomized
trial (Doctor et al., 2018), and was associated with a 31% increase in prescription drug
monitoring program enrollment in a survey (Ebbert et al., 2018).
As these findings suggest, physicians do not consistently use formal guidance in
making treatment decisions, sometimes comparing informational resources with their
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own experience to determine their quality (Cook, Sorensen, Hersh, Berger, & Wilkinson,
2013). In the survey of psychiatrists, which found that 85% placed high value on their
own experiences, only 61% and 39%, respectively, gave practice guidelines and FDA
criteria a “more than average” importance ranking (Rajendran et al., 2012). Physicians
may also consider perceived social norms in making decisions (Donohue et al., 2018;
Ponnet, Wouters, Van Hal, Heirman, & Walrave, 2014).
Medical Decision-Making: Summary and Implications for a Theory-Based Model
The findings of studies on medical decision-making suggest that, consistent with
their medical training, physicians place high value on patient needs and preferences. They
define professionalism as autonomy to perform tasks that reflect the high level of
expertise and complexity for which they were trained. Rather than relying solely on
published knowledge in making decisions, they are likely also to consider professional
norms, their personal experiences, and salient events.
These findings had several implications for the theory-based model presented and
operationalized in Chapter 3. First, consistent with an understanding of the clinical and
business importance of physician-patient relationships, the theory-based model included
predictors (IVs) for the nature of those relationships and the derivation of revenue from
patient volume or satisfaction. Second, the understanding that autonomous decisionmaking to promote high-quality care is a core professional value, coupled with the
findings of research on the outcomes of E-HRs presented later in this chapter, informed
the hypotheses in the theory-based model by highlighting the contrast between
occupational norms and the new demands placed on the medical practice environment by
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meaningful use and CDS. Third, the understanding of the role of experience in medical
decision-making informed the inclusion of a predictor (IV) for new versus continuing use
of ADHD medication.
In the next section, I consider response to evidence-based guidelines as an
interaction between this cognitive decision-making process and the environment in which
medical decisions are made. I focus on barriers to evidence-based practice. Some, but not
all, of these barriers were cited as part of the rationale for the introduction of CDS into
medical practice (Bates et al., 2003; Stead et al., 2011).
Barriers to Evidence-Based Medical Practice
As originally conceptualized in the 1970s and 1980s and formally defined for the
first time in 1991 (Djulbegovic & Guyatt, 2017; Guyatt, 1991), the term evidence-based
medicine referred to the replacement of conventional wisdom with findings of
randomized controlled trials (Sackett, 2010) to be used as a starting point in medical
decision-making (Djulbegovic & Guyatt, 2017). The term was later expanded to clarify
the roles of clinical judgment (Sackett et al., 1996) and patient preference (Djulbegovic &
Guyatt, 2017). Ideally, evidence-based medicine is not an automated, thought-free
conformity to clinical rules; it is meant to reflect a synthesis of high-quality evidence
with clinical observation and professional assessment (Djulbegovic & Guyatt, 2017;
Sackett & Rosenberg, 1995).
One core tenet of evidence-based medicine supported the rationale for the
HITECH ACT. Specifically, recognition of the need for unbiased evaluations of the
totality of evidence (Djulbegovic & Guyatt, 2017), gave rise to the Cochrane
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Collaboration, a framework for systematic review and meta-analysis (Cochrane
Community, 2019). In turn, awareness of the volume of this base of evidence led to the
concept of point-of-care information delivery strategies, in which physicians could be
provided with evidence-based guidance as they were making decisions (Djulbegovic &
Guyatt, 2017). Such automated support was viewed by key stakeholders as crucial to
improving health care quality and safety (IOM, 2000, 2001).
Evidence for and Against Use of CDS in Evidence-Based Decision-Making
Some commonly described cognitive or environmental barriers to evidence-based
practice are consistent with the stakeholder view of automated support as essential. These
include lack of awareness of the guideline or of deviations from it and constraints on time
or on other resources (Baatiema et al., 2017; Chan et al., 2017; F. Fischer et al., 2016).
Another commonly reported barrier, patient resistance to guideline-based practice (Arts
et al., 2016; Dempsey et al., 2014; Matthys et al., 2014), potentially could be mitigated
with timely algorithms. In the survey of VA providers on benzodiazepine-opioid
coprescribing, the most commonly cited need was structured guidance that providers
could use in interacting with patients who refused discontinuation (Hawkins et al., 2017).
In contrast, other barriers to evidence-based practice may represent reactions to
the guidance itself. These include disagreement with guideline recommendations (Chan
et al., 2017; Cloutier et al., 2018; F. Fischer et al., 2016; Matthys et al., 2014) and the
related concern that recommendations based on population-level evidence may not apply
to the complex needs of individual patients (Arts et al., 2016). In routine practice,
physicians see a heterogenous patient population whose characteristics may not be well-
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represented by the homogeneous samples used in randomized controlled trials (Makady
et al., 2017). Trials of ADHD medications commonly exclude patients with comorbid
cardiovascular or psychiatric disorders (see Castells et al., 2018; Huss et al., 2014;
Philipsen et al., 2014). In contrast to these sample characteristics, real-world prevalence
estimates for psychiatric comorbidities among adults with ADHD are high: 11–35% for
SUD; 19–53% for depression or dysthymia, and 34–47% for anxiety disorders (Q. Chen
et al., 2018; Fairman et al., 2018; Katzman, Bilkey, Chokka, Fallu, & Klassen, 2017;
Kooij et al., 2019; Mao & Findling, 2014). This discrepancy may make it difficult for
clinicians to apply ADHD-guideline recommendations to treatment decisions.
Evidence-Based Prescribing: Summary and Implications for a Theory-Based Model
Evidence-based prescribing may be viewed as the outcome of an interaction
between the cognitive processes of physicians and environmental influences, such as
available knowledge and time. Specifically, physicians may engage in non-evidencebased prescribing because of lack of information, need for assistance in managing patient
expectations, or lack of awareness that their behaviors depart from evidence-based
guidelines—problems that could potentially be addressed by CDS-delivered knowledge.
Less easily addressed by the provision of knowledge are disagreement with guideline
content or challenges in applying guidelines to individual patients. Physicians who have
been trained to value high-quality care may be reluctant to accept CDS-delivered
guidance, and meaningful use incentives to use that guidance, unless these tools appear to
result in better patient outcomes.
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For this reason, the question of quality-of-care outcomes associated with E-HR
technology and with meaningful use, and physicians’ opinions of those outcomes, were
important in determining the hypotheses in the theory-based model. These questions are
considered in the next two sections. After a review of the rationales for CDS and
meaningful use, the chapter turns to experience with E-HRs and CDS before and after
HITECH Act implementation, then to attitudes of physicians toward meaningful use.
CDS and Meaningful Use
The idea of applying electronic technologies to medical decision-making to make
“the practice of evidence-based medicine a reality” (Bates et al., 2003, p. 523) emerged in
about the year 2000 (IOM, 2000, 2001). Proponents suggested that the concept was
analogous to “mass customization” procedures used in other industries, which leverage
high-technology tools to provide personalized services to a large base of consumers
(Bates & Gawande, 2003, p. 2526). Several core assumptions undergirded the approach.
One was that use of electronic technology was essential because of increasing
complexity in care delivery, such as the need to adjust dosages for kidney impairment or
customize treatment for genetic variation (Bates & Gawande, 2003; Stead et al., 2011).
Systems would, proponents suggested, help providers by anticipating and meeting needs
that “have not been consciously realized,” for certain medical orders (Bates et al., 2003,
p. 525) and allow physicians to spend more time in patient care, “empowered by … a
network of brains and computers” (Stead et al., 2011, p. 430). Despite this notion of
empowerment, arguments for increased use of electronic technologies were also based in
part on an assumption that forcing functions, which are system features that constrain
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available treatment choices, would improve patient safety by making unsafe decisions
impossible (Emanuel et al., 2008). For example, when physicians at one hospital found a
way to work around an E-HR function intended to reduce non-evidence-based use of
growth hormone, hospital administrators identified them from system log-ins and
engaged them in “targeted discussions” about their choices (Bates et al., 2003, p. 526).
Another assumption was that certification of E-HR systems through a central
federal office, coupled with assistance provided to physicians by regional technical
assistance centers, would facilitate interoperability, which is information exchange to
enable rapid access to a comprehensive health history across all sites of care (Buntin et
al., 2010). More broadly, the information exchange that would come from widespread
adoption of E-HRs was viewed as a way to change “the mind-set of the [physician]
workforce” by increasing its focus on the measurement and management of quality
(Buntin et al., 2010, p. 1216).
Evidence About E-HRs and CDS Prior to HITECH Act Implementation
Advocacy for widespread use of E-HR and CDS in medical decision-making was
somewhat supported by evidence available at the time. Consistent with the notion that
physicians could not be expected to keep up with the volume of available research
evidence without automated assistance, more than 480,000 Medline-indexed articles were
published in the year 2000 (see U.S. National Library of Medicine, 2019). Moreover,
many early studies of adoption of CDS or E-HRs documented potential or realized
improvements in quality, safety, or efficiency (CBO, 2008). Despite these findings, the
base of evidence about CDS and E-HRs in office-based prescribing was limited, partly
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because most studies had been conducted in inpatient hospital settings (CBO, 2008).
Moreover, as of August 2012, no studies of CDS-guided prescribing had examined
technology-related adverse effects as primary outcomes, and few trials measured these
risks (Bright et al., 2012; Carling et al., 2013).
Additionally, reported outcomes were mixed and mostly minimal, especially in
office-based care (Bright et al., 2012; CBO, 2008). In a systematic review by Garg et al.
(2005), 11 of 16 studies of CDS-assisted prescribing suggested improvements, but of
studies that measured patient outcomes, none showed improvements. In other systematic
reviews, Wolfstadt et al. (2008) found reductions in adverse drug events in five of 10
studies of CDS; Lainer, Mann, and Sönnichsen (2013) found that unsafe prescribing was
reduced in three of six randomized trials of CDS published through March 2011; and
Shojania et al. (2010) found in a meta-analysis of 21 comparisons that computerized
reminders were associated with a median 3.3 percentage-point improvement in
prescribing behaviors. In one systematic review and meta-analysis of randomized
controlled trials published from 1999–2012, which assessed CDS systems linked to
patient-specific medical data, Moja et al. (2014) found inconsistent effects. Of three
outpatient studies included in that review, one reported process-of-care improvements but
a “failed clinical outcome” (Holbrook et al., 2011, p. 1742); one reported no
improvements in four of six outcomes (McCowan et al., 2001); and one, conducted in a
specialty clinic, found improvement (Robbins et al., 2012).
Studies of E-HRs or CDS based on NAMCS data produced similarly mixed
findings (Linder et al. 2007; Romano & Stafford, 2011; Samal, Linder, Lipsitz, & Hicks,
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2011). Outcomes, estimated in these studies using multivariate analyses adjusted for
patient and provider characteristics, included no change in 14 of 17 quality indicators
(Linder et al., 2007) and no improvement in any of 12 indicators of prescribing quality
(Romano & Stafford, 2011). One NAMCS study did find a modest but clinically and
statistically significant improvement in blood pressure control with CDS reminders
(79%) compared with no reminders (74%; Samal et al., 2011). Together with the smallersample studies, these NAMCS findings suggested that in physician-office settings, CDS
would be expected to have no significant association with the safety of prescribing
decisions. This evidence, along with literature on E-HR-related cognitive demands
presented later in this chapter, informed the hypotheses for RQ1.
E-HR Cost Estimates as a Foundation for the HITECH Act
Despite equivocal evidence about effects of E-HRs and CDS on quality of
medical care, mathematical models published beginning in 2003 suggested the possibility
of large savings to the health care system from increased use of electronic technologies
(CBO, 2008), including one estimate of $81 billion annually from improved efficiency,
safety, and chronic disease management (Hillestad et al., 2005). However, these
projections of large cost savings were based on questionable evidence, according to a
CBO (2008) analysis. For example, authors of the $81 billion estimate excluded from
their calculations all studies with unfavorable results for E-HRs, stating that they “chose
to interpret” negative findings “as likely being attributable to ineffective or not-yeteffective implementation” (Hillestad et al., 2005, p. 1105). Reflecting a more
comprehensive assessment, a meta-analysis of randomized controlled trials of CDS
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published through January 2011 found “modest evidence” of a “trend toward” lower
costs in 22 studies conducted in inpatient or outpatient settings and mixed evidence about
cost-effectiveness in outpatient care (Bright et al., 2012, p. 32).
Still, the possibility of savings, and the perception that implementation costs were
a barrier to adoption, led to the idea of paying physicians to use E-HRs in medical
decision-making (Terry, 2013). One study of 14 small primary care practices suggested
start-up costs, including equipment and staff time, averaging $44,000 (R. H. Miller,
West, Brown, Sim, & Ganchoff, 2005). This estimate was the basis for meaningful use
provisions of the HITECH Act (Terry, 2013), discussed next.
Meaningful Use Program Overview
Meaningful use regulations developed under the HITECH Act had their roots in
the 2004 establishment of the Office of the National Coordinator (ONC) of Health
Information Technology (CBO, 2008), which certified E-HR systems as required by the
law and continues to play a key role in the program (Cohen et al., 2018). Overarching
goals were similar to those previously described for CDS and E-HRs: improvements in
medical decisions and patient outcomes, increased efficiency, and changing the way that
physicians think about quality of care (Buntin et al., 2010; Terry, 2013). A phased
approach (Table 2) was used to minimize provider burden while encouraging progress in
an escalator concept (Blumenthal & Tavenner, 2010). Each meaningful use phase, known
as a stage, included menu objectives, from which physician offices could choose, and
core objectives, which were mandatory except when inapplicable (e.g., physician writes
fewer than 100 prescriptions annually; Wright, Feblowitz, Samal, McCoy, & Sittig,

63
2014). Menu objectives are not discussed here because they were unrelated to prescribing
(e.g., public health surveillance; CMS, 2012a).
Table 2
Key Dates for Meaningful Use Program Rules and Implementation
Event
Rule for E-HR certification
issueda

Date
June 2010

Requirements
ONC-certified system required to receive payments

Final Stage 1 rules publishedb

July 2010

• 15 core objectives
• 5 of 10 menu objectives
• Report > 1 population health measure using E-HR

First opportunity to file for
Stage 1 achievementb,c

April 2011

• Based on 90 or more consecutive days of use

Stage 2 start dated

January 2014

• 17 core objectives
• 3 of 6 menu objectives

Final Stage 3 rules and
modified Stage 2
requirements publishede

October 2015

• Modified Stage 2 requirements, retaining core
objectives
• Stage 3 optional in 2017, mandatory in 2018

Note. E-HR = electronic health record; ONC = Office of the National Coordinator.
a
Blumenthal and Tavenner (2010). bHalamka (2010). cKibbe (2010). dCMS (2012b). eCMS (2015).

Prescription-related core objectives at stage 1, achieved by 12% of Medicare
providers as of May 2012 (Wright et al., 2013), included ordering of at least one
medication electronically for more than 30% of patients; electronically recorded lists of
diagnoses, medications, and drug allergies for more than 80% of patients; electronic
transmission of more than 40% of medication orders; and ability to perform druginteraction checks (D. R. Levinson, 2017). In practice, physician offices typically
exceeded these metrics because once the computer infrastructure for a measure was built,
it was relatively easy to apply it to more than the minimum number of prescriptions
(Wright et al., 2014). For example, at stage 1, 63% of physicians ordered more than 70%
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of prescriptions by computer, 62% transmitted more than 70% of prescriptions
electronically, and 89% had electronic lists of diagnoses and medication allergies for
more than 90% of patients (Wright et al., 2014). Stage 2, implemented on the start date
for the current study, required use of increased E-HR functionality, such as CDS checks
for drug-drug and drug-allergy interactions (CMS, 2012a, 2012b).
Financial incentives for meaningful use were substantial, depending on speed of
implementation: up to $63,750 in Medicaid, with various achievement dates permissible,
and up to $44,000 in Medicare for providers achieving stage 1 by 2011 or 2012 (see
Kibbe, 2010). Slower implementation yielded lower payments (e.g., up to $24,000 in
Medicare for implementation by 2014). Additionally, penalties were imposed for failure
to engage in meaningful use, including Medicare payment reductions of 1% in 2015 and
2% in 2016 (Kibbe, 2010; Monica, 2017).
Together, these findings suggest that physician offices that achieved meaningful
use experienced substantial changes in the practice environment. Because only 9 months
elapsed between publication of final program rules (July 2010) and the earliest filing date
(April 2011), these changes may have been implemented quickly for offices that applied
early in the program. In the next section, macrolevel outcomes of meaningful use
implementation are presented, followed by a discussion of linkages between these
outcomes and physician opinions of the value of meaningful use.
Physician Experiences With Meaningful Use
Implementation of the HITECH Act in 2011 was followed by growth, as intended,
in the extent and sophistication of E-HR use nationwide. Prevalence of E-HR use by U.S.
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physicians increased from an estimated 35% in 2007 to 57% in 2011 and 72% in 2012
(Hsiao & Hing, 2014). Among small practices, use prevalence for key E-HR medicationrelated metrics increased from 2007–2010 to 2012–2013: from 29% to 51% for inclusion
of medication lists, from 25% to 70% for electronic transmission of prescriptions to
pharmacies, and from 17% to 46% for drug-interaction checks (Rittenhouse et al., 2017).
By April 2014, 70% of U.S. physicians were using an E-HR to prescribe, and 96% of
pharmacies were able to accept electronic prescriptions (Gabriel & Swain, 2014).
Benefits of meaningful use. Early reports identified several benefits of the
expanded use of electronic technologies brought about by meaningful use achievement.
These included increased adherence to health care process behaviors included in
meaningful use metrics (e.g., smoking-cessation interventions; Ancker et al., 2015),
improved within-facility access to information (Jamoom, Patel, King, & Furukawa,
2013), easier remote access to patient records (King, Patel, Jamoom, & Furukawa, 2014),
increased information exchange with other providers and patients (Audet, Squires, &
Doty, 2014; Jamoom et al., 2013), and perceived benefits of CDS for error prevention
(King et al., 2014). Most of these early results represented physician opinion (see Audet
et al., 2014; Jamoom et al., 2013; King et al., 2014), not objectively measured outcomes.
Effects of meaningful use on quality of care. Studies conducted after HITECH
Act implementation found few objectively measured improvements in quality associated
with use of E-HRs (see Harle, Cook, Kinsell, & Harmon, 2014; Harman, Rost, Harle, &
Cook, 2012; M. J. Miller et al., 2017) or with meaningful use achievement (see Afonso et
al., 2017; Grinspan et al., 2017; Jung et al., 2017; Kern et al., 2015; Samal et al., 2014;
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Unruh et al., 2017), although providers that applied for meaningful use may have had
better care processes prior to implementation (Grinspan et al., 2017). Associations of EHR use with care metrics included an increased likelihood of prescribing an opioid for
chronic pain (Harle et al., 2014), no change or reduced likelihood of treatment for
depression (Harman et al., 2012), and no significant difference in depression screening
rates among patients prescribed a medication that could cause depressive symptoms (M.
J. Miller et al., 2017). Results of the meaningful use studies, all conducted in single states
or health systems rather than in national samples, included no significant change in eight
measures of quality (e.g., vaccination, cancer screening) among Medicaid primary care
providers (Grinspan et al., 2017); improvements in one screening measure, but not in
other screenings or in hospitalization rates among Medicare providers (Jung et al., 2017);
no significant change on any of nine quality measures in a large primary care provider
sample (Kern et al., 2015); and no significant difference in Medicare beneficiary hospital
readmission rates (Unruh et al., 2017). An exception was a study conducted in one
academic medical center, which identified improvements in four measures, no change in
two, and one worsened, after progression from stage 1 to stage 2 (Levine et al., 2017).
A persistent challenge to improving quality of care with meaningful use is
override, in which physicians do not accept or even view a CDS recommendation
(Baysari, Tariq, Day, & Westbrook, 2017). Reported rates of override during prescribing
with CDS have remained high for 20 years, ranging from 49–96% in studies published
before 2010 (Isaac et al., 2009; van der Sijs, Aarts, Vulto, & Berg, 2006), from 53–60%
in studies of one academic medical system published in 2013 and 2014 (Nanji et al.,
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2014; Slight et al., 2013), and from 73–94% in recent studies (Genco et al., 2016; Nanji
et al., 2018). One large health system reported a 69% override rate for high- or mediumseverity alerts when a customized alerting database was used for outpatient prescribing in
2014–2015, which increased to 92% when the same health system switched to an
industry award-winning (K. Murphy, 2019) commercial system (Wright et al., 2018).
Related to high override rates is the commonly documented problem of excessive
noise-to-signal ratio (Marcilly, Ammenwerth, Vasseur, Roehrer, & Beuscart-Zéphir,
2015), referring to the inundation of providers with clinically unimportant or questionable
warnings (Carli, Fahrni, Bonnabry, & Lovis, 2018; Horsky, Phansalkar, Desai, Bell &
Middleton, 2013; Zazove et al., 2017). One systematic review of studies with standard
statistical measures of accuracy applied to CDS warnings found sensitivity (percentage of
harms detected) ranging from 38–91% and positive predictive values (PPV; percentage of
warnings that represent true harms) of only 8–14% for drug-dosage interaction and 2–
48% for drug-drug interactions, although PPV was better in more advanced systems at
17–97% (Carli et al., 2018). Similarly, in one system that required physicians to enter
into the E-HR their reasons for overrides, retrospective clinical reviews conducted by a
multidisciplinary team found that 53% of overrides for outpatients (Nanji et al., 2014)
and 61% of overrides for inpatients (Nanji et al., 2018) were clinically appropriate.
Systematic evidence of harms. Systematic investigations of technology-related
harm included a comprehensive quantitative analysis of U.S. data based on computerized
prescribing errors reported to the U.S. Pharmacopeia MEDMARX system (Schiff et al.,
2015), coupled with naturalistic observation of order entry using 13 different E-HR
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systems to determine how those errors might have occurred (Slight et al., 2016).
Investigators found that 79% of erroneous prescriptions reported to MEDMARX could
be ordered in the E-HR, typically with either no difficulty (28%) or after minor
adjustments (28%), and often (61%) with no CDS-delivered warning (Schiff et al., 2015).
Examples included a 1000-fold overdose of thyroid hormone and a potentially dangerous
disease-antidiabetic medication combination. In a follow-up analysis, Amato et al. (2017)
studied all prescribing errors at six sites participating in a study of computerized
prescribing and found that 52% were technology-related, including 7% in which the
technology facilitated the error and 45% in which the technology failed to prevent the
error. Commonly reported consequences of technology-related errors include delay or
duplication of treatment and incorrect medication or dosage (Amato et al., 2017; Howe et
al., 2018; Korb-Savoldelli et al., 2018; Slight et al., 2016).
Increases in physician workload. Instead of the improvements in efficiency
envisioned by proponents of CDS and meaningful use, investigators using time-motion
analyses found that electronic technologies may increase physician administrative
workload, from 16% to 28% of work time spent on documentation in one meta-analysis
(see Baumann, Baker, & Elshaug, 2018). Among these findings were 49% of the inoffice day spent on E-HR tasks and only 27% with patients, plus 1–2 hours after-work
time on the E-HR in a four-state study of office-based physicians (Sinsky et al., 2016)
and 52% of total visit-related time devoted to E-HR tasks by family practitioners in Texas
(Young, Burge, Kumar, Wilson, & Ortiz, 2018). Added workload does not appear to be
alleviated by increased experience in using the E-HR. Arndt et al. (2017) conducted a
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time-motion analysis using E-HR event-logging records over a 3-year period beginning 5
years after full implementation of an award-winning E-HR (K. Murphy, 2019) in one
large health system and found that physicians spent an average of 5.9 hours per 11.4-hour
workday on the E-HR, of which 44% was for clerical work and 24% for inbox
management.
Cognitive demands of meaningful E-HR use. The cognitive challenges
encountered by physicians with meaningful use of CDS and E-HRs fall into several
categories, all related to human-machine-environment interaction. These include
problems of usability, unanticipated user responses, business practices, and training gaps.
These challenges are linked to evidence of a lack of basis in psychological theory,
discussed in this section, and to physician opinions about E-HRs and meaningful use,
discussed in the next section.
Usability. Gaps in E-HR usability, defined as human-machine-environment
interactions that do not produce the intended outcome, have been identified as an
important source of CDS- and E-HR-related errors (Ratwani et al., 2016; Ratwani et al.,
2018). E-HR system devices and messaging commonly do not conform to humancomputer interface design standards for colors, fonts, placements, and message content
(Horsky et al., 2013; Savoy, Patel, Flanagan, Weiner, & Russ, 2017; Virginio & Ricarte,
2015). Using a 26-item instrument validated for measurement of CDS-alert compliance
with human-factors design principles, Phansalkar et al. (2014) found that among 14
different systems, performance scores ranged from 31–71%, averaging 53%. Results
were particularly poor for clarity, underlying logic and prioritization of alerts, and
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provision of suggested actions. Commonly identified problems include incomplete screen
layout, such as showing only a partial medication list (Brown et al., 2017); inconsistent
medication names (Quist et al., 2017; Schiff et al., 2016); “dropdown” and
“autopopulate” lists that contain both incorrect and correct options; and incorrect CDS
content, such as wrong medication choice information or failure to identify combination
products accurately (Brown et al., 2017; Quist et al., 2017; Slight et al., 2016).
Unanticipated user responses. “Workarounds” developed by staff because of
functionality problems, or because staff do not know how to use the intended
functionality, may create safety hazards (Schiff et al., 2016). Examples include ordering
or discontinuing a medication in a free-text field instead of a drug-order field, preventing
checks on safety or dosage (Slight et al., 2016) or resulting in duplicate therapy (Yang et
al., 2018), and manual processes developed because of poor functionality for the clinical
task, such as inability to order different dosages of the same medication for morning and
evening administration (Slight et al., 2016). Automation bias, which is over-reliance on
technology at the expense of cognitive processing of relevant information, has also been
documented in CDS-assisted medication orders (Lyell et al., 2017; Lyell, Magrabi, &
Coiera, 2018).
On-site customization of E-HR features can also compromise system function
(Ratwani et al., 2018). In a qualitative study by Slight et al. (2016), investigators found at
one facility a dangerous flaw of which management had been unaware until informed by
the research team; all E-HR alerts had been inadvertently turned off 6 months previously
during a system upgrade. At a different site, investigators found that an information
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systems director had suppressed the E-HR’s ability to identify duplicate medications in
one screen to reduce system “noise” (Slight et al., 2016, p. 313).
Business practices. The business practices of E-HR vendors may contribute to
negative physician experience with systems in several ways. First, proprietary technology
may hamper health care coordination because different systems do not share information
(Ratwani et al., 2016; Samal et al., 2016), a problem described in one review as an
“interprofessional Tower of Babel” (Bernstein, Kogan, & Collins, 2014, p. 229).
Researchers who studied one integrated behavioral-medical provider network reported a
complex work-around necessary because one mental health center (MHC) and its
integrated physician office used different E-HRs: daily medication lists printed by the
MHC were manually recorded by a medical office physician assistant on paper, which
was scanned for the medical office E-HR, with updates then manually keyed into the
MHC’s system (Cifuentes et al., 2015). A related challenge is that contractual
arrangements may limit the ability of E-HR users and researchers to report usability
problems in the detail necessary for investigation and correction, such as providing visual
images of problematic order entry screens (Ratwani et al., 2019). There is no central
federal repository of information about E-HR-related adverse events, such as that
currently used to report medical device-related adverse events to the FDA.
Finally, despite the assumption that meaningful use would facilitate qualityimprovement efforts (Buntin et al., 2010), one mixed-methods study of 1,492
geographically diverse U.S. practices found limited ability to generate clinically
meaningful reports because vendors charged high fees for minimal customization (e.g.,
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reporting by date range or by clinician) or required office staff to learn database query
language (Cohen et al., 2018). Although 82% of participants were using an ONCcertified system, only 61% could generate clinical quality reports from the E-HR.
Training gaps. An additional problem inhibiting meaningful use is lack of
alignment between medical training content and the skills necessary to use CDS in
making medical decisions (Hersh et al., 2014; Pageler, Friedman, & Longhurst, 2013).
One detailed assessment of this issue, which resulted in a call for massive medical school
curricular reform (Stead et al., 2011), was published in April 2011, the month that
meaningful use filings began (see Wright et al., 2013). This timing highlights the contrast
between the way that physicians had been trained and the new expectations for medical
practice quickly placed on them. Unmet training needs are commonly mentioned in
discussions of E-HR usability challenges (Ratwani et al., 2016).
Meaningful Use: Summary and Implications for a Theory-Based Model
The evidence reviewed in this section suggested that although physicians
recognize the potential value of CDS and E-HRs (Schiff et al., 2016), they experience
substantial challenges in meaningful use of these technologies in clinical practice. These
challenges include excessive noise-to-signal ratio and the related problem of overrides,
usability problems and behavioral responses in the practice environment not anticipated
by system developers, business practices that impair quality improvement, and gaps
between medical education content and training needs.
The field of psychology suggests an explanation for these challenges that may be
framed within the social cognitive theoretical construct of human-environment
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interaction (Bandura, 1989), a failure of E-HR system design to account for the ways and
environmental circumstances in which people interact with technology (Savage et al.,
2017). Holden (2011), a cognitive health psychologist who specializes in human-factors
analyses of individual-device-environment interactions, has described E-HR system
failures as the result of simplistic paradigm that fails to address cognition as a mediator
between computer systems and work output. Consistent with Bandura’s notion of
interactive agency, although he did not cite it explicitly, Holden suggested that
unexpected user behaviors, such as “workarounds,” result from a process of adaptation
that allows physicians to cope both with the complexity inherent in medical practice and
with new complexities introduced by E-HRs. To the extent that the adaptation described
by Holden was the result of a medical education process intended to produce autonomous
and flexible cognition (see Berkhout et al., 2018), it is reasonable to suggest that
physicians think and behave creatively when exposed to electronic technology because
they are trained, as an occupational norm, to do so in response to any new environmental
condition (Bandura, 2001). If so, the expectations of E-HR-system proponents that
physicians would readily adopt suggestions produced by CDS, and that failure to do so
would represent “irrational” thinking (Cho & Bates, 2018, p. 114), were contrary to
psychological theory.
This theory-based assessment is consistent with the evidence about CDS available
prior to passage of the HITECH Act in suggesting no significant association of CDS with
prescribing behavior. In addition to informing the hypothesis for RQ1, the assessment

74
and supporting evidence provided a process measure to explain physician attitudes
toward meaningful use and technologies mandated by the HITECH Act, discussed next.
Physician Opinions About Meaningful Use
Given the problems that physicians encounter in using E-HRs for clinical care,
negative opinions of them, expressed in peer-reviewed survey reports (Emani et al., 2017;
Shanafelt et al., 2016; Weeks et al., 2015) and in a growing volume of popular-press
accounts (Fry & Schulte, 2019; Gawande, 2018; J. Levinson et al., 2017) and white
papers (Henry, 2018), are not surprising. These reactions are consistent with the issues
identified in research on outcomes of CDS and E-HRs and comprise two main areas of
concern.
Concerns Expressed by Physicians
The first area of concern is lack of clinical benefit or the introduction of clinical
harms. In the first physician survey conducted after HITECH Act implementation, 59%
of respondents said (agreed or strongly agreed) that meaningful use would contribute to
decline in “the art of medicine”, 50% said that it would improve quality of care, and 30%
said that it would ensure accurate patient information (Weeks et al., 2015, p. 126). In
separate surveys conducted, respectively, before and after qualification for meaningful
use at two academic medical centers, rates of agreement or strong agreement with
statements about possible quality improvements from meaningful use declined, from 29%
to 21% on improvement in patient-centeredness, from 39% to 31% on decreases in
medical errors, and from 27% to 21% on the ability to deliver high-quality care (Emani et
al., 2014, 2017).
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The second area of concern is relegation of clerical tasks to physicians instead of
to administrative support staff who were previously responsible for these functions,
which one survey respondent described as analogous to “asking the pilot to scrub the
floor rather than flying the plane” (Emani et al., 2017, p. 1048). Shanafelt et al. (2016)
noted a strong association between E-HR use, time spent on clerical tasks, and
occupational dissatisfaction. A related concern is the belief that time spent in the E-HR,
“checking off boxes” (Emani et al., 2017, p. 1048), detracts from engagement with and
care for the patient (Colligan et al., 2016; Gawande, 2018).
These negative opinions may be exacerbated by increasing system sophistication.
In one survey of primary care physicians, Babbott et al. (2014) found that degree of EHR sophistication was positively associated with job stress and negatively associated
with job satisfaction. Similarly, in the academic medical center survey, opinions about
meaningful use were less positive among stage 2 than stage 1 providers (Emani et al.,
2017). Perhaps indicating the degree of user frustration with CDS, investigators in one
large hospital network that is a leader in the study of E-HRs (see Schiff et al., 2016)
developed a “cranky comments heuristic” after noticing that certain text patterns in
physician overrides (e.g., multiple sequential exclamation points and words like “dumb”
and “please stop”) often accurately identified problems in CDS logic (Aaron, McEvoy,
Ray, Hickman, & Wright, 2019, p. 37). Systematic investigation of these “cranky
comments” increased predictive accuracy of error identification and produced the
unexpected finding of malfunctions in at least 26% of the E-HR’s decision rules.
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Physician Opinions: Summary and Implications for a Theory-Based Model
Literature reviewed for this study suggested generally poor opinions of
meaningful use, and of technologies promoted by meaningful use, among physicians.
This lack of value physicians ascribe to these technologies suggests, according to selfdetermination theory, that the meaningful use program represents controlled motivation.
Supporting this interpretation was a commentary in which a group of physicians, among
them a former hospital vice president of information technology (J. Levinson et al.,
2017), described the problem with E-HRs as a combination of clinically inappropriate
design and coercion: “people who take care of patients did not design or choose these
systems. They were foisted upon us” (para. 6). This theory-based understanding was the
foundation of the hypothesis for RQ2, which is detailed in Chapter 3.
Summary
In this chapter, I considered social cognitive theory as a framework within which
ongoing reciprocal engagement of humans with their environments can be characterized
as a continuous process, informed by knowledge, of adaptation to changing circumstance.
I described the knowledge available to physicians in making ADHD medication
prescribing decisions, the medical training and values that influence their decisionmaking processes, and barriers to evidence-based medical practice. In the final sections
of the chapter, I considered inconsistencies, suggested by the literature review, between
the effects of widespread adoption of electronic technologies that were envisioned by
HITECH Act developers and those indicated by psychological theory and evidence.
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Proponents of the HITECH Act assumed that implementation of sophisticated
electronic technology in the medical practice environment would change not only
prescribing behavior, but also cognitive patterns of medical decision-making. In contrast,
the theory-based approach suggested that those cognitive patterns are deeply engrained as
a result of long-standing professional traditions, are the product of limited observational
learning opportunities for use of electronic technologies in decision-making, and are
unlikely to change without retraining, if at all. Moreover, literature suggested that
dysfunction in E-HR systems has produced new challenges to patient safety that threaten
what physicians are trained to believe is their highest occupational norm, engaging with
and providing high-quality care to patients, and that the primary problem CDS was
intended to address, lack of readily available knowledge, is only one of several important
barriers to compliance with guideline recommendations. Finally, the literature review
suggested extensive, empirically supported opposition among physicians both to E-HRs
as currently implemented and, more broadly, to regulatory mandates to use them.
The review also suggested several gaps in the research literature, which were
addressed in this study. Foremost, no studies comparing theory-based with atheoretical
approaches to interventions on physician behavior were identified. Additionally, although
the theory-based assessments discussed in this chapter appear to explain survey findings
that most physicians have subjectively unfavorable experiences with and opinions of
CDS and meaningful use, specific evidence about the associations of these policies with
objectively measured prescribing behaviors is limited. Studies that used objective
behavioral measures to assess outcomes of meaningful use were based on single facilities
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or states, rather than on nationally representative data. Finally, as a relatively new topic
with important population-health implications, potentially unsafe ADHD-medication
prescribing is understudied.
Whether a theory-based approach better explains this prescribing behavior than
does the atheoretical approach used in HITECH Act development was the core empirical
question underlying the research questions and hypotheses presented in Chapter 3. Also
presented in Chapter 3 are an overview of the study design, a detailed description of the
nationally representative archival data set that was the study data source, and definitions
of all study variables. The population, sampling frame, sampling methodology, and
sample inclusion and exclusion criteria are described, as is the statistical methodology for
comparing the predictive accuracy of the atheoretical and theory-based models.
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Chapter 3: Research Method
Suboptimal outcomes associated with widespread implementation of electronic
technologies in U.S. medical practices, including problems in safety (Brown et al., 2017;
Schiff et al., 2016) and usability (Ratwani et al., 2016), have been attributed by some
observers to design flaws (Phansalkar et al., 2014) resulting from inconsistencies between
system features and psychological theory or evidence about human-machine-environment
interaction (Ratwani et al., 2016; Savage et al., 2017). Similarly, the strategy of paying
physicians to perform according to externally determined metrics, which was
foundational to the HITECH Act of 2009 (see Buntin et al., 2010), has been criticized for
inconsistency with psychological theories of human motivation (Himmelstein et al.,
2014; Kao, 2015). Evidence of an association between physician occupational
dissatisfaction and use of E-HRs (Shanafelt et al., 2016), particularly of more
sophisticated systems (Emani et al., 2017), supports these concerns.
To address the understudied question of whether theory-based interventions have
the potential to produce better outcomes than the more typical (L. Liang et al., 2017)
atheoretical approaches to changing physician behavior, the purpose of this quantitative
study was to compare two models of potentially unsafe ADHD-medication prescribing
for adults: one theory based and the other atheoretical. In this chapter, I present
information about the study’s sampling frame and design; the archival data set that was
analyzed to answer the research questions; operationalization of all study variables; and
methods for statistical analyses, including quantitative comparison of the predictive
accuracy of the theory-based and atheoretical models.
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Research Design and Rationale
The study was a retrospective, cross-sectional analysis of visits made by adults to
U.S. office-based physicians, recorded and publicly available in the archival NAMCS
data set. This research design addressed several gaps in available theory-based
information about interventions intended to change physician behavior. Foremost, the
study provided, for what the literature review suggested is the first time, a quantitative
comparison of theory-based and atheoretical approaches to the prediction of physician
prescribing behaviors. Additionally, the study provided U.S. national information about
the associations of CDS and meaningful use with an objective behavioral measure of
prescribing, improving on previous assessments based mostly on subjective measures of
physician opinion (see Emani et al., 2017; King et al., 2014) or on single-facility or
single-state samples (see Grinspan et al., 2017; Levine et al., 2017). Finally, the study
provided theory-based information about potentially unsafe prescribing of ADHD
medications to adults, a relatively new topic in the literature on evidence-based
prescribing (Fairman et al., 2018). Use of the NAMCS, a nationally representative source
of data on objectively measured prescribing behaviors, facilitated fulfillment of these
goals for the research.
The outcome (DV) for this study was potentially unsafe prescribing of ADHD
medications to adults, measured as a binomial, based on two clinical scenarios: (a)
potentially unsafe medication versus a safer treatment among all adults with ADHD who
were prescribed any treatment (i.e., either an ADHD medication or psychotherapy) and
(b) potentially unsafe medication versus any other option (i.e., safer medication or no
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medication) among adults with CVD or SUD for whom an ADHD medication was
potentially unsafe. These measures were defined using sources presented in Chapter 2,
including evidence-based guidelines (see Bolea-Alamañac et al., 2014; Post & Kurlansik,
2012) and federal prescribing information (see FDA, 2002, 2007a).
The key predictors (IVs) of interest were environmental factors: (a) CDS and
meaningful use provisions (in both the theory-based and atheoretical models, with
opposing hypotheses), (b) derivation of physician revenue from patient satisfaction or
volume (theory-based model only), and (c) nature of experience (professional
relationship) with the patient and medication (theory-based model only). Additional
predictor variables, included in both models, were knowledge measures. These included
clinical and demographic characteristics of the patient and physician specialty.
Methodology
Target Population and Sample
The target population for this research was office visits made by patients aged 17
years or older to U.S. office-based physicians. This target population was chosen because
CDS and meaningful use were intended to address decision-making, including
prescribing, that takes place during physician-patient encounters, including office visits
(see Blumenthal & Tavenner, 2010) and because diagnostic criteria for ADHD apply to
persons aged 17 years or older (American Psychiatric Association, 2013). The estimated
total target population size exceeded 662 million office visits in 2016, reported by the
CDC in its annual summary of NAMCS results (Rui & Okeyode, 2019).
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Archival data set sampling process. The NAMCS probability sampling design
is multistage, stratified, and cluster randomized (CDC, 2019b). Sequential sampling
stages include (a) random selection of physicians, using national lists provided by the
American Medical Association (AMA) and American Osteopathic Association (AOA),
stratified by each of 15 specialties (e.g., general practice, internal medicine,
cardiovascular disease, psychiatry); (b) random selection of 1 week (of 52) for each
sampled physician; and (c) simple random sampling of visits within that week (CDC,
2015a). Sampling weights provided in the data set are calculated by the NCHS as
multiplicative inverses of sample selection probabilities, with additional adjustments for
nonresponse based on numerous indicators of physician characteristics obtained from
AMA and AOA lists and from an initial interview with the physician or office staff (Hing
et al., 2016; U.S. Department of Commerce, 2016). More detail on these methods is
provided below in the section on archival data collection, quality, and screening.
Subsample of archival data set for current study. The study sample included
all office visits made by patients aged 17 years or older from 2014 to 2016, excluding
visits made for emergency care or to a surgeon. These respective exclusions were made
using the NAMCS field ERADMHOS, which indicates that the patient was sent directly
from the office to an emergency room or hospital, and SPECCAT, which includes a code
for surgical care specialty. Visits were further subsampled to include only those made by
patients with an ADHD diagnosis in Scenario A and by patients with CVD or SUD in
Scenario B. Methods of measurement for diagnoses are described under
Operationalization of Constructs.
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Archival data collection procedures. After physicians are sampled from the
AMA and AOA lists, they are contacted by letter from the NCHS and advised to expect
additional contact from an NAMCS field worker, a representative of the U.S. Bureau of
the Census (n.d.). Physicians can access an online informational web page that explains
the survey’s purpose and importance, as well as the legal authority under which it is
conducted. After physicians agree to voluntary participation, field workers administer an
initial induction interview, which is used to gather general information about the
physician and office setting, including revenue sources, practice ownership, meaningful
use status, and use of various E-HR and CDS functions (U.S. Department of Commerce,
2016).
For each sampled visit, NAMCS field workers use the medical record to abstract
items according to a standardized protocol that is detailed in an automated, laptop-based
tool (CDC, 2019b). Visit-related measures include patient demographics (e.g., age, sex,
race); payment sources for the visit (e.g., private insurance, Medicaid); clinically
important biometrics and health behaviors (e.g., blood pressure, tobacco use; body mass
index); up to five listed diagnoses made at the visit; a complete list of prescribed
medications and treatments, including psychotherapy, with an indicator of whether each
medication is new or continued from a previous visit; whether the physician seen at the
visit is the patient’s primary care provider; and number of visits made by the patient to
the office during the previous 12 months (CDC, 2019b).
In addition to these visit-related variables, field workers collect indicators of
numerous clinically important medical conditions regardless of when these were
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diagnosed, based on a prompt that asks, “Regardless of the diagnoses written above, does
the patient now have…” (CDC, 2019b, p. 50). For example, a patient with depression
who sees a physician for an ear infection would have the infection recorded in the visit
diagnosis list, and depression recorded as a medical condition indicator from the entire
medical record, regardless of whether depression was diagnosed at the visit. Medical
condition indicators are considered a “gold standard” against which the accuracy of visit
diagnoses may be measured (Asao, McEwen, Lee, & Herman, 2015, p. 650). Medical
condition indicators relevant to the current study included measures of ADHD, CVD,
SUD, depression, renal (kidney) disease, and diabetes (see CDC, 2019b).
Archival data quality, cleaning, and screening. Data collection procedures for
the NAMCS are regularly assessed in ongoing quality-improvement processes (CDC,
2019b; Rui & Okeyode, 2019). Recent studies and recommendations are summarized in
Table 3. These evaluations suggest that NAMCS data are reliable and valid. Additionally,
a comprehensive assessment of sample external validity in 2012 based on numerous
factors indicated nonsignificant differences between participants and nonparticipants on
most measures prior to weighting, and minimal (< 1–2 percentage points for all but one
indicator) potential nonresponse bias on visits after weighting (Hing et al., 2016). A
caveat to these assessments is that NAMCS methods are reviewed annually and
sometimes updated with changes that are typically, but not always, minor, so that
evaluations of data quality performed in one year may not fully represent the effects of
methods in other years. Details of sampling methods and weight calculations during the
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study period and of the NCHS analysis of nonresponse bias (Hing et al., 2016) are shown
in Appendix A.
Table 3
Recent Quality Assessments of NAMCS Data
Assessment type
(source)
Accuracy of
induction interview
(Halley et al., 2017)

Reason

Methods and results

Recommendation

Policy changes,
including E-HRs,
affecting practice
environment

Ethnographer-observed induction
interview
Most items answered easily
Minor difficulties in addressing some
administrative items

Instruction to ask
administrative staff
when physician is
unsure

Coding quality (Rui
& Okeyode, 2019)

Regular validation
process

Validation sample of 11.6% of records
reviewed by external auditor
Error rates of 0.03–0.8%

No protocol change

Accuracy of ICD-10
coding (D. T. Lau,
Strashny, Phan,
Blum, & BurkeBebee, 2018)

Industry-wide transition
from ICD-9 to ICD-10
system

All visits from final quarter of 2014
coded using both methods
Error rate of 5%

Minor changes to
instructions for
coding and record
abstracting

Nonresponse bias
(Hing et al., 2016;
Appendix A)

Decline in physician
participation ratea

Before weighting, no significant
differences between participants and
nonparticipants on the majority of 82
indicators; modest (typically 1–5
percentage point) differences on a
minority of indicators; large (10–13
percentage point differences only on
visit volume quartiles

Overall assessment
of minimal
nonresponse bias
after weighting
Could not rule out
bias on unmeasured
characteristics

After weighting, minimal (< 1–2
percentage point) potential bias on all
indicators except visit volume
(maximum difference of 8 percentage
point potential bias for lowest visit
volume quartile)
Note. E-HR = electronic health record; ICD = International Classification of Diseases.
a
Participation, defined as consenting and providing data for at least one sampled visit, exceeded 70% prior to 2002 (Hing, Schappert,
Burt, & Shimizu, 2005) but had declined to 38.4% by 2012 (Hing et al., 2016) and was 29.5–39.3% in 2014–2016 (CDC, 2017, 2018,
2019b).

Concordant with these assessments of data quality, NAMCS data are used as
nationally representative in an extensive body of peer-reviewed literature, including
academic research and public health surveillance reports (CDC, 2019c). NAMCS
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measures of E-HR use and features demonstrated good convergent validity with those
obtained from other national samples, including American Board of Family Medicine
professional certification data collected from 85% of U.S. family practitioners (Xierali et
al., 2013) and the Health Tracking Physician Survey (Li, 2011).
Quantitative assessment of sample size adequacy for archival data set.
Because of the complex sampling design, the NCHS does not recommend a priori power
calculations to determine the adequacy of NAMCS sample size (CDC, 2019b). Instead,
the NCHS recommends post hoc assessments of statistical reliability, using software that
adjusts for the design effect (i.e., homogeneity of variance; see Groves et al., 2009), such
as the SPSS Complex Samples module (CDC, 2019b). Estimates that do not conform to
statistical reliability standards are generally not reported by the NCHS or, depending on
the nature of the problem, are flagged for higher-level review prior to publication (Parker
et al., 2017).
The recommended method for determining statistical reliability depends on the
type of estimate. All estimates other than proportions (i.e., percentages) are considered
statistically reliable if they meet both of two criteria: (a) the relative standard error (ratio
of the standard error to the estimate) is < 30% and (b) the estimate is based on > 30 cases
(CDC, 2019b). For proportions, estimates should meet all of the following criteria: (a)
design-effect adjusted denominator of > 30 visits; (b) total absolute width of the 95%
confidence interval (CI), calculated using a method appropriate for complex samples, of
< 0.30; and (c) relative CI (absolute CI width divided by the estimate) of < 130% (Parker
et al., 2017). If the absolute CI width is unusually small (< 0.05), the NCHS also
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recommends ensuring > 8 degrees of freedom. The SPSS Complex Samples procedure
for CI estimation is based on the logit-transformation method (IBM SPSS, n.d.), which in
simulation analyses produced results similar to those of the Clopper-Pearson method
(Neusy & Mantel, 2016) used by the NCHS (Parker et al., 2017).
Operationalization of Constructs
In this section, I describe a priori plans for operationalization of all variables. As
described later in this chapter, a priori planned statistical analyses included assessments
of sample size, multicollinearity, and statistical reliability. For a few predictor variables,
these assessments resulted in post hoc changes to the a priori definitions described here.
These changes, along with the rationales for each, are explained in Chapter 4.
Figure 2 summarizes the study’s two statistical models, one theory based (right
side) and the other atheoretical (left side). The figure depicts the cognitive act of

Figure 2. Summary of statistical models. BBW = black-box warning; CDS =
computerized decision support.
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prescribing as an integration and synthesis of information from various sources
(knowledge construct, top, solid-line rectangles), influenced by environmental factors
(dotted rectangles), to create outcome expectations (unobserved variable, center) for each
potential decision (Bandura, 1989; Kelder et al., 2015). Arrows indicate hypothesized
associations. Because knowledge construct variables were hypothesized to act in the
same way in both the theory-based and atheoretical models, they were included in both
models, although not specifically addressed by any study research question.
Knowledge construct predictors. Table 4 shows definitions of all knowledge
construct predictors grouped by the categories shown at the top of Figure 2. The overall
approach to measurement of the variables was similar to that used by Fairman et al.
(2018), with modifications to reflect NAMCS data formats, particularly the availability of
medical condition indicators. For clinical risk, summary indices planned a priori included
a cardiovascular risk score developed for office-based practice to estimate baseline risk of
a cardiac event in people without CVD (D’Agostino et al., 2008) and the Charlson
Comorbidity Index, a validated summary measure of chronic disease burden based on
mathematically weighted combinations of diagnoses (Quan et al., 2011).
Additional clinical risk measures included whether the patient had a medical
condition indicating a black-box (highest-severity) warning level; and whether the
physician was a cardiologist, indicating both expertise for assessment of cardiovascular
disorders and a need for specialty-level cardiac care. Other relevant clinical measures
included the psychiatric comorbidities of depression and anxiety (see Mao & Findling,
2014) and whether the prescriber was a psychiatrist, indicating both expertise for
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Table 4
Knowledge Construct Independent (Predictor) Variables and Definitions
Construct type
Clinical risk, cardiovasculara
Age
BMI
SBP, treated
SBP, untreated
Current smoking
Diabetes

NAMCS variable name or measurement method
AGE
BMI
BPSYS, NCMED (indicates new or continued prescription; combine with medication lists in
Appendix B to identify antihypertensives)
USETOBAC
DIABTYP0; DIABTYP1; DIABTYP2 (TYP indicates diabetes type)

Clinical risk, Charlson Comorbidity Indexb
Cancer, nonmetastatic
CANCER condition indicator; ICD-9 and ICD-10 codes to measure metastasis (weight = 2)
Cancer, metastatic
CANCER condition indicator; ICD-9 and ICD-10 codes to measure metastasis (weight = 6)
Connective tissue /rheumatic
ICD-9 and ICD-10 codes (weight = 1)
disease
Dementia
ALZHD condition indicator (weight = 1)
Diabetes requiring medication
DIABTYP0; DIABTYP1; DIABTYP2; medication lists in Appendix B to identify
treatment, uncomplicated
antidiabetic medications (weight = 1)
Diabetes with complications
ICD-9 and ICD-10 codes (weight = 2)
(renal, eye, neurologic)
HIV
HIV condition indicator (weight = 6)
Liver disease, mild
ICD-9 and ICD-10 codes (weight = 1)
Liver disease, severe
ICD-9 and ICD-10 codes (weight = 3)
Myocardial infarction history
ICD-9 and ICD-10 codes (weight = 1)
Paraplegia
ICD-9 and ICD-10 codes (weight = 2)
Peptic ulcer
ICD-9 and ICD-10 codes (weight = 1)
Peripheral vascular disease
ICD-9 and ICD-10 codes (weight = 1)
Pulmonary disease
ASTHMA or COPD condition indicators; ICD-9 and ICD-10 codes for other lung diseases
(weight = 1)
Renal disease
CKD, CRF, or ESRD (weight = 2)
Clinical risk, other
“Black box” warning diagnosis
Cardiologist

ETOHAB; SUBSTAB
SPECR physician specialty code; 08 = cardiovascular disease

Other clinical factors
Depression
Anxiety
Psychiatrist

DEPRN condition indicator
ICD-9 and ICD-10 codes
SPECR physician specialty code; 11 = psychiatry

Demographic characteristics
Male sex
Younger age
White or Hispanic Race
Medicaid insurance
Urban location

SEX; 1 = female; 2 = male
AGE; groups aged 18–25 years; 26–49 years; 50 years or older (McCabe et al., 2019)
RACERETH; 1 = White non-Hispanic; 2 = Black non-Hispanic; 3 = Hispanic; 4 = other,
non-Hispanic
PAYTYPER indicates primary expected source of payment for the visit; 1 = private
insurance; 2 = Medicare; 3 = Medicaid, CHIP, or other state-based program
MSA; 1 = metropolitan statistical area; 2 = not a metropolitan statistical area

Note. Variable names shown in all caps indicate NAMCS fields. ICD codes are in Appendix C. Sources for NAMCS variable
information were CDC (2017, 2018, 2019b). BMI = body mass index; CKD = chronic kidney disease; COPD = chronic obstructive
pulmonary disease; CRF = chronic renal failure; ESRD = end-stage renal disease; ETOHAB = alcohol abuse; HIV = human
immunodeficiency virus; ICD = International Classification of Diseases; MSA = metropolitan statistical area; PVD = peripheral
vascular disease; SBP = systolic blood pressure; SUBSTAB = substance abuse.
a
Summary score indicates likelihood of a cardiac event (D’Agostino et al., 2008). bWeighted results are summed to indicate total
comorbidity burden (Quan et al., 2011). CEBVD, CHF, and myocardial infarction are typically included in the Charlson comorbidity
index but were excluded a priori because they were included in the outcome measure.
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assessment of psychological disorders and increased likelihood of prescribing an ADHD
medication despite potential risks (see Leslie et al., 2012). Demographic characteristics
commonly associated with controlled substance prescribing included male sex, younger
adult age, White or Hispanic race, Medicaid insurance, and urban-area office location
(see Fairman et al., 2017; McCabe et al., 2019; Rigg & Monnat, 2015).
Environmental-influence construct predictors. Definitions of environmental
predictors, categorized by theoretical construct, are shown in Table 5. Except where
otherwise indicated, all were drawn from the induction interview. To address the findings
of Halley et al. (2017) that physicians may have difficulty recalling administrative
arrangements in that interview, the a priori statistical analysis plan included validation of
meaningful use reports against ONC standards for E-HR functionality (see Patel,
Jamoom, Hsiao, Furukawa, & Buntin, 2013). Because medication-related CDS is just one
of many meaningful use criteria (Wright et al., 2014), it was expected a priori that many
physicians would have used CDS without achieving meaningful use. It was also expected
that a small number of physicians would have achieved meaningful use without CDS
because of exemptions from some core measures (e.g., for writing fewer than 100
prescriptions annually; see Wright et al., 2014).
Additional classification methods were planned for the two environmentalconstruct variables unique to the theory-based models (bottom two sections of Table 5).
The a priori definition of revenue from patient volume or satisfaction was based on
meeting any of the following criteria: (a) Compensation was based in part on satisfaction
surveys (COMPSAT). (b) Compensation was based in part on the practice’s financial
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Table 5
Environmental Construct Independent (Predictor) Variables and Definitions
Variable
Definition
Meaningful use, both atheoretical and theory-based models
EMEDREC
Whether the practice has an E-HR: 1 = yes, all electronic; 2 = yes, part paper, part
electronic; 3 = no
HHSMU
Whether the practice E-HR meet meaningful use criteria: 1 = yes; 2 = no; code as
2 if no E-HR
PRMCARER
Percentage of practice revenue from Medicare (to be used only to assess whether
physician may have been subject to penalties for failure to achieve meaningful
use): 1 = < 25%; 2 = 26–50%; 3 = 51–75%; 4 = > 75%
ECPOE, ECPOER,
Validation of meaningful use status (core E-HR functioning; all years): electronic
ESCRIP, ESCRIPR
prescribing and prescription transmission; recording of patient demographics,
EDEMOG, EDEMOGR
medication allergy lists, and problem lists; CDS for guideline-based care
EMEDALG,
reminders and warnings (Patel et al., 2013)
EMEDALGR
EPROLST, EPROLSTR
EREMIND, EREMINDR
EWARN, EWARNR
CDS, both atheoretical and theory-based models
ECPOE, ECPOER
Whether the office has computerized capability to order prescriptions
electronically: 1 = yes; 2 = no
EWARN, EWARNR
Whether the electronic prescribing function warns of drug interactions or
contraindications: 1 = yes; 2 = no (code as 2 if no electronic prescribing function)
Revenue, theory-based model only
COMPFIN
Binomial indicator of compensation based on financial performance of practice
COMPSAT
Binomial indicator of compensation based on satisfaction surveys of this
physician’s patients
EMPSTAT
Employment status; 1 = full owner; 2 = part owner; 3 = employee; 4 = contractor
PHYSCOMP
Best description of physician’s compensation: 1 = fixed salary; 2 = share of
practice billings or workload; 3 = mixed; 4 = hourly; 5 = other
PRPATR
Percentage of revenue that comes from patient payments: 1 = < 25%; 2 = 26–50%;
3 = 51–75%; 4 = > 75%
REVFFSR
Percentage of revenue that comes from a usual and customary fee-for-service rate:
1 = < 25%; 2 = 26–50%; 3 = 51–75%; 4 = > 75%
Nature of professional relationship, theory-based model only
SENBEFORa
New or established patient: 1 = established; 2 = new patient
PRIMCAREa
Whether this physician is the patient’s primary care provider: 1 = yes; 2 = no
PASTVISa
Number of visits this patient made to this practice in past 12 months (intervalscale)
NCMEDa
Whether the ADHD medication is new or continued (i.e., is patient history with
medication known to the physician)
Note. Variable names shown in all caps indicate NAMCS fields. Sources for NAMCS variable information were CDC
(2017, 2018, 2019b). ADHD = attention-deficit hyperactivity disorder; CDS = computerized decision support; E-HR =
electronic health record; NAMCS = National Ambulatory Medical Care Survey.
aIndicates a variable collected from the medical record rather than the induction interview.
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performance (COMPFIN) or on share of practice billings (PHYSCOMP). (c) Physician
was a full owner or part owner of the practice (EMPSTAT). (d) Percentage of revenue
from either patient payments or fee-for-service payments exceeded 25% (PRPATR and
REVFFSR). A priori planned categories for the physician-patient relationship were as
follows: patient is new (i.e., no previous relationship, SENBEFOR = 2; reference group);
patient is established, but physician is not the primary care provider (SENBEFOR = 1;
PRIMCARE = 2); physician is the primary care provider (PRIMCARE = 1). Additional
categorizations based on number of previous visits (PASTVIS), depending on the
variable’s distribution and available sample size, were also included in the a priori plan.
Dependent variable (outcome) measures. Figure 3 summarizes the binomial
dependent variable measures and definitions used in each of the two clinical scenarios.

Figure 3. Scenario subsamples (rectangles, left side) and treatment options. Indicator of
clonidine or guanfacine safety for most patients means that uses of clonidine are
potentially unsafe in patients with severe CVD, end-stage renal disease, low blood
pressure, or slow heart beat (see FDA, 2010). Uses of guanfacine are potentially unsafe in
patients with low blood pressure or slow heart beat (see FDA, 2013). No instances of
potentially unsafe use of clonidine or guanfacine were observed in the final study sample.
See Appendix C for diagnosis codes. ADHD = attention-deficit hyperactivity disorder;
CVD = cardiovascular disease; SUD = substance use disorder.
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For both scenarios, lists of safer treatment choices were based on treatment guidelines
current during the study period, which recommended atomoxetine for patients at risk of
abuse (see Bolea-Alamañac et al., 2014; Fields et al., 2017; Post & Kurlansik, 2012), and
on federal prescribing guidance (FDA 2002, 2007a). Thus, although a current European
guideline recommends extended-release stimulants or lisdexamfetamine as appropriate
alternatives for patients with SUD (Kooij et al., 2019), they were not defined as such in
this study. For the psychotherapy option in Scenario A, the a priori plan was to use the
NAMCS indicators, PSYCHOTH, which indicates whether the physician recommended
any treatment intended to change the patient’s behaviors or symptoms, and MENTAL,
which indicates mental health counseling (CDC, 2019b). Table 6 specifies the a priori
methods for measuring the diagnoses represented in Figure 3.
Table 6
Measures of Scenario Subsampling and Designation of Potentially Unsafe Prescription
Diagnosis

Role in
Scenario A
Subsampling
criterion

Role in
Scenario B
None

CVDa

Reflected in
the outcome

Subsampling
criterion

Medical condition codes: CAD, CEBVD, CHF, or IHD; or
ICD-9 or ICD-10 codes: angina, arrhythmia, cardiomegaly,
cardiomyopathy, congenital heart anomaly, hypertensive heart
disease, history of heart attack, or valvular disorder

SUD

Reflected in
the outcome

Subsampling
criterion

ETOHAB; SUBSTABb

ADHD

NAMCS variable name or measurement method
ICD-9 and ICD-10 diagnoses until 2016. Medical condition indicator
beginning in 2016

Note. Variable names shown in all caps indicate NAMCS fields. Sources for NAMCS variable information were CDC (2017, 2018,
2019b). ADHD = attention-deficit hyperactivity disorder; CAD = coronary artery disease; CEBVD = cerebrovascular disease; CHF =
congestive heart failure; CVD = cardiovascular disease; IHD = ischemic heart disease; NAMCS = National Ambulatory Medical Care
Survey; SUD = substance use disorder.
a
Adapted from Fairman et al. (2018) to indicate serious CVD, accounting for differences between claims-based and NAMCS coding
(L. Davis, personal communication, August 5, 2019). bData collectors are advised to code for ETOHAB if the medical record indicates
“alcoholism, excessive alcohol use, heavy, problem drinking, binge, or chronic drinking/drinker” (CDC, 2019b, p. 144) and for
SUBSTAB if it indicates “addiction, illicit drug use, or injection/intravenous drug use/user” (p. 146).
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Statistical Analysis Plan
The study research questions and hypotheses are summarized below.
RQ1: What is the quantitative association of medication-related CDS in the
practice environment with potentially unsafe prescribing of ADHD medications,
measured as a binomial, in a logistic regression model that accounts for knowledge
construct variables?
Ho1: (theory-based). Medication-related CDS is not significantly associated with
potentially unsafe prescribing of ADHD medications.
Ha1: (atheoretical). Medication-related CDS is associated with decreased odds of
potentially unsafe prescribing of ADHD medications, particularly for patients who have a
medical condition with a black-box warning.
RQ2: What is the quantitative association of meaningful use in the practice
environment with potentially unsafe prescribing of ADHD medications, measured as a
binomial, in a logistic regression model that accounts for knowledge construct variables?
Ho2: (atheoretical). Meaningful use is associated with decreased odds of
potentially unsafe prescribing of ADHD medications.
Ha2: (theory-based). Meaningful use is associated with increased odds of
potentially unsafe prescribing of ADHD medications.
RQ3: Which model—that based on atheoretical interventions, or that based on
theory-derived predictors—better explains the binomial measure of potentially unsafe
ADHD-medication prescribing, where better explanation is defined as coefficients in the
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expected direction, predictive accuracy measured with the c-statistic, and model fit
measured with the –2LL statistic?
Ho3: The atheoretical model better explains potentially unsafe prescribing of
ADHD medications.
Ha3: The theory-based model better explains potentially unsafe prescribing of
ADHD medications.
Software and testing procedures. In accordance with NCHS guidance for
NAMCS data (CDC, 2019b), all analyses were performed using the SPSS Complex
Samples module (v. 25.0), which adjusts variance estimates and statistical test results for
the sampling design effect (see Groves et al., 2009). Statistical significance tests were
based on an a priori alpha value of .05. The first analytic step was to characterize the four
outcome measure groups (two scenarios, binomial measure of potentially unsafe versus
safer for each) on all variables shown in Tables 4 and 5, assessing the statistical reliability
of subgroup estimates. These assessments were used to identify variables for inclusion in
remaining analyses and to calculate estimates of statistical precision for all results.
Statistical testing procedures. To answer the study research questions, I
conducted bivariate and logistic regression analyses using Complex Samples procedures
for four models—atheoretical and theory-based for each of the two clinical scenarios.
Bivariate analyses included a description of sample characteristics for each of the two
scenarios, and calculations of rates of potentially unsafe prescribing for each sample
subgroup. In the first stage of multivariate modeling, I assessed coefficients for
multicollinearity using a method recommended by Midi, Sarker, and Rana (2010).
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Specifically, because multicollinearity diagnostics are not available for logistic regression
in SPSS, I performed linear regressions of the outcome measures on predictors solely for
the purpose of obtaining tolerance and variance inflation statistics, which are standard
collinearity measures (see Warner, 2013). Despite the binary dependent variable, this
procedure was appropriate because these measures are affected only by relationships
among independent variables, not by independent-dependent variable relationships (Midi
et al., 2010). I tested the remaining predictors in logistic regression models for statistical
reliability based on NCHS standards (see CDC, 2019b). As planned a priori, I assessed
predictors for inclusion in the final models based both on the results of these tests and on
theoretical considerations.
In the final modeled logistic regressions, odds ratios and 95% CIs indicated the
odds multiplier for each predictor (e.g., meaningful use) relative to its corresponding
reference category (e.g., no meaningful use; see Warner, 2013). CI spans from < 1 to > 1
indicated nonsignificant associations. To answer RQ1 and RQ2, respectively, I compared
the two competing models on coefficients for CDS and meaningful use.
RQ3 was answered by comparing the predictive accuracy of the atheoretical with
theory-based models, based on three standard criteria. The first criterion was whether
coefficients for each of the environmental predictors were in the expected directions (e.g.,
odds ratio > 1 where a positive predictor was hypothesized; see Warner, 2013). The
second criterion was predictive accuracy based on the concordance (c) statistic, which
measures the percentage of all possible combinations of paired cases in the data set with
divergent outcomes (i.e., one visit potentially unsafe, the other safer) in which the
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prediction and outcome are concordant (i.e., the predicted probability of a potentially
unsafe prescription is greater for the potentially unsafe case than for the safer case; see
Austin & Steyerberg, 2012). A c-statistic value of .5 indicates that a model performs no
better than chance, and a 1 indicates perfect prediction.
The third criterion was statistical significance of improvement in fit, comparing
the theory-based with the atheoretical models, using a χ2 test of change in –2LL, with
degrees of freedom equal to the difference in the number of model predictors (Pampel,
2000). Because the SPSS Complex Samples logistic regression procedure does not report
–2LL automatically, I calculated –2LL for each of the two competing models using the
SPSS Compute function and the standard formula below, applied to each visit case:

LLi = (Y × ln [P]) + ((1 – Y) × ln [1 – P]));

then summed across the data set using the Complex Samples frequencies procedure to
adjust totals for the design effect (see Groves et al., 2009);
𝑛𝑛

−2𝐿𝐿𝐿𝐿𝑠𝑠𝑠𝑠𝑠𝑠 = −2 � 𝐿𝐿𝐿𝐿𝑖𝑖
𝑖𝑖=1

where Y is the actual outcome, P is the predicted probability of the outcome, and ln
indicates a natural-log transformation (see Pampel, 2000).
Threats to Validity
Internal. As in any study with a nonexperimental design, the foremost threat to
internal validity was the possibility of influence on the study outcome by unmeasured
confounding factors (see Warner, 2013), such as symptom severity, patient demands, or
features of the medical practice environment not captured in the study predictors (IVs).
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The measures of model accuracy and fit, described previously, informed an assessment of
this issue by providing an indication of the overall quality of the models. An additional
potential confounding factor was the imposition of meaningful use penalties (see Monica,
2017), which could not be measured directly using NAMCS data. A sensitivity analysis
estimated the potential effect of this factor as the number of visits made to providers who
had not achieved meaningful use by 2015 and derived at least 51% of revenue from
Medicare (PRMCARER). The possibility of residual confounding was considered in
interpretation of the results.
An additional potential threat to internal validity was the lack of direct
information about psychological mediators, such as physician cognition or emotion, that
might have been obtained from a qualitative or survey study of physician experiences
with or opinions of E-HRs. Mitigating this potential threat, the current study’s hypotheses
were informed by a large body of qualitative and quantitative evidence about the effects
of E-HR use in routine practice (see Schiff et al., 2016). Another possibility was
misclassification of exposure because of omissions of relevant data on psychiatric
diagnoses (e.g., SUD) or procedures (e.g., psychotherapy) from the medical record (see
Madden et al., 2016). I assessed these situations with data transformations and sensitivity
analyses, consistent with APA standards for analyses of archival data (see Applebaum et
al., 2018), and accounted for these assessments in data interpretation.
The final threat to internal validity was the possibility that CDS warnings were
not transmitted successfully to, or viewed by, physicians. A related question is the degree
to which CDS systems placed a higher priority on black-box patient diagnoses than on
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other potential safety issues. To validate the use of a black-box warning as indicating a
greater probability of a high-severity alert in a CDS, I reviewed information provided by
several proprietary knowledge bases, which are sources used by system developers in
populating CDS algorithms (see C. M. Cheng, DeLizza, & Kapusnik-Uner, 2013; C. M.
Cheng, DeLizza, & Kapusnik-Uner, 2014; Fung, Kapusnik-Uner, Cunningham, HigbyBaker, & Bodenreider, 2017). Searches were conducted manually for three medications,
amphetamine, atomoxetine, and methylphenidate, using subscriptions available by
membership in a health sciences university community for three knowledge bases: Facts
and Comparisons (Wolters Kluwer, 2019a), Lexicomp (Wolters Kluwer, 2019b), and
Micromedex (IBM Watson, 2019). In the three knowledge bases, black-box warnings
were displayed prominently, on the drug information landing screen for Facts and
Comparisons and Lexicomp, and via a designated tab for black-box warnings in
Micromedex. Additionally, First Databank, another commonly used information source
(see Fung et al., 2017), reported an initiative to represent black-box content
comprehensively in CDS one year prior to the current study’s start date (see C. M. Cheng
et al., 2013). Because of the many different systems and configurations in use in the
United States (CDC, 2015c), this validation exercise does not prove that all CDS
warnings for these medications accurately represented black-box information. It does
indicate that the hypothesized interaction effect for black-box warnings in the atheoretical
model was reasonable.
External. Several potential limitations on external validity were noted prior to
data analysis. One possibility considered was that NAMCS participants and
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nonparticipants differed in unmeasured ways that affected the generalizability of the data,
even after application of weights to adjust for sampling design and nonresponse. Previous
quantitative research suggested against this possibility, including the NCHS finding of
minimal nonresponse bias measured across numerous physician and visit characteristics
in 2012 (see Hing et al., 2016; Appendix A) and several studies finding little nonresponse
bias in physician surveys with low response rates (see McFarlane et al., 2007; Willis et
al., 2013; Ziegenfuss et al., 2012). Nonetheless, to assess this possibility, study analyses
included comparisons with other available published data on adult patients diagnosed
with ADHD, CVD, or SUD (see Compton et al., 2018; Fairman et al., 2017; Kooij et al.,
2019; Xian et al., 2019) or using prescribed ADHD medications (see Compton et al.,
2018; Fairman et al., 2018). A comparison with available national data on E-HR use
(ONC, 2019) was also performed.
It is also possible that patients with a formal diagnosis of ADHD, a selection
criterion for Scenario A, were not representative of all U.S. residents who have ADHD.
Previous research has found that ADHD diagnosis and treatment vary by demographic
characteristics, such as race or geographic location, to a degree that is unlikely to be
explained by neurobiology (Fairman et al., 2017; Gellad et al., 2014). This potential
threat to external validity was partly addressed by Scenario B, which was not limited to
patients with an ADHD diagnosis. The sample also lacked external validity for patients
referred to emergency care, such as for an acute cardiac event, and for surgeons.
An additional threat to external validity arose from the decision by the NCHS to
allow physicians to submit patient E-HRs in lieu of on-site data collection in 2016 (CDC,
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2019b). Because these data could not be included in the final 2016 data set, and because
the technological capabilities or practice patterns of physicians who chose E-HR data
collection may have systematically differed from those of other participants, I performed
sensitivity analyses on key findings excluding 2016, to assess whether any external
validity problem caused by this issue affected study results.
Ethical Procedures
NAMCS data are collected under provisions of the NCHS Ethics Review Board
(2018), which reviews all protocols for treatment of human subjects. Data are publicly
available online without permission or registration required for access. They are
anonymous and include no identifiable information about patients or physicians. Details
that might have the potential to identify a person or visit are truncated (e.g., age 92 or
older; body mass index less than 12 or greater than 64; CDC, 2019b). Thus, ethical
considerations related to recruitment, participant refusal, data collection, and
confidentiality were not applicable in this study. The Walden University Institutional
Review Board (IRB) approved the study on October 29, 2019 (approval number 10-2919-0761704). I considered careful interpretation and dissemination of study findings as
the most important ethical consideration for this project because of the visibility of the
topics of E-HRs (e.g., Fry & Schulte, 2019) and substance abuse (e.g., Seth et al., 2018).
Accordingly, data interpretations were conservative, emphasizing limits on statistical
reliability and considering the current study findings in the context of previous research
on physicians’ responses to interventions on their behavior.
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Summary
This quantitative study comprised retrospective, cross-sectional analyses of a
nationally representative sample of U.S. office-based physician visits made by adults.
The study outcomes (DVs) were binary indicators of whether a potentially unsafe
medication was prescribed, based on objective behavioral measures. Predictors (IVs)
were grouped into categories of knowledge constructs (e.g., patient characteristics,
clinical risk, physician specialty) and environmental constructs (i.e. CDS, meaningful
use, revenue sources, and experience with the patient (i.e., nature of physician-patient
professional relationship) and medication (i.e., whether new or continued). Standard
statistical measures from logistic regression analyses, including odds ratios, 95% CIs, and
measures of predictive accuracy and goodness of fit, were used to compare the relative
merits of theory-based and atheoretical approaches to explaining the study outcomes.
In Chapter 4, I present study findings. These include descriptive characteristics of
the sample and both bivariate and multivariate analyses of the relationships between the
outcomes and predictors. Also included are assessments of sample generalizability,
quantitative measures of multicollinearity and reliability, and sensitivity analyses to
assess the potential effects of threats to external and internal validity on study results.
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Chapter 4: Results
The purpose of this quantitative study was to assess the relative strengths of
atheoretical and theory-based approaches to promotion of evidence-based medicine by
comparing logistic regression models on standard measures of accuracy and fit. The
binary outcome (DV) measure was potentially unsafe prescribing of ADHD medications
for adults seen in office-based physician visits. Key predictor (IV) measures, representing
environmental constructs in social cognitive theory, included CDS, meaningful use,
revenue derived from patient volume or satisfaction, and experience with the patient and
medication. Additional predictors were knowledge-construct variables, including
expertise (i.e., physician specialty) and information necessary for prescribing (e.g.,
patient characteristics; Kelder et al., 2015). These knowledge-construct predictors were
considered exogenous to the office visit and were treated as equivalent in the two models.
Research questions and hypotheses included the following:
RQ1: What is the quantitative association of medication-related CDS in the
practice environment with potentially unsafe prescribing of ADHD medications,
measured as a binomial, in a logistic regression model that accounts for knowledge
construct variables?
Ho1: (theory-based). Medication-related CDS is not significantly associated with
potentially unsafe prescribing of ADHD medications.
Ha1: (atheoretical). Medication-related CDS is associated with decreased odds of
potentially unsafe prescribing of ADHD medications, particularly for patients who have a
medical condition with a black-box warning.
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RQ2: What is the quantitative association of meaningful use in the practice
environment with potentially unsafe prescribing of ADHD medications, measured as a
binomial, in a logistic regression model that accounts for knowledge construct variables?
Ho2: (atheoretical). Meaningful use is associated with decreased odds of
potentially unsafe prescribing of ADHD medications.
Ha2: (theory-based). Meaningful use is associated with increased odds of
potentially unsafe prescribing of ADHD medications.
RQ3: Which model—that based on atheoretical interventions, or that based on
theory-derived predictors—better explains the binomial measure of potentially unsafe
ADHD-medication prescribing, where better explanation is defined as coefficients in the
expected direction, predictive accuracy measured with the c-statistic, and model fit
measured with the –2LL statistic?
Ho3: The atheoretical model better explains potentially unsafe prescribing of
ADHD medications.
Ha3: The theory-based model better explains potentially unsafe prescribing of
ADHD medications.
In this chapter, I explain sequential steps in data collection and processing,
discuss characteristics of patients and physicians included in each of the study’s two
clinical scenarios, and assess the sample’s external validity by comparing its
characteristics with those of other large samples. Following a descriptive overview of
rates of potentially unsafe prescribing, I consider the assumptions and findings of the
logistic regression analyses and of several sensitivity analyses. The chapter concludes
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with a summary of answers to the research questions. Throughout the chapter, counts of
visits are raw and unweighted, percentages and odds ratios (ORs) are weighted as
nationally representative estimates, and all statistical tests and confidence intervals (CIs)
are adjusted for the multistage sampling design using the IBM SPSS (V25.0) Complex
Samples module.
Data Collection and Processing
After receiving approval from the Walden University IRB to access the study data
on the NCHS website, I downloaded all NAMCS records of U.S. office-based physician
visits made from 2014 to 2016 and combined them into a single analytic file. The file
contained all study predictors (IVs) and data needed to compute the binary outcome
(DV), as described in Chapter 3. From that data set of visits (unweighted N = 87,207), I
excluded visits made by patients younger than 17 years (n = 12,939) or by those sent to
emergency care (n = 344), and visits made to surgeons (n = 25,640), leaving an
unweighted total of 48,284 visits.
Post Hoc Analytic Adjustments
During initial data processing and prior to creation of the cohorts (i.e., groups of
visits) for Scenario A and Scenario B, I identified several unexpected practice patterns.
These, along with the data transformations used to resolve them and rationales for each,
are summarized in Table 7. In accordance with the recommendations of the APA
(Applebaum et al., 2018), which represent general reporting standards for quantitative
research, and of the International Society for Pharmacoeconomics and Outcomes
Research, which are specific to archival medical data (Berger, Mamdani, Atkins, &
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Table 7
Data Modifications Made After Accessing Data and Prior to Analyses of Results
Practice pattern
• Missing data on BMI and
blood pressure for 47% of
visits.
• Unable to calculate the
planned cardiovascular risk
score.

Data modification
Replace risk score with
interval scale age.

Rationale
• Imputation technique not feasible
because of large number of
affected records.
• Age known to be the primary
predictor of cardiovascular risk.a

• Missing data on meaningful
use variable for 1,231 of
48,284 visits.
• Most were “unknown” in
induction interview.

Base meaningful use
indicator, when missing, on
specific system functions
(e.g., electronic problem
lists, electronic reminders).

• In a priori validation assessment,
96% of physicians who reported
meeting meaningful use criteria
had 6 or 7 of required functions,
and 83% had all 7.

• Generic, rather than brand,
forms of Kapvay and Intuniv
were prescribed.

Code generics as Kapvay
and Intuniv for patients with
ADHD and without
hypertension.

• Consistent with product labels for
these medications.b

• For 230 of 2,270 substance
abuse visits, counseling was
provided without an explicit
diagnosis of SUD.

Count the provision of
alcohol abuse counseling or
substance abuse counseling
as an indicator of substance
use disorder.

• Substance abuse counseling is
recommended for hazardous use,
even if not dependent.c
• Many abuses of ADHD
medications are hazardous but not
necessarily dependent.d

• For 1,181 visits provided by
psychiatrists or mental health
providers, no explicit code for
psychotherapy or counseling
was included in the record.

Count a visit with a mental
health provider or
psychiatrist as psychological
counseling, even if not
explicitly coded as such.

• Excluding these as “no treatment”
visits from Scenario A could have
resulted in external validity error
• 975 included a diagnosis of a
psychiatric disorder

• The variable REVFFSR,
planned for use as an indicator
of patient revenue, was coded
for a higher than expected
number of visits and may have
represented a payment
calculation method rather than
source of payment.

Remove fee-for-service
revenue from the definition
of patient-derived revenue.
Base only on the other a
priori indicators:
compensation type,
ownership status, patient
payments, and payment on
satisfaction measures.

• No published criteria for patientderived revenue were identified in
the literature review.
• Of 31,306 visits coded with
REVFFSR, 9,097 were to
physicians paid a salary, and
11,891 to physician employees.

Note. Generic names for Kapvay and Intuniv, respectively, are clonidine and guanfacine. ADHD = attention-deficit hyperactivity
disorder; BMI = body mass index; REVFFSR = percentage of revenue from “usual, customary, and reasonable fee-for-service” (CDC,
2019b, p. 79); FDA = U.S. Food and Drug Administration.
a
Karmali, Goff, Ning, and Lloyd-Jones (2014). bFDA (2010, 2013). cMoyer and Preventive Services Task Force (2013); B. Shapiro,
Coffa, and McCance-Katz (2013). dCompton et al. (2016); Weyandt et al. (2016).
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Johnson, 2009), I planned three sensitivity analyses to assess the effects of these data
transformations: (a) exclude substance abuse visits in which abuse counseling was
provided without a specific diagnosis of SUD, (b) exclude visits made to mental health
professionals without a specific indicator for psychotherapy, and (c) modify the definition
of patient-derived revenue to reflect only direct financial compensation. These sensitivity
analyses, along with the analysis of results excluding 2016 that was planned a priori, are
reported in the Additional Analyses section later in the chapter.
Formation of Scenario Cohorts
Of 48,284 sampled visits, 902 included a diagnosis of ADHD. Of these, 810
qualified for inclusion in the Scenario A cohort by the prescribing of a treatment:
medication only (n = 300, 35.5%), psychotherapy or counseling only (n = 108, 11.9%), or
both (n = 402, 52.6%). The Scenario B cohort comprised 9,101 visits made by patients
with CVD only (n = 6,858, 72.3%), SUD only (n = 1,963, 24.1%), or both CVD and SUD
(n = 280, 3.6%). Of Scenario B visits, 155 (1.6%) included the prescribing of ADHD
medication. Of Scenario B cohort visits where medication was prescribed, 88 (54.8%)
were made by a patient with an ADHD diagnosis.
Statistical Testing Procedures
As planned a priori, the statistical testing process included assessments of sample
size adequacy and multicollinearity, discussed in this section, and logistic regression
coefficient statistical reliability. These tests were used to measure adherence of analyses
to NCHS statistical reliability standards (see CDC, 2019b) and to the assumptions of
logistic regression analysis (see Warner, 2013).
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Sample size adequacy. Sample size assessments of the four study subgroups (i.e.,
binary indicator of potentially unsafe medication versus safer option for each of two
scenarios) produced mixed findings. Most estimates in Scenario A (Appendix D) and
nearly all in Scenario B (Appendix E) met NCHS standards for CI width. However, no
estimates in Scenario A had a design effect-adjusted denominator of > 30 (see Parker et
al., 2017). In Scenario B, estimates for the potentially unsafe medication group, but not
for the safer group, met the denominator standard.
For two predictors (IVs), the cell (subgroup) sizes in the crosstabulation between
the independent and dependent variables were so small that the variables had to be
excluded from multivariate modeling. The first was black-box warning in Scenario A,
because only nine of 81 potentially unsafe prescriptions were for patients without SUD.
The second was continued versus new prescription in Scenario B, because nearly all (11
of 12) safer prescriptions were continued (i.e., only one new).
Multicollinearity assessments. Multicollinearity must be assessed when using
multivariate techniques because excessive overlap in variance among independent
variables makes model coefficients unreliable (Fox, 1991). Using the method described
by Midi et al. (2010), I performed linear regression analyses to assess multicollinearity
based on tolerance (i.e., 1 – R2 for each predictor regressed on all other predictors; see
Warner, 2013) and on variance inflation factor (i.e., reciprocal of tolerance, a measure of
coefficient instability; see Fox, 1991). Because one variable, age, showed considerable
multicollinearity with the a priori age-category indicators (aged 26–49 years; aged > 50
years; Appendix F), I replaced the categorical variables with interval-scale age.
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Statistics for CDS and meaningful use did not indicate excessive multicollinearity
(models without interaction terms: tolerance = .360–.414 for Scenario A; tolerance =
.572–.574 for Scenario B), likely because the requirement for CDS in meaningful use
may be waived (see Wright et al., 2014). A follow-up analysis (not shown in appendix)
indicated that of those with meaningful use, 6.3% in Scenario A and 3.1% in Scenario B
did not have CDS.
Results
Sample Description
Sample characteristics for visits in each clinical scenario are shown in Table 8.
Several differences between the cohorts were consistent with the selection criteria for
each. In Scenario A, the plurality (47.8%) of adult patients treated for ADHD were aged
26–49 years; in Scenario B, most (81.8%) patients with CVD or SUD were aged 50 years
or older, likely because the most prevalent selection criterion in this group was CVD.
Mean (standard deviation) ages were 35.8 (14.4) years in Scenario A and 64.3 (17.1)
years in Scenario B. Consistent with these demographic characteristics, private insurance
was the dominant source of payment (57.0%) in Scenario A, whereas Medicare was
predominant (54.2%) in Scenario B.
Depression and anxiety were more common in Scenario A (35.1% and 28.7%,
respectively), than in Scenario B (16.3% and 6.1%, respectively). Consistent with these
differences, psychiatric visits were common (60.6%) in Scenario A, but most Scenario B
visits (69.5%) were provided by physicians who did not specialize in either cardiology or
psychiatry. Use of CDS and achievement of meaningful use were more common in
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Table 8
Sample Characteristics, U.S. Office-Based Physician Visits Made by Adults, 2014–2016

All patients
Age group (years)b
17–25
26–49
50 or older
Sex
Female
Male
Race and ethnicity
White, non-Hispanic
Black, non-Hispanic
Hispanic
Other
Primary payment source
Private
Medicaid
Medicare
Other
Office location
Urban
Nonurban
Physician specialty
Cardiology
Psychiatry
Neither of these
Black-box diagnosis
Yes
No
Charlson comorbiditiesc
None
One
Two
Three or more
Psychiatric comorbidities
Depression
Anxiety
Relationship with patient
New
Established, not PCP
PCP
Environmental features
CDS
Meaningful use
Patient-derived
revenue

Scenario A: patients with ADHD
Unweighted
Weighted %a
95% CI
n
810
100.0
NA

Scenario B: patients with CVD or SUD
Unweighted n
Weighted %a
95% CI
9,101

100.0

NA

251
401
158

31.0
47.8
21.3

[26.2, 36.2]
[41.6, 54.0]
[17.1, 26.1]

259
1,326
7,516

3.0
15.2
81.8

[2.3, 3.8]
[13.1, 17.6]
[79.2, 84.2]

423
387

53.4
46.6

[48.0, 58.7]
[41.3, 52.0]

4,192
4,909

46.1
53.9

[44.2, 48.0]
[52.0, 55.8]

708
34
43
25

86.3
4.7
5.6
3.4

[82.2, 89.6]
[2.8, 7.8]
[4.0, 8.0]
[2.0, 5.5]

7,503
735
571
292

77.4
9.4
9.3
3.9

[74.5, 80.1]
[8.0, 10.9]
[7.3, 11.8]
[3.1, 4.9]

439
95
46
189

57.0
13.1
5.6
24.2

[47.0, 66.5]
[8.4, 19.9]
[3.5, 9.0]
[15.1, 36.5]

2,670
663
4,725
440

31.8
7.6
54.2
6.4

[29.5, 34.1]
[6.2, 9.4]
[51.5, 56.9]
[4.7, 8.7]

756
54

91.9
8.1

[80.3, 96.9]
[3.1, 19.7]

8,120
981

90.0
10.0

[86.8, 92.6]
[7.4, 13.2]

3
493
314

0.2
60.6
39.2

[0.1, 1.0]
[50.8, 69.6]
[30.2, 49.0]

2,882
492
5,727

25.2
5.3
69.5

[20.7, 30.2]
[4.0, 7.0]
[64.6, 74.0]

105
705

11.4
88.6

[8.0, 16.0]
[84.0, 92.0]

2,243
6,858

27.7
72.3

[24.3, 31.3]
[68.7, 75.7]

767
35
6
2

94.1
4.3
0.9
0.7

[91.1, 96.1]
[2.7, 6.9]
[0.3, 2.8]
[0.1, 3.6]

5,257
1,921
1,150
773

56.7
21.1
12.8
9.4

[53.4, 60.0]
[19.2, 23.1]
[11.4, 14.3]
[7.0, 12.5]

307
215

35.1
28.7

[28.8, 41.9]
[22.6, 35.6]

1,443
502

16.3
6.1

[14.6, 18.1]
[4.7, 7.9]

66
503
220

9.5
64.8
25.7

[6.5, 13.5]
[57.1, 71.8]
[19.4, 33.3]

1,133
4,610
3,147

10.7
44.2
45.1

[9.3, 12.2]
[39.7, 48.8]
[40.8, 49.4]

469
474
732

65.1
60.9
92.0

[53.3, 75.3]
[49.2, 71.5]
[86.1, 95.6]

7,901
8,036
7,435

89.6
87.8
85.7

[86.4, 92.1]
[84.4, 90.6]
[82.4, 88.5]

Note. ADHD = attention-deficit hyperactivity disorder; CDS = computerized decision support; CI = confidence interval; CVD =
cardiovascular disease; NA = not applicable; PCP=primary care provider; SUD = substance use disorder.
a
Percentage of total visits after application of sample weights, accounting for design effect (Groves et al., 2009) using IBM SPSS for
Complex Samples. Design effect-adjusted denominators < 30 for all estimates; interpret results cautiously. bMean (standard deviation)
ages (years) were 35.8 (14.4) in Scenario A and 64.3 (17.1) in Scenario B. cBased on weighted combinations of diagnoses, summed to
indicate total comorbidity burden (Quan et al., 2011).
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Scenario B (89.6% and 87.8%, respectively) than in Scenario A (65.1% and 60.9%,
respectively), likely reflecting greater adoption of E-HRs by nonspecialists than by
specialists (see Patel et al., 2013).
Assessment of External Validity
Comparisons of patient and provider-office characteristics in the present sample
with those of national and other large-sample data suggested generally good external
validity (Appendix G). A few exceptions were consistent with methodological
differences between the current study sample and those of previous work. The most
notable was that the reported rates of prescribed stimulant use among persons with SUD
were much higher in a household survey by Compton et al. (2018), such as 25.8% of
those with opioid use disorder, than in the current study of office visits (4.1%). Despite
this difference, the rate of SUD among adults with ADHD was reported in a review
article as 11% (Kooij et al., 2019), compared with 11.4% in the present sample of visits
made by adults receiving treatment for ADHD (i.e., either medication or psychotherapy).
Also similar were the rates of E-HR use reported by the U.S. ONC (2019) for 2014–2015
(82.8–86.9%) as a percentage of physicians, compared with this sample’s percentage of
visits in that time period (89.1%).
Characteristics of patients with CVD reported in a large registry study (Xian et
al., 2019) were similar, but not identical, to those of patients with CVD in the present
national sample, with statistically significant differences on Pearson χ2 test
(http://vassarstats.net/newcs.html) due partly to large sample size (N = 3,232 in Xian et
al., 2019; N = 7,138 in the current study). Examples include prevalence rates for diabetes
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(39.8% versus 31.8%, respectively, χ2[1] = 62.92, p < .001), hypertension (85.2% versus
74.0%, χ2[1] = 158.3, p < .001), and percentage female (36.2% versus 46.3%, χ2[1] =
90.55, p < .001). Comparisons to the sample of patients with ADHD reported by Fairman
et al. (2018) were similar for percentage female (53.3% in the present sample, 51.1%
reported by Fairman et al., 2018) and percentage with SUD (11.7–18.8% vs. 10.0%,
respectively), but the age distributions differed somewhat. These differences were not
tested for statistical significance because of large sample size (N = 91,588) in the study
by Fairman et al. When interpreting these results, researchers should note that the study
by Fairman et al. was limited to commercially insured patients.
Bivariate Measures of Study Outcomes and Knowledge Construct Predictors
Of visits included in Scenarios A and B, respectively, 81 (weighted 8.3%, 95% CI
[5.6, 12.1]) and 143 (weighted 1.5%, 95% CI [1.1, 2.0]) included the prescribing of a
potentially unsafe medication (see Table 9). In Scenario A, significant bivariate
knowledge-construct predictors of potentially unsafe prescribing included male sex and
White, non-Hispanic race. In Scenario B, significant bivariate knowledge-construct
predictors included younger age; male sex; White, non-Hispanic race; private or other
non-public payment source; psychiatrist specialty; depression; and anxiety. In both
scenarios, black-box medical condition was a significant positive predictor, although the
rates for Scenario A are difficult to interpret because of the small cell sizes described
previously.
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Table 9
Percentage of Visits Resulting in Potentially Unsafe Prescription for ADHD Medication,
by Knowledge-Construct Predictors, U.S. Office-Based Physician Visits Made by Adults,
2014–2016
Scenario A: patients with ADHD
Weighted %a
95% CI
P
valueb
All patients
8.3
[5.6, 12.1]
NA
Age group (years)
.182
17–25
6.2d
[3.1, 12.3]
26–49
10.7
[6.7, 16.6]
50 or older
5.8c,d
[2.9, 11.5]
Sex
.039
Female
6.0c
[3.7, 9.7]
Male
10.8
[2.6, 6.7]
Race and ethnicity
.037
White, non-Hispanic
9.1c
[6.1, 13.4]
Black, non-Hispanic
5.5c,d
[1.7, 16.2]
Hispanic
2.5c,d
[0.6, 9.7]
Other
0.7c,d
[0.1, 5.5]
Primary source of payment
.097
Private
6.6c
[4.2, 10.3]
Medicaid
6.1c,d
[2.6, 13.7]
Medicare
5.5c,d
[1.7, 16.5]
Other
15.3c,d
[6.6, 31.5]
Office location
.740
Urban
8.1c
[5.4, 12.0]
Nonurban
10.3c,d
[2.5, 33.6]
Physician specialty
.261
Cardiology
Not calculated; n = 3
Psychiatry
8.7c
[5.1, 14.6]
Neither of these
7.3
[4.3, 12.0]
Black-box diagnosis
< .001
Yes
67.8d
[50.2, 81.5]
No
0.6c,d
[0.3, 1.2]
e
Charlson comorbidities
.719
None
8.0c
[5.3, 12.0]
One
14.2c,d
[5.2, 33.3]
Two
Not calculated; n = 6
Three or more
Not calculated; n = 2
Depression
.732
No
7.9c
[4.7, 13.2]
Yes
8.9
[5.5, 14.1]
Anxiety
.099
No
9.5c
[6.2, 14.2]
Yes
5.3c,d
[2.7, 10.1]

Scenario B: patients with CVD or SUD
Weighted %a
95% CI
P
valueb
1.5
[1.1, 2.0]
< .001
8.5
[4.7, 14.9]
4.4
[2.9, 6.5]
0.7
[0.4, 1.1]
.040
1.1
[0.8, 1.6]
1.8
[1.2, 2.7]
< .001
1.8
[1.3, 2.5]
0.5d
[0.2, 1.6]
0.2d
[0.1, 0.7]
0.5d
[0.1, 2.8]
< .001
2.2
[1.4, 3.2]
1.5d
[0.7, 2.9]
0.2d
[0.1, 0.4]
8.4c
[4.6, 14.8]
.503
1.5
[1.1, 2.1]
1.1d
[0.5, 2.6]
< .001
0.3c
[0.1, 0.7]
13.5
[8.8, 20.3]
1.0
[0.7, 1.5]
< .001
4.1
[2.8, 5.8]
0.5
[0.3, 0.9]
.060
2.1
[1.5, 2.9]
0.7
[0.4, 1.3]
0.7c
[0.1, 3.8]
0.7b,c
[0.2, 3.0]
< .001
1.1
[0.8, 1.6]
3.4
[2.2, 5.2]
.004
1.3c
[1.0, 1.8]
3.6d
[1.8, 7.2]

Note. ADHD = attention-deficit hyperactivity disorder; CI = confidence interval; CVD = cardiovascular disease; SUD = substance use
disorder.
a
Percentage of total visits after application of sample weights, accounting for design effect (see Groves et al., 2009). bPearson χ2 test,
adjusted for design effect (see Groves et al., 2009).cIndicates an estimate that failed the design effect-adjusted denominator check.
d
Indicates an estimate that failed checks on absolute or relative confidence interval width. eBased on weighted combinations of
diagnoses, summed to indicate total comorbidity burden (Quan et al., 2011).
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Assessment of Assumptions for Logistic Regression Analysis
Logistic regression analysis facilitates quantitative assessments of the associations
of predictor variables with binary outcomes (DVs). The study data and model met
assumptions for the technique, including an outcome with two, mutually exclusive
categories (i.e., potentially unsafe versus safer) and statistically independent observations
(see Warner, 2013). An assumption common to all multivariate techniques, that the
model be correctly specified (see Warner, 2013), is assessed in the presentation of results
for RQ3.
Statistical Reliability of Logistic Regression Coefficients
Predictors chosen for inclusion in the models were based on the literature review
described in Chapter 2. Initial logistic regression modeling of all predictors revealed that
most coefficients did not meet NCHS statistical reliability standards of relative standard
error < 30% and > 30 cases (see CDC, 2019b; Appendix H). Using the a priori
procedures described in Chapter 3, I made decisions about these coefficients based on
statistical and theoretical considerations. To balance statistical precision against inclusion
of all coefficients suggested by the theoretical frameworks, I removed from the equations
any knowledge-construct factor meeting both of the following criteria: (a) the standard
error exceeded the absolute value of the coefficient estimate (β), and (b) the estimate was
based on < 30 cases. For the measures of physician-patient relationship, this change was
made by replacing the graded measure, encompassing both primary care provider
relationship and number of previous visits, with a single dummy-variable indicator for
primary care provider. I maintained the integrity of the process by making only one such
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decision rule, applying it equally to both models and scenarios, and testing no additional
decision rules or models. It should be noted that even after this procedure, most
coefficients did not meet NCHS standards; results should be interpreted cautiously.
Assessments of Study Research Questions
Final, full logistic regression analyses for the atheoretical and theory-based
models are shown in Appendix I and Appendix J, respectively. The tables accompanying
the analyses of each research question, shown in the next section, are excerpts of relevant
sections from each of these full models. As planned a priori, both the atheoretical and
theory-based models included knowledge-construct factors. Both models included
coefficients for the environmental-construct predictors CDS and meaningful use, with
competing hypotheses for each. The theory-based model included, in addition, predictors
for patient-derived revenue, primary care provider relationship with the patient, and
experience with the medication (i.e., continued versus new).
Both models were statistically significant overall for both scenarios: atheoretical
models, Scenario A χ2(9) = 31.03, p < .001, Scenario B χ2(12) = 306.59, p < .001;
theory-based models, Scenario A χ2(12) = 36.41, p < .001, Scenario B χ2(13) = 305.68, p
< .001 (Table 10). Knowledge-construct predictors significantly associated with
potentially unsafe prescribing were similar in the atheoretical and theory-based models
(Appendix I; Appendix J) and consistent with most bivariate results described previously.
These included older age in Scenario B and anxiety in both scenarios, which were
negatively associated with the outcome, and psychiatric care in both scenarios, which was
positively associated with the outcome.
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Table 10
Model Statistics, Scenarios A and B, Complex Samples Logistic Regression Analyses of
U.S. Office-Based Physician Visits Made by Adults, 2014–2016

Atheoretical model
Unweighted number of visits
Number of physicians (strata)
“c” (concordance) Statistic
Nagelkerke R2
Model χ2 (critical χ2; df), p
Theory-based model
Unweighted number of visits
Number of physicians (strata)
“c” (concordance) Statistic
Nagelkerke R2
Model χ2 (critical χ2; df), p

Scenario A: patients with ADHD,
potentially unsafe prescription versus
any other treatment (safer medication
or psychotherapy)

Scenario B: patients with CVD or SUD,
potentially unsafe prescription versus no
potentially unsafe prescription

669
301 (101)
.572
.099
31.03 (16.92; df = 9), p < .001

8,685
1659 (130)
.870
.243
306.59 (21.03; df = 12), p < .001

669
301 (101)
.587
.116
36.41 (21.03; df = 12), p < .001

8,685
1659 (130)
.871
.243
305.68 (22.36; df = 13), p < .001

Note. Critical χ2 calculated for α = .05. ADHD = attention-deficit hyperactivity disorder; CVD = cardiovascular disease; df =
degrees of freedom; LL = log likelihood; SUD = substance use disorder.

Results for RQ1: CDS
RQ1 addressed the association of CDS with the binary outcome of potentially
unsafe prescribing. The theory-based hypothesis was that CDS is not significantly
associated with the study outcome; and the atheoretical hypothesis was that CDS is
associated with a significant decrease in the outcome, especially for patients with blackbox warning status. As described previously, the black-box variable, and its interaction
term with CDS, could not be tested in Scenario A because of small cell counts.
In the atheoretical models, CDS was not significantly associated with the outcome
in either clinical scenario (Scenario A: OR = 0.538, 95% CI [0.127, 2.284]; Scenario B:
OR = 0.245, 95% CI [0.053, 1.137]; Table 11). In Scenario B, the interaction term for
CDS with black-box warning was also nonsignificant (OR = 1.836, 95% CI [0.400,
8.428]). Results for CDS were similarly nonsignificant in the theory-based model of
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Scenario A (OR = 0.570, 95% CI [0.128, 2.531]) but indicated a significant decrease in
odds of the outcome in Scenario B (OR = 0.402, 95% CI [0.180, 0.898]). The
nonsignificant results should be viewed as inconclusive because the coefficients were not
statistically reliable. Based on the one significant result observed, findings indicated
partial support for the atheoretical hypothesis that CDS is associated with decreased odds
of prescribing potentially unsafe ADHD medications to adults.
Table 11
Results for CDS, Scenarios A and B, Complex Samples Logistic Regression Analyses of
U.S. Office-Based Physician Visits Made by Adults, 2014–2016

Predictor

Reference
Group
Atheoretical model
CDS
No CDS
BBW × CDS No
interaction
Theory-based model
CDS
No CDS

Scenario A: patients with ADHD,
potentially unsafe prescription versus
any other treatment (safer medication or
psychotherapy)
β
SE
OR
95% CI

Scenario B: patients with CVD or SUD,
potentially unsafe prescription versus no
potentially unsafe prescription
β

SE

OR

–0.620 .733 0.538 [0.127, 2.284]
Not included in model; removed in
sample size-adequacy test

–1.406
0.608

.782
.777

0.245
1.836

[0.053, 1.137]
[0.400, 8.428]

–0.563

–0.913

.410

0.402

[0.180, 0.898]

.756

0.570

[0.128, 2.531]

95% CI

Note. Bold text denotes a statistically significant predictor. Excerpted from full atheoretical and theory-based models shown in
Appendix I and Appendix J, respectively. ADHD = attention-deficit hyperactivity disorder; BBW = black-box warning; CDS =
computerized decision support; CI = confidence interval; CVD = cardiovascular disease; OR = odds ratio (exponentiated β); SE =
standard error; SUD = substance use disorder.

Results for RQ2: Meaningful Use
RQ2 addressed the association of meaningful use achievement with the study
outcome, with decreased odds hypothesized in the atheoretical models and increased odds
hypothesized in the theory-based models. In the atheoretical models, the coefficients for
meaningful use were positive and statistically significant in both Scenario A (OR =
4.961, 95% CI [1.124, 21.898] and Scenario B (OR = 2.865, 95% CI [1.265, 6.488];
Table 12). Results were similar in the theory-based models, although the coefficient in
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Scenario A was not statistically significant (Scenario A: OR = 4.046, 95% CI [0.823,
19.884]; Scenario B: OR = 2.922, 95% CI [1.275, 6.698]). Thus, results generally
supported the theory-based hypothesis, suggesting meaningful use is associated with
approximately tripled odds of prescribing potentially unsafe ADHD medications to
adults.
Table 12
Results for Meaningful Use, Scenarios A and B, Complex Samples Logistic Regression
Analyses of U.S. Office-Based Physician Visits Made by Adults, 2014–2016

Predictor

Reference
Group
Atheoretical model
Meaningful
No
use
meaningful
use
Theory-based model
Meaningful
No
use
meaningful
use

Scenario A: patients with ADHD,
potentially unsafe prescription versus any
other treatment (safer medication or
psychotherapy)
β
SE
OR
95% CI

Scenario B: patients with CVD or SUD,
potentially unsafe prescription versus no
potentially unsafe prescription
β

SE

OR

1.602

.753

4.961

[1.124, 21.898]

1.053

.417

2.865

[1.265, 6.488]

1.398

.807

4.046

[0.823, 19.884]

1.072

.423

2.922

[1.275, 6.698]

95% CI

Note. Bold text denotes a statistically significant predictor. Excerpted from full atheoretical and theory-based models shown in
Appendix I and Appendix J, respectively. ADHD = attention-deficit hyperactivity disorder; CI = confidence interval; CVD =
cardiovascular disease; OR = odds ratio (exponentiated β); SE = standard error; SUD = substance use disorder.

Results for RQ3: Predictive Accuracy and Model Fit
Changes to several environmental-construct predictors, described previously,
prevented full testing of either the atheoretical or theory-based models. These changes
included (a) removal of the term for interaction of CDS with black-box warning in
Scenario A, (b) removal of the indicator for continued versus new prescription in
Scenario B, and (c) recoding of the variable for physician-patient relationship to a binary
indicator of primary care provider status in both scenarios. Assessments of the relative
merits of the atheoretical and theory-based models included whether coefficients were in
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the predicted direction; the c (concordance) statistic, which measures predictive accuracy;
and change in the –2LL statistic, which measures model fit.
Direction of coefficients. As noted in the discussions of RQ1 and RQ2, results
for CDS were inconclusive but provided some support for the atheoretical hypothesis,
and results for meaningful use supported the theory-based hypothesis. Two additional
coefficients for variables unique to the theory-based models were not statistically
significant: primary care provider status in both scenarios (Scenario A: OR = 0.873, 95%
CI [0.287, 2.656]; Scenario B: OR = 1.088, 95% CI [0.475, 2.495]) and experience with
the medication (i.e., continued versus new prescription) in Scenario A (OR = 0.773, 95%
CI [0.438, 1.366]; Table 13). The coefficient for patient-derived revenue in Scenario A
indicated significantly reduced odds of the outcome (OR = 0.390, 95% CI [0.156,
Table 13
Results for Variables Unique to the Theory-Based Models, Scenarios A and B, Complex
Samples Logistic Regression Analyses of U.S. Office-Based Physician Visits Made by
Adults, 2014–2016

Predictor
Patientderived
revenue

Reference
Group
No revenue
on this basis

Scenario A: patients with ADHD,
potentially unsafe prescription versus
any other treatment (safer medication or
psychotherapy)
β
SE
OR
95% CI

Scenario B: patients with CVD or SUD,
potentially unsafe prescription versus no
potentially unsafe prescription
β

SE

OR

–0.941

.465

0.390

[0.156, 0.976]

0.113

.374

1.119

[0.538, 2.330]

.423

1.088

[0.475, 2.495]

95% CI

PCP

Physician is
not the PCP

–0.136

.564

0.873

[0.287, 2.656]

0.085

Continuing
prescription

New
prescription

–0.257

.289

0.773

[0.438, 1.366]

Not included in model; removed in
sample size adequacy test

Note. Bold text denotes a statistically significant predictor. ADHD = attention-deficit hyperactivity disorder; CI = confidence interval;
CVD = cardiovascular disease; OR = odds ratio (exponentiated β); PCP = primary care provider; SE = standard error; SUD =
substance use disorder.
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0.976]), contrary to the theory-based hypothesis. In Scenario B, the coefficient for
patient-derived revenue was not significant (OR = 1.119, 95% CI [0.538, 2.330]).
C (concordance) statistic. The c-statistic is measured on a scale of .5, indicating
a model that performs no better than random assignment, to 1.0, indicating a model that
perfectly predicts the outcome (Austin & Steyerberg, 2012). As noted in the description
of Table 10, both the atheoretical and theory-based models had weak predictive accuracy
(.572 and .587, respectively) for Scenario A, whereas both models had excellent
predictive accuracy (.870 and .871, respectively) for Scenario B. These findings indicated
that the Scenario B model was generally better specified than was the Scenario A model.
Additionally, these c-statistics indicated only modest improvement for the
theory-based model in Scenario A, and no improvement in Scenario B, compared with
the atheoretical model.
Statistical significance of change in model fit. Results of tests of between-model
differences in fit are shown in Table 14. For both Scenarios A and B, results indicated
change in model χ2 less than critical χ2 for the theory-based model compared with the
atheoretical model, indicating no significant improvement in goodness of fit.
Summary of results for RQ3. Assessments of coefficient direction produced
mixed results, mostly in favor of the atheoretical model. Only the results for meaningful
use were consistent with the theory-based hypotheses. Moreover, the theory-based
models did not improve predictive accuracy or fit compared with the atheoretical models.
Nonetheless, findings for RQ3 should be viewed as somewhat inconclusive because
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Table 14
Atheoretical and Theory-Based Model Fit, Scenarios A and B, Logistic Regression
Analysis of U.S. Office-Based Physician Visits Made by Adults, 2014–2016

Baseline (no predictor) model –2LL
Model –2LL
Model χ2 (change in –2LL)

Scenario A: patients with
ADHD
Atheoretical
Theory-based
410.09
410.09
379.07
373.69
31.03
36.41

Model χ2 change: atheoretical to theory-based models
Degrees of freedom (change in
3
number of variables )
Model χ2 (change)
5.38
Critical χ2 (df), α = .05
7.81 (3)

Scenario B: patients with
CVD or SUD
Atheoretical
Theory-based
1335.71
1335.71
1029.11
1030.02
306.59
305.68

1
–0.91
3.84 (1)

Note. ADHD = attention-deficit hyperactivity disorder; CVD = cardiovascular disease; df = degrees of freedom; LL = log likelihood;
SUD = substance use disorder.

neither the atheoretical nor theory-based models could be fully tested, and because of
modest predictive accuracy in the models of Scenario A.
Additional Analyses
Sensitivity analyses, logistic regression models. Sensitivity analyses included
calculations of model c-statistics, ORs, and 95% CIs for key environmental-construct
predictors under several conditions: (a) excluding 2016, (b) excluding visits with
substance abuse counseling but no code for SUD, and (c) modifying the definitions of
patient-derived revenue (Table 15). A planned sensitivity analysis of visits to mental
health professionals without a specific indicator for psychotherapy was not performed
because it affected only six visits in Scenario A, and, by design, it did not affect Scenario
B, in which neither selection criteria nor outcome were affected by psychotherapy.
Findings for meaningful use and primary care provider relationship were
consistent across most models. For CDS, sensitivity analyses were consistent with main
findings in Scenario A, but four of seven analyses in Scenario B indicated an association
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Table 15
Sensitivity Analyses on Key Findings, Logistic Regression Models of U.S. Office-Based
Physician Visits Made by Adults, 2014–2016
CDS
n
Scenario A, atheoretical
Original model

669

Exclude 2016

540

A priori definition, SUDa

662

Scenario A, theory-based
Original model

669

Meaningful use

Primary care
provider
OR [95% CI]

Patient-derived
revenue
OR [95% CI]

Cstatistic

OR [95% CI]

OR [95% CI]

0.538
[0.127, 2.284]
0.379
[0.053, 2.699]
0.492
[0.115, 2.101]

4.961
[1.124, 21.898]
5.488
[0.731, 41.184]
4.839
[1.099, 21.320]

NA

NA

.572

NA

NA

.576

NA

NA

.569

0.570
[0.128, 2.531]
0.420
[0.050, 3.516]
0.519
[0.115, 2.347]

4.046
[0.823, 19.884]
4.795
[0.515, 44.607]
3.893
[0.779, 19.455]

0.873
[0.287, 2.656]
0.651
[0.248, 1.707]
0.719
[0.257, 2.016]

0.390
[0.156, 0.976]
0.593
[0.161, 2.184]
0.370
[0.146, 0.936]

.587

Exclude 2016

540

A priori definition, SUDa

662

Patient revenue,
ownership or shareb

669

0.501
[0.116, 2.165]

4.188
[0.872, 20.117]

0.837
[0.326, 2.146]

0.410
[0.194, 0.865]

.587

Scenario B, atheoretical
Original model

8,685

0.245
[0.053, 1.137]
0.219
[0.064, 0.751]
0.245
[0.053, 1.142]

2.865
[1.265, 6.488]
1.805
[0.732, 4.450]
2.865
[1.254, 6.544]

NA

NA

.870

NA

NA

.887

NA

NA

0.402
[0.180, 0.898]
0.497
[0.215, 1.150]
0.396
[0.174, 0.902]
0.388
[0.169, 0.890]

2.922
[1.275, 6.698]
1.782
[0.708, 4.485]
2.904
[1.253, 6.729]
2.576
[1.093, 6.073]

1.088
[0.475, 2.495]
1.247
[0.512, 3.039]
1.124
[0.480, 2.631]
1.157
[0.507, 2.641]

1.119
[0.538, 2.330]
0.970
[0.405, 2.324]
1.066
[0.486, 2.341]
0.554
[0.324, 0.948]

Exclude 2016

7,429

A priori definition, SUDa

8,487

Scenario B, theory-based
Original model

8,685

Exclude 2016

7,429

A priori definition, SUDa

8,487

Patient revenue,
ownership or shareb

8,685

.587
.582

.871
.889
.875

.867

Note. Bold text denotes a statistically significant predictor. CI = confidence interval; OR = odds ratio; SUD = substance use disorder.
a
Excludes visits in which a patient was defined as at risk of a potentially unsafe prescription solely by receiving substance abuse
counseling, without a diagnosis of substance use disorder in the medical record. bDefine patient-derived revenue only if physician is a
full or part owner of the practice or describes the primary source of compensation as based on share of billings.

of CDS with reduced rates of potentially unsafe prescribing (e.g., Scenario B,
atheoretical, excluding 2016: OR = 0.219, 95% CI [0.064, 0.751]). Considered together
with the small sample size in Scenario A and the limited statistical reliability of the CDS
measure in both scenarios, the most reasonable conclusion from these findings is that
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CDS may be associated with decreased potentially unsafe prescribing of ADHD
medication, but results are uncertain.
Results were sensitive to the definition of patient-derived revenue (Table 15;
Table 16). The a priori construct for this indicator was revenue derived from either
patient satisfaction or volume. When the measure was narrowed to reflect a direct
relationship between patient volume and compensation, defined as practice ownership or
share of billings, theory-based model fit generally improved, with a significantly better fit
in the theory-based than the atheoretical model of Scenario B. Additionally, in both
scenarios, patient-derived revenue using the modified definition was associated with
significantly decreased odds of the outcome (Scenario A: OR = 0.410, 95% CI [0.194,
0.865]; Scenario B: OR = 0.554, 95% CI [0.324, 0.948]). Thus, measuring patientderived revenue as direct financial compensation may improve model fit, but with an
effect opposite that of the theory-based hypothesis.
Table 16
Logistic Regression Model Fit Changes Using an Alternative Definition of PatientDerived Revenue, U.S. Office-Based Physician Visits Made by Adults, 2014–2016

Model χ2 (change in –2LL)
Change in degrees of freedom
Critical χ2, α = .05

Scenario A: patients with
ADHD
Original
Ownership or
definition
billing share
5.38
7.02
3
3
7.81
7.81

Scenario B: patients with
CVD or SUD
Original
Ownership or
definition
billing share
–0.91
7.05
1
1
3.84
3.84

Note. ADHD = attention-deficit hyperactivity disorder; CVD = cardiovascular disease; LL = log likelihood; SUD = substance use
disorder.

Follow-up bivariate analysis. Although CDS and meaningful use achievement
are linked because CDS is one criterion for meaningful use, a small number of sampled
visits were made to physicians who qualified for meaningful use despite no medication-
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related CDS (Scenario A: n = 37; Scenario B: n = 245). To explore the mutual
associations of CDS and meaningful use with the outcome, I performed a descriptive
follow-up analysis of rates of potentially unsafe prescribing, accounting for both
variables (Table 17). Consistent with logistic regression findings, results suggested
independent effects of CDS as a negative predictor, and meaningful use as a positive
predictor, of the study outcome. An exception is that among those with CDS in Scenario
B, rates were approximately equal for those with and without meaningful use.
Table 17
Rates of Potentially Unsafe Prescribing of ADHD Medications, by CDS Use and
Meaningful Use Achievement, U.S. Office-Based Physician Visits Made by Adults, 2014–
2016

With meaningful use
Without meaningful use

Scenario A
With CDS
Without CDS
% [95% CI]
% [95% CI]
9.5
17.5
[5.6, 15.4]
[4.2, 50.7]
5.5
6.1
[1.3, 20.1]
[3.1, 11.5]

Scenario B
With CDS
Without CDS
% [95% CI]
% [95% CI]
1.2
7.7
[0.8, 1.7]
[2.5, 21.1]
1.3
3.1
[0.5, 3.3]
[1.6, 5.8]

Note. ADHD = attention-deficit hyperactivity disorder; CDS = computerized decision support; CI = confidence interval.
a
Pearson χ2 test of between-group difference, comparing CDS versus no CDS, adjusted for complex sampling design (Groves et al.,
2009).

Meaningful use penalties. As planned a priori, I estimated the number of
sampled visits made to physicians who might have been subject to meaningful use
penalties. Counts were small: two of 810 in Scenario A, both in the safer treatment group;
and 104 of 9,101 in Scenario B, 103 safer treatment and one potentially unsafe. The
interpretability of these findings is limited because no specific indicator of meaningful
use penalties was recorded in the NAMCS.
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Summary
This exploratory and preliminary assessment of the relative merits of atheoretical
and theory-based models of potentially unsafe prescribing, a binary outcome measure,
produced mixed findings. Results for RQ1, which assessed the association of CDS with
the study outcome, were inconclusive in most main analyses; however, sensitivity
analyses suggested an association of CDS with decreased odds of potentially unsafe
prescribing, a finding not consistent with the theory-based hypothesis. Analyses of RQ2
suggested increased odds of the outcome for providers with meaningful use achievement,
consistent with the theory-based hypothesis.
RQ3 was whether theory-based models improve predictive accuracy and fit,
compared with atheoretical models. In addition to the finding for CDS described above,
findings not consistent with theory-based hypotheses included a nonsignificant
relationship between the outcome and primary care provider status; a reduced rate of the
outcome for providers who derive revenue from patients, particularly when measured as
direct financial compensation; and no significant improvement in fit for theory-based
compared with atheoretical models except when patient-derived revenue was defined as
direct financial compensation. Limiting these findings were low rates of statistical
reliability for most coefficients, modest predictive accuracy for Scenario A, and the
inability to test either model fully because of changes in several environmental-construct
predictors made during data quality assessments.
In Chapter 5, I discuss the interpretation of study findings, overall and focusing
on implications of the two unexpected results for CDS and for patient-derived revenue. I
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describe limitations, both those known a priori and those that became evident during data
analysis. Comparing findings of this study with those of previous work, I describe
recommendations for future research and practice. I close with discussions of the positive
social changes that could result from a more interdisciplinary, psychology-informed
approach to interventions on physician decision-making and of potential contributions
health psychologists could make to these efforts.
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Chapter 5: Discussion, Conclusions, and Recommendations
To promote the well-being of individuals and populations, which is an APA
(2014) objective for preventive health interventions, efforts to encourage evidence-based
medical decision-making must cause more benefit than harm to patients and physicians.
The current study was conducted in response to a possible association between the
atheoretical foundation of the Health Information Technology for Economic and Clinical
Health (HITECH Act and its unintended harms (see Ratwani et al., 2019; Schiff et al.,
2015) and to calls in the health psychology literature for research that is based in theory,
measures behavioral outcomes objectively, and assesses broad policy interventions
affecting population health (see Conner & Norman, 2017; Prestwich et al., 2015;
Prestwich et al., 2018). To assess whether a theory-based approach might improve on
current, mostly atheoretical interventions on medical decisions (see L. Liang et al., 2017),
I mapped constructs of social cognitive theory and self-determination theory to predictors
of potentially unsafe prescribing of ADHD medications to adults, and compared two
logistic regression models of this outcome: one atheoretical based on assumptions of
HITECH Act proponents, and the other based on psychological theory and evidence.
In this chapter, I discuss the contributions and limitations of this study, and
consider implications for theory-based research in health psychology and for positive
social change. In considering these implications, I adopt contemporary definitions of (a)
health psychology as an interdisciplinary field that applies psychological knowledge not
only to individual health, but also to health care and health-related social policy (see
Marks, Murray, Evans, & Estacio, 2015) and (b) health psychology-informed
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interventions as multilevel, having expanded beyond the discipline’s initial focus on
individuals and families to include health care providers, institutions, and communities
(see Glanz, Rimer, & Viswanath, 2015). In accordance with this expanded view, I
consider implications of the study findings for knowledge about health-system effects on
medical decision-making, an environmentally influenced cognitive process (see
Djulbegovic & Elqayam, 2017). I consider autonomous motivation as a key theoretical
construct that may connect the findings of the current study with contemporary trends in
health care delivery, informing future research applications of this study’s theoretical
constructs to decisions made by physicians. Finally, I suggest the potential for
contributions by health psychologists, both to research and to physician-focused
interventions conducted as part of multidisciplinary team collaboration.
Study Findings and Interpretation
Findings provided only limited support for theory-based hypotheses. The RQ1
hypothesis of a nonsignificant association between computerized decision support (CDS)
and the outcome, framed by social cognitive theory and informed by literature on
cognitive norms in medical practice, was not supported. Also not supported were the
RQ3 hypotheses of increased rates of the outcome for those who derive revenue from
patient volume or satisfaction, and of better predictive accuracy and fit for theory-based
than for atheoretical models. Countering these findings was support for the selfdetermination theory-based RQ2 hypothesis of a positive relationship between
meaningful use of electronic health records (E-HRs), as required by the HITECH ACT,
and the outcome. Somewhat limiting the contribution of these results to knowledge about
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health-system influences on medical decision-making, neither model could be fully tested
because of the removal or recoding of several environmental-construct predictors, and
because statistical reliability of the multivariate estimates was suboptimal. In this section,
I interpret three key findings in the context of the study literature review.
RQ1: CDS
Study findings suggested an association between medication-related CDS and
reduced odds of the study outcome. This finding is consistent with research implicating
time constraints and lack of awareness of guidelines, respectively, as systemic and
cognitive barriers to evidence-based practice (see F. Fischer et al., 2016). However, this
association is inconsistent with the two main conclusions of the literature review. The
first conclusion was that CDS guidance may conflict with cognition shaped by medical
training, which emphasizes individual biomedical expertise (see Berkhout et al., 2018;
Stead et al., 2011) and attention to individual patient needs (see Arts et al., 2016). This
point is especially important when framed in social cognitive theory, with its emphasis on
occupational norms as a key determinant of behaviors, values, and personal identity (see
Bandura, 2001). The second conclusion was that CDS has produced suboptimal results in
prior research, including high override rates (see Wright et al., 2018), failure to conform
to standards from human-factors psychology (see Phansalkar et al., 2014), and minimal
or null effects in most office-based studies (see M. J. Miller et al., 2017; Moja et al.,
2014). In this section, I consider two key points in interpretating this finding:
heterogeneity in previous research on CDS, and the use of social cognitive theory when
studying CDS.
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Heterogeneity in previous research. Many assessments of null effects for CDS
in previous research were based on review articles and meta-analyses comprising studies
with heterogeneous samples and outcomes, such as hospital length of stay in inpatients,
use of antibiotics, mortality, health-related quality of life, and virologic failure in patients
with human immunodeficiency virus (Bright et al., 2012; Moja et al., 2014). Results of
the current study may reflect unique characteristics of this sample and prescribing
problem, a fluctuation typical in research of this type. Such heterogeneity in results for
various types of medical decisions has been observed in the few cognitive theoryinformed studies of health care decision-making, such as R2 values ranging from 0.1% to
40% for cognitive theory-based studies of physician behaviors in the systematic review
by Godin et al. (2008). Although this heterogeneity may reflect methodological
differences, as suggested by Godin et al., a later study of physicians and nurses in the
United Kingdom, conducted using a uniform methodology applied to various diabetes
care behaviors, similarly indicated considerable variation in percentage of variance
explained by social cognitive theory, ranging from 9% for providing weight counseling to
50% for foot examinations (Presseau et al., 2014). Therefore, the type of health decision
being studied, which is a function of the specific clinical scenario faced by the physician,
may affect the explanatory power of a theoretical construct or intervention. Because
clinical scenario is generally not modifiable, Presseau et al. (2014) suggested that
identifying modifiable intervention-related factors, which may affect either intention or
the gap between intention and behavior, is important in theory-based investigations of
medical decision-making.
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In that respect, the consistency of guidance for ADHD medications over the 3year study period may provide valuable information in this research. This consistency
may have contributed to study findings by making the need for a CDS warning in E-HRs,
or for acceptance of the warning by physicians, particularly clear. Both the American
family practitioner guidelines current during the study period (Post & Kurlansik, 2012)
and a later British guideline (Bolea-Alamañac et al., 2014) addressed the possibility of
stimulant misuse and recommended atomoxetine for patients with substance use disorder
(SUD). Although the family practitioner guideline did not recommend cardiovascular risk
assessment, the British guideline did. A U.S. Substance Abuse and Mental Health
Services Administration (2013) publication prior to the current study period documented
a 3.5-fold increase in ADHD-medication emergency department visits by adults from
2005 to 2010, consistent with later published evidence about the risks of stimulant
overdose (Fulde & Forster, 2015). Finally, FDA safety guidance for ADHD medications,
used in defining the outcome measure, did not change during the study period. Therefore,
it is possible, although not investigated in this study, that this consistency influenced the
credibility of the information for physicians, a factor identified as important in qualitative
research on their use of informational resources (see Cook et al., 2013).
Aligning with this possibility, although also not measuring it directly,
investigators in a failed theory-based intervention to promote the prescribing of thiazides
(a type of blood pressure medication) attributed their results, in part, to extensive
exposure to information about thiazides prior to the study (Presseau et al., 2016). Family
physicians included in that sample reported high baseline rates of intentions to prescribe

132
thiazides, positive beliefs about them, perceptions that others thought they should
prescribe them, and self-efficacy for prescribing (Presseau et al., 2016). These results
may be framed within the social cognitive theory suggestion that observational learning
of a behavior (e.g., prescribing) is more likely when knowledge is delivered by influential
sources, which can include mass media or information delivered by role models
(Bandura, 1999; Kelder et al., 2015). Knowledge consistently provided by multiple
sources, including medical literature and federal guidance about ADHD medications,
may have represented such influence for the physicians in the current study. Nonetheless,
whether these psychological mediators directly influenced ADHD prescribing was not
measured, a point revisited in discussions of study limitations and recommendations for
future research.
Effect of using social cognitive theory. Another possible explanation for the
positive results for CDS may stem from the inclusion of both CDS and meaningful use in
this study’s conceptual models. This design decision reflected the holistic nature of social
cognitive theory, which acknowledges different types of environmental influences that
may either facilitate or prevent desired behaviors, such as opportunities for learning, as
well as physical barriers, rewards, or punishments (see Kelder et al., 2015). This
theoretical feature is important because HITECH Act proponents intended CDS and
meaningful use to affect different constructs: readily available knowledge (i.e., removing
a cognitive barrier at the individual level; see Bates et al., 2003) for CDS, and motivation
to use that knowledge (i.e., rewarding desired behavior at the system level; see Buntin et
al., 2010) for meaningful use. Moreover, CDS and meaningful use represented two
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distinct, albeit related, policy interventions (Wright et al., 2014). However, no previous
research identified in this study’s literature review addressed these interventions
simultaneously. It was feasible to do so in the current study because of the large national
sample of 301 physicians in Scenario A and 1,659 physicians in Scenario B.
In contrast, investigators studying one provider office would typically be unable
to measure CDS and meaningful use simultaneously because a single office-based system
either does or does not meet meaningful use requirements. Therefore, it is possible that in
work conducted after the HITECH Act implementation, the effects of the two variables—
decreased odds for CDS and increased odds for meaningful use—counteracted each
other, resulting in a null overall effect. This explanation is supported by the multivariate
findings and by the follow-up bivariate analysis of CDS and meaningful use reported in
Chapter 4, which suggested opposing effects for these two interventions. If so, the current
study contributes to knowledge about social cognitive theory-based analyses of medical
decisions by highlighting the possibility of disparate effects for health-system
environmental influences that are targeted to knowledge, such as CDS, versus motivation,
such as meaningful use.
More broadly, the finding may suggest a benefit of the multilevel approach used
in contemporary definitions of health psychology (see Glanz et al., 2015) and in social
cognitive theory, which recognizes ongoing mutual interactions of environment and
individual (see Bandura, 1989). In discussing the value of applying social cognitive
theory to health-promotion efforts, Bandura (2004) noted that the theory is one of only
two theoretical approaches to encompass both individual-level factors (e.g., knowledge,

134
self-efficacy) and health-system factors, including social or economic structures, that may
pose barriers to desired health behaviors. In an earlier article, Bandura (2001) suggested
that psychology contributes to positive change by “discovering principles about how to
structure environments” (p. 13). A multilevel perspective on human-environment
interaction enables researchers to study the effects of health-system interventions on
individual health-related behaviors and changes in practice that may promote better
intervention development.
Social cognitive theory does not alone indicate whether a given type of reward
will act as a facilitator or barrier to good decision-making. Rather, social cognitive theory
provides a theoretical framework within which specific environmental effects can be
analyzed. Self-determination theory was used in the current study to address that gap in
social cognitive theoretical constructs. Findings for meaningful use, framed within that
theory, are discussed next.
RQ2: Meaningful Use
Results of this study suggested increased odds of potentially unsafe prescribing
among meaningful use providers. The current study extended the available base of
evidence on meaningful use, as a macrolevel economic structure that may influence the
health-related behaviors of individuals (see Bandura, 2004), in two ways. First, rather
than self-reported behavior or opinion, which may lack validity (see Conner & Norman,
2017), current study results represent an objectively measured behavior, meeting a
recently identified need in health psychology (see Prestwich et al., 2018). Second, the use
of a national sample extended knowledge derived from previous studies of objective
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behavioral outcomes that were conducted in single states or health systems (see Grinspan
et al., 2017; Jung et al., 2017; Kern et al., 2015; Levine et al., 2017; Samal et al., 2014;
Unruh et al., 2017). This national scope was consistent with the multilevel focus of health
promotion suggested by Bandura (2004) and with recent calls in the health psychology
literature for research on population-level influences on health (see Conner & Norman,
2017). In the next section, I interpret this finding in the context of previous research on
meaningful use, and consider the finding in light of self-determination theory.
Previous research on meaningful use. Like state- or institution-level research,
the current study did not produce favorable findings for the meaningful use program, but
the findings of minimal or mixed results in previous research contrast with the finding of
approximately tripled odds of potentially unsafe prescribing in the current study. This
discrepancy may be attributable to the specific prescribing problem addressed in this
research. Like studies of CDS, research on meaningful use is heterogenous and has
covered diverse topics including vaccination, cancer screening, hospitalizations, and
quality of primary care. Such heterogeneity in studies of medical decisions is typical (see
Godin et al., 2008; Moja et al., 2014), representing a known challenge in applying single
theoretical constructs or theories to different health-related behaviors (Presseau et al.,
2014), particularly in health psychology where consideration of broad systemic
influences on various populations and health outcomes is considered important (APA,
2014; Bandura, 2004; Marks et al., 2015).
Findings of two studies comparing offices with and without meaningful use,
conducted in a large health system with a single E-HR including CDS (Samal et al.,
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2014; Levine et al., 2017), suggest another possible explanation for the present research
finding of relatively large effects of meaningful use. Both studies, like most other
previous research, produced mixed outcomes for meaningful use, with better results on a
few measures and worsened or similar results on others. However, the difference for
patients with depression was the largest observed in either study; 42% of patients in
meaningful use offices and 68% of those in offices without meaningful use received
depression treatment for > 12 weeks (Samal et al., 2014).
The similarity of that study’s result for depression and the current study’s result
for ADHD medications may represent a phenomenon described by Cifuentes et al.
(2015): the challenge of carrying out interprofessional communications among behavioral
and medical providers, the clinical ideal for patients with ADHD (Kooij et al., 2019),
using electronic means. For example, one qualitative focus-group study of health
professionals in an academic medical center, conducted approximately 2 years after
implementation of an E-HR, indicated several cognitive and work-process challenges
related to the replacement of face-to-face with electronic communication, such as
variations in ways that different specialists (e.g., physical therapist versus physician)
recorded information in E-HR fields and lack of confidence that notes were being
received or read by others (Bardach, Real, & Bardach, 2017). This explanation is also
supported by qualitative research, conducted by a social cognitive psychologist who
specializes in human-factors engineering (i.e., human-computer-environment interaction)
in health care, documenting new challenges in interprofessional communications after EHR implementation (Holden, 2011). Examples included extra time spent typing messages
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via email instead of having a conversation; perceptions of communications as less
clinically complete because of the constrained E-HR format; and problematic workprocess changes, such as the actions of one physician who avoided E-HR data entry
requirements for in-person medical orders by stepping into the hallway and calling nurses
from his cell phone. Together, these findings suggest that the negative effects of
meaningful use described by clinicians in surveys (e.g., Emani et al., 2017) may be
exacerbated in mental health care, such as for ADHD, partly because of the added burden
E-HRs may pose for interprofessional communications. Implications of this suggestion
for additional research are discussed later in the chapter.
Self-determination theory and meaningful use. The finding of higher odds of
potentially unsafe prescribing for meaningful use providers is consistent with several
conclusions reached in the synthesis of self-determination theory with findings of the
literature review. First, self-determination theory indicates an association between
controlled motivation and poor task performance (Deci & Ryan, 2008a). Second, also
consistent with self-determination theory, surveys of physicians documented opposition
to the meaningful use program based on lack of clinical benefit, introduction of clinical
harms, and diversion from important medical care tasks to clerical work (Emani et al.,
2017; Shanafelt et al., 2016; Weeks et al., 2015), resulting in a perception of being forced
by meaningful use requirements to use technologies that do not provide value (J.
Levinson et al., 2017; Weeks et al., 2015). Findings of the current study are also
consistent with the results of a meta-analysis linking task-contingent tangible rewards
with decreased intrinsic motivation (Deci et al., 1999) and of a study conducted in a
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single corporation, which indicated that managerial agreement with self-determination
principles (e.g., promoting autonomy, considering subordinate perspectives) was
associated with better employee perceptions of the company and job satisfaction, except
under adverse economic conditions (Deci et al., 1989).
Thus, although autonomous motivation was not directly measured in the current
study, and no research applying self-determination theory to medical decision-making
was identified in the literature review, results generally support the use of selfdetermination theoretical constructs, particularly autonomous motivation, in predicting
medical decisions. However, these findings contrast with those for patient-derived
revenue, which was based on the same theory. In the next section, I consider this
discrepancy.
Patient-Derived Revenue: Coefficient Evaluation in RQ3
Several findings for patient-derived revenue were not as hypothesized according
to self-determination theory. In the main theory-based analysis of Scenario A, revenue
derived from either patient volume or satisfaction was associated with reduced odds of
potentially unsafe prescribing of ADHD medications. Additionally, sensitivity analyses
produced the unexpected finding that narrowing the definition of this predictor to direct
financial compensation alone, measured as either practice ownership or share of billings,
was associated with reduced odds of potentially unsafe prescribing in both Scenario A
and Scenario B. Moreover, use of the narrower definition improved model fit, suggesting
better explanatory power when basing the patient-derived revenue measure solely on
direct monetary compensation without considering revenue derived indirectly from bonus
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payments based on patient satisfaction measures. Such a pattern might seem to suggest a
purely economic, rather than psychological, phenomenon.
Interpretation of this seemingly anomalous finding should reflect the theoretical
rationale of the a priori hypothesis for patient-derived revenue in this study. This
hypothesis was based on the constructs of integrated and identified motivation, which are
subtypes of autonomous motivation produced by external rewards for a valued outcome
(Deci & Ryan, 2008b; Prestwich et al., 2018), and on evidence that physicians value
patient relationships (Colligan et al., 2016; Tak et al., 2017). The rationale underlying the
hypothesis was that physicians would attempt to preserve the valued outcome of patient
relationships by prescribing even if potentially unsafe, a phenomenon described in
research suggesting fear of lost patient relationships as a determinant of potentially
inappropriate prescribing (Anderson et al., 2014; Sirdifield et al., 2013; Wallis et al.,
2017). Thus, as external rewards linked to the valued outcome of patient relationships,
both direct financial compensation from patients and bonus payments based on patient
satisfaction would be expected to have the same effect, according to this application of
the theory: increasing autonomous motivation for the valued goal of retaining
relationships, thereby increasing potentially unsafe prescribing.
A simpler and more direct application of the theoretical construct of autonomous
motivation, specifically the assertion that perceived autonomy improves task performance
(Deci & Ryan, 2008a), would have produced an alternative hypothesis that obtaining
revenue directly from patient care activities increases a physician’s sense of autonomy,
thereby improving medical decision-making, the physician’s primary task, and reducing
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the rate of potentially unsafe prescribing. This alternative hypothesis, which would have
been supported by study findings, is also consistent with several contemporary trends in
health care, all linked with the theoretical construct of autonomous motivation.
Autonomy and quality of care. The first is a desire expressed by physicians for
greater control over medical practice (J. Shapiro, Astin, Shapiro, Robitshek, & Shapiro,
2011), particularly on tasks that promote patient well-being, which physicians are trained
to see as their highest obligation (Cooke et al., 2006). Concern over lost autonomy has
been reflected in physician commentaries implicating the supplanting of clinical
judgment with E-HR-delivered guidance as a key cause of frustration, burnout, and
departures from the practice of medicine (Wright & Katz, 2018). Corroborating the
importance of control over medical practice for physicians, one mixed-methods analysis
of a diverse sample of physicians suggested that occupational satisfaction is increased by
practice ownership and by authority to make business decisions, such as the purchase of
new medical equipment, that affect quality of care (Friedberg et al., 2013). These
findings suggest that physicians perceive autonomy as important for the quality of care
that they provide. Such a perception is unsurprising given the process of medical
education, described in Chapter 2, which is intended to prepare physicians for lifelong,
self-direct learning and independent decision-making to promote the well-being of
patients (ACGME, 2019; Berkhout et al., 2018).
Innovative delivery arrangements. This desire for autonomy may be responsible
for the second, relatively recent, phenomenon of direct patient contracting, such as
“concierge” or retainer-fee arrangements that minimize third-party influence on
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physician-patient relationships by asking patients to pay for personalized care and
enhanced access (Doherty & Medical Practice and Quality Committee [MPQC], 2015).
These arrangements were described in one literature review as a way to combat
requirements, such as excessive paperwork and restrictions on office visit time, that “are
undermining traditional medical practices” (Doherty & MPQC, 2015, p. 951). Although
the prevalence of direct patient contracting arrangements is difficult to estimate, it
appears to be increasing, prompting a call from the American College of Physicians for
“independent research” to evaluate both the factors underlying these arrangements and
their effects on “access to care, especially for vulnerable populations” (Doherty &
MPQC, 2015, p. 951).
Physician employment. Both trends and the current study findings should be
interpreted in the context of a much broader trend: the long-term decline in the rate of
practice ownership among physicians in the United States, estimated at 72% in 1994
(Kletke, Emmons, & Gillis, 1996), 53% in 2012, and 46% in 2018 (Kane, 2019).
Accompanying this trend was an increased rate of employment in practices owned by
hospitals or health systems (Kane, 2019) to approximately 44% of U.S. physicians in
2018 (Physicians Advocacy Institute, 2019). Compared with physician-owned practices,
hospital-owned practices have higher rates of some recommended care processes, such as
discussing clinical quality data (28% and 44%, respectively) and writing quality reports
(64% and 79%, respectively; Lindner et al., 2019). Nonetheless, these hospital-owned
arrangements, intended to improve care coordination, have instead been associated in a
limited body of research with few or no effects on quality of care (Scott, Orav, Cutler, &

142
Jha, 2017; Short & Ho, 2019) and with increased use of services providing minimal
clinical benefit (Mafi, Wee, Davis, & Landon, 2017). The current study’s findings on
meaningful use (i.e., increased odds of potentially unsafe prescribing) and direct financial
compensation (i.e., decreased odds) are consistent with this previous work and extend
knowledge by suggesting that the loss of autonomy derived from meaningful use, and the
increased autonomy derived from direct financial compensation, may predict quality of
prescribing, a type of medical task not previously assessed in this body of research.
Application to theory. Viewed as a whole, these findings suggest autonomy as a
core determinant of intrinsic motivation for medical practice, consistent with selfdetermination theory (Deci & Ryan, 2008a) and with concerns expressed in the literature
about how extrinsic rewards for performance on externally determined metrics affect the
quality of health care (Himmelstein et al., 2014; Kao, 2015). Broadly, the findings again
point to the value of multilevel psychological perspectives on health, as described by
Bandura (2004). Specifically, meaningful use and practice-ownership structures may be
appropriately framed as system-level influences on physicians and their decisions,
potentially affecting the health of individual patients (Marks et al., 2015).
Limitations of the Study
Before considering the implications of this study, important limitations should be
acknowledged. These include limitations on internal validity, external validity, and scope.
Most were anticipated a priori, and some were addressed with sensitivity analyses.
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Internal Validity
No direct measurement of mediators. Although study hypotheses were
developed by linking theoretical constructs to predictors and outcomes, these constructs
(e.g., outcome expectations, value) were not directly measured. Whether physicians
received or read CDS-delivered guidance is also unknown. For this reason, study results
represent intention-to-treat estimated associations of environmental characteristics with
prescribing behaviors, not direct measures of the psychological experiences underlying
those behaviors. Mitigating this limitation, study hypotheses were based on a large body
of qualitative and quantitative evidence about cognitive and emotional response to
meaningful use, CDS, and E-HRs (e.g., Emani et al., 2017; Slight et al., 2016).
Unmeasured confounding factors. As in any nonexperimental study, results
could have been affected by unmeasured confounding factors, such as symptom severity,
demands for medication from patients or family members, or unmeasured features of the
medical practice environment. Physicians who achieved meaningful use may have
systematically differed from other physicians in ways, such as attitudes toward clinical
guidelines or comfort with technological devices, that could have affected the
relationships between CDS or meaningful use and the study outcome but could not be
measured in this study. Potential attitudinal confounding factors include agreement or
disagreement with guidelines (e.g., Cloutier et al., 2018; F. Fischer et al., 2016) or with
their application to individual patient circumstances (Arts et al., 2016), or general
propensity to practice evidence-based medicine. For example, Grinspan et al. (2017)
found that even after statistical adjustments for several characteristics of patients (sex,
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age, comorbidities, zip code) and physicians (generalist versus surgeon or medical
specialist, sex, urban versus rural practice, and practice size), providers who chose
meaningful use participation had slightly better care practices before meaningful use
implementation than did nonparticipants.
Assessments of model quality and fit help to assess the possibility of such
unmeasured confounding factors because they indicate the extent of residual confounding
after multivariate adjustment (see Warner, 2013). In this study, logistic regression models
of Scenario B were better specified and achieved better predictive accuracy than did
models of Scenario A. Nonetheless, even with the approximately 87–89% predictive
accuracy measured for Scenario B, and especially with the much lower 57–59% accuracy
for Scenario A, the possibility of residual confounding remains.
Misclassification of exposure. Although the quality of coding by NAMCS data
collectors is excellent (see D. T. Lau et al., 2018; Rui & Okeyode, 2019), the accuracy of
data extracted from the medical record depends on the content of the record. Two
challenges may have affected measurements in this study. First, ADHD did not become a
medical condition indicator in the NAMCS until 2016 (CDC, 2019b). Thus, it may not
have been recorded as a diagnosis in all visits in which ADHD medication was
prescribed, even for patients who had ADHD. Second and related, “diagnosing for
dollars” (Braun & Cox, 2005, p. 425), which is intentionally misdiagnosing mental health
conditions to maximize reimbursement, and the tendency of patients to seek care from
behavioral providers unknown to the physician (Madden et al., 2016) may have resulted
in the omission of relevant psychiatric diagnoses from medical records. This problem
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may have been the cause of one issue identified early in data processing, the provision of
substance abuse counseling without a recorded diagnosis of SUD. Mitigating this
limitation, this issue was identified in only a small proportion (230 of 2,270) substance
abuse visits. Additionally, sensitivity analyses, which are the recommended approach to
methodological concerns in analyses of archival medical data (Berger et al., 2009),
suggested generally robust findings.
Sample size. A final limitation on internal validity, which was anticipated a priori
but could not be quantified prior to accessing the NAMCS data, was small design effectadjusted sample size, particularly in Scenario A, likely because of the low, albeit
increasing, prevalence of diagnosed and treated ADHD among U.S. adults (see Fairman
et al., 2017). Because this problem affected the statistical precision of some bivariate
estimates and most multivariate estimates, some of which did not meet NCHS statistical
reliability standards (see CDC, 2019b; Parker et al., 2017), results should be considered
preliminary. However, typical sample sizes in health psychology research on medical
decisions are small: 56–80 per intervention subgroup in a theory-based process
evaluation of the failed thiazide intervention (Presseau et al., 2016); 18 general
practitioners in a theory-based assessment of antibiotic prescribing in Australia (Sargent,
McCullough, Del Mar, & Lowe, 2017); 21–34 general practitioners per group in a
randomized trial of a theory-based intervention on antibiotic prescribing in Sweden
(Milos et al., 2013); and a total of 374 physicians in four theory-based studies of clinical
decisions in the meta-analysis by Godin et al. (2008). Therefore, awareness of statistical
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imprecision should be balanced against the contribution made by the large, national
sample used in this research.
External Validity
Two potential limitations on external validity were anticipated a priori and
assessed in sensitivity analyses. One was the NCHS decision to allow E-HR submission
in lieu of onsite data collection in 2016 (CDC, 2019b). Although this decision eventually
resulted in the exclusion of these records from the NAMCS, sensitivity analyses
suggested results were robust to this issue.
A second potential limitation was that NAMCS participants may have differed
systematically from nonparticipants. Quantitative assessments, both in this study and in
previous research, suggested against this possibility. First, as reported in Chapter 3,
comparisons of NAMCS participants and nonparticipants suggested minimal or no
nonresponse bias on more than 80 indicator categories after application of sample
weights in a study by Hing et al. (2016). Second, two sets of numeric findings reported in
Chapter 4, the use of numerous weighting strata (n = 101 in Scenario A and n = 130 in
Scenario B) and similar characteristics of the current study sample and samples reported
in previous research, suggested good external validity for target populations including
patients with ADHD, CVD, or SUD. The E-HR use rate measured in this study was also
similar to that reported in national samples during the study time period.
Further supporting confidence in the external validity of this study’s findings is a
body of research evidence indicating little to no nonresponse bias in surveys of
physicians, despite low response rates. One was a “reluctant respondent” analysis, a
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commonly used bias-assessment technique (Goyder, 1987), which indicated that repeated
efforts to contact nonrespondents to a physician survey on cancer care increased response
rate without changing results (Willis, Smith, & Lee, 2013). Another study found no
nonresponse bias on patient characteristics, including several clinical measures of
diabetes management, in a physician survey with a 36% response rate (Ziegenfuss et al.,
2012), and another showed only male sex and questionnaire length significantly
associated with nonresponse in a physician survey with a 47% response rate (McFarlane,
Olmsted, Murphy, & Hill, 2007).
Countering these quantitative assessments is the possibility of social desirability
bias (Groves et al., 2009) or topic-salience bias (Goyder, 1987) in the decision to
participate in the NAMCS. For example, in the process evaluation of the thiazide
intervention, survey respondents were more likely than nonrespondents to be universityaffiliated (9% versus 2%, respectively, p = .009) and to belong to a professional
physician organization (44% versus 31%, p = .030). Although those data were not
weighted on numerous characteristics to adjust for nonresponse bias, as NAMCS data
are, they suggested that physicians who are more knowledgeable or interested in
evidence-based medicine may be more likely to respond to survey requests. Such
attitudinal biases may be more nuanced and difficult to assess than the quantitative
measures reported by Hing et al. (2016) or in previous studies (see McFarlane et al.,
2007; Willis et al., 2013; Ziegenfuss et al., 2012). Thus, although many factors that
typically affect survey response (Goyder, 1987) are either similar for all physicians (e.g.,
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socioeconomic status) or adjusted by NAMCS weights (e.g., age group, sex), the
possibility of nonresponse bias cannot be completely ruled out.
Study Scope
The only major discrepancy between the sample characteristics and previously
reported results was a higher use rate for prescribed stimulants reported by adults with
SUD in household interviews (see Compton et al., 2018) than recorded in office visits in
this study. This issue may reflect a constraint on study scope known a priori. Specifically,
NAMCS records represent only information known to the physician (predictors) and
decisions made by the physician (outcomes) during a single office visit, not actions taken
by patients after the visit. Patients choose whether to seek recommended psychotherapy,
fill prescriptions, take medications, or divert a controlled substance by selling or giving it
away (Compton et al., 2018; Ford, Thomas, Byng, & McCabe, 2019). For this reason,
results of this study do not generalize to all sources of potentially unsafe ADHD
medications, including family and friends, a common source of illicit prescription
medications for young adults (see McCabe, Teter, Boyd, Wilens, & Schepis, 2018).
Unknown to the physicians in this study, patients with or without SUD may have diverted
their prescribed medication to others, although SUD increases the likelihood of obtaining
medication directly from a physician (see Compton et al., 2018; McCabe et al., 2018).
Although this scope constraint has little relevance for the current study findings, which
were limited a priori to medical decisions made during one office visit, it does highlight
the value of current recommendations to query all young adults, not just those prescribed

149
controlled substances, regarding medication abuse (McCabe et al., 2019).
Communications of this type could not be assessed in this study.
Finally, also known a priori, results of this study do not generalize to every form
of inappropriate prescribing of ADHD medications. Whether the patient’s symptoms
warranted a prescription, a medical judgment that may rely on information not recorded
in the medical record, was not measured in this research. Thus, some potentially unsafe
prescribing may have been medically necessary, and some safer prescribing may have
been medically unnecessary. This question was beyond the scope of this study.
Recommendations for Future Research
The foremost recommendation arising from the current study is a need for more
theory-based analyses, and perhaps additional comparisons of atheoretical with theorybased approaches, in research on medical decision-making. Considering the limited body
of theory-based research on medical decisions published in the 15 years since Bandura
(2004) called for multilevel analyses of the effects that health-system structures have on
individuals, a reasonable question for health psychology may be why so little scholarship
in the field has addressed physicians’ responses to health-system interventions on their
behavior. Such a body of work would be consistent with the social cognitive theoretical
construct of emergent interactive agency (Bandura, 1989); with Bandura’s (2001)
suggestion that psychology should inform the development of environmental structures to
promote psychosocial health; and with the APA (2014) goal of using psychology to
advance the well-being of individuals and populations. Nonetheless, as noted in Chapter
1, theory-based studies of physician decision-making (Godin et al., 2008) or of
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interventions on the medical decision-making process (L. Liang et al., 2017) are
uncommon. Further highlighting the issue for health psychology, of 14 theory-based
studies identified in reviews of guideline-promotion evaluations (see L. Liang et al.,
2017, n = 8) or of physician behaviors (see Godin et al., 2008, n = 6), only two were
published in health psychology journals; most were published in medical journals.
This problem has been observed in the field of health psychology as a whole,
which, despite theories explicitly acknowledging environmental influences on
psychological phenomena, has generally put most research focus on the behaviors and
characteristics of individuals (Kelder et al., 2015; Sallis & Owen, 2015). In this section, I
consider how this gap might be addressed in multilevel analyses of medical decisionmaking that acknowledge both environmental and individual influences, informing these
suggestions with the findings of this study and previous research. The discussions below
address psychological mediators, heterogeneity of outcomes, and research methods.
Psychological Mediators
Findings of the current study suggested the feasibility of mapping theoretical
constructs to archival data to predict prescribing decisions, with modest accuracy in
Scenario A and excellent accuracy in Scenario B. Additional theory-based research could
extend the current study’s preliminary work by supplementing objectively measured
behavioral data with survey data on psychological mediators (see Warner, 2013).
Examples could include measures of behavioral intentions (see Presseau et al., 2016) in
assessing CDS, or of motivation to practice medicine (see Himmelstein et al., 2014) in
assessing meaningful use. Additionally, if independent associations of CDS and
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meaningful use with prescribing behavior are confirmed in additional research, preferably
with larger samples, mediation analysis could help to determine whether these
interventions act on different psychological phenomena as intended by their developers:
knowledge and cognition for CDS (see Bates et al., 2003) and motivation for meaningful
use (see Buntin et al., 2010).
Such approaches could potentially contribute not only to the study of medical
decisions, but also to the field of health psychology, where direct measurement of
theoretical constructs is limited even in theory-based studies (see Prestwich et al., 2014;
Prestwich et al., 2015). For example, in an analysis of all studies of diet or exercise
interventions included in two systematic reviews published in health psychology journals
(Health Psychology Review and Health Psychology), Prestwich et al. (2014) found that
only 56% reported a basis in any psychological theory. Of the studies identified by their
authors as theory-based, 10% linked all intervention components to one or more
theoretical constructs; 45% linked at least one intervention component to theory; and
49% measured any theoretical constructs in the postintervention period.
Examination of psychological mediators would likely also have value for
additional questions and health-system effects, consistent with the vision advanced by
Bandura (2004). For example, the current study results for patient-derived revenue
suggest a need for more research into the effects of practice ownership versus
employment arrangements on physician decision-making and health care quality, perhaps
along with assessment of direct patient contracting arrangements as suggested by the
American College of Physicians (see Doherty & MPQC, 2015). Such research could be
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set in the social cognitive theoretical framework, with ownership arrangements as
environmental facilitators or barriers (see Kelder et al., 2015) to making evidence-based
medical decisions or to positive health outcomes for individual patients. In addition to
psychological mediators described above, such as examining whether autonomous
motivation mediates the association between practice ownership or direct contracting and
quality of care (see Scott et al., 2017; Short & Ho, 2019), this work might also measure
environmental mediators. Because preliminary research links hospital ownership with
increased time spent on reporting tasks (Lindner et al., 2019), mediators might include EHR use and time allowed for office visits.
Context-specific assessment of mediators. Research of this type could also
facilitate richer exploration of interactions among different health-system initiatives. For
example, research could assess whether practice ownership arrangements that enable
physicians to choose or refuse meaningful use participation change the effect of
meaningful use on task performance. Adding a direct measure of autonomous motivation
to such an analysis would help to answer the question of whether the meaningful use
effect is due to E-HR system features, which have been associated with occupational
stress (see Babbott et al., 2014), or to autonomy as a core issue.
Similarly, research on whether locally developed CDS systems have lower rates
of override than commercial systems do, as suggested in the research by Wright et al.
(2018) in a single health system, might benefit from direct measurement of psychological
mediators. Examples include intrinsic (i.e., task-specific) versus extraneous (i.e., devicerelated) cognitive load, automation bias (see Lyell et al., 2018), behavioral habituation
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(see Baysari et al., 2017), or perceived autonomy in the work context (see Deci et al.,
1989). Findings for the first three mediators might suggest attributing override
differences between locally developed and commercial systems to system features,
whereas a finding for the fourth mediator might suggest that being forced to switch to a
system over which physicians have no control negatively affects autonomous motivation
and, therefore, task performance, independent of system features.
In addition to providing valuable information for improvement of decision
support systems, analyses of this type might extend theory by linking specific theoretical
constructs (e.g., cognitive load, autonomous motivation) to specific types of professional
task performance outcomes. For example, to follow up on previous research suggesting
an association between E-HR use and impaired interprofessional communication
(Bardach et al., 2017; Holden, 2011), a study could address whether E-HRs have a
greater effect on measures of cognitive load (see Lyell et al., 2018) for mental health care
tasks, where greater interprofessional collaboration may be needed to address both
physical and psychosocial needs (see Kooij et al., 2019), than for acute illnesses.
Heterogeneity of Outcomes
An additional research area, examination of clinical and theoretical factors
underlying physician response to CDS-delivered guidance and other interventions on
their behavior, is suggested by the heterogeneous results obtained for CDS in previous
work (see Moja et al., 2014), by the somewhat positive results for CDS in the current
study, and by the mixed outcomes of theory-based interventions (see Godin et al., 2008;
Milos et al., 2013; Presseau et al., 2016). Previous work has examined the associations of
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types (e.g., drug-drug interactions, allergies) or severity of CDS messages with overrides
(Nanji et al., 2014; Wright et al., 2018). To extend this work to E-HRs as a health-system
intervention, a surveillance process similar to that currently used for medical devices (see
Ratwani et al., 2019) could provide archival data on system features and outcomes.
Analyses of these data could be framed in theory-based studies to provide guidance for
future system development. The nature of these studies would depend on available data,
but a health psychologist might, in general, supplement quantitative data (e.g., type of
medication, length of medication list, patient age, diagnosis) with results of previous
qualitative or quantitative research to identify situations where risk of technology-related
adverse events is high. Possible examples include circumstances for which few
opportunities for observational learning occur in medical training (see Stead et al., 2011);
or lengthy lists of medications or diagnoses, which might increase likelihood of
automation bias (see Lyell et al., 2018) or difficulties comprehending screen display (see
Brown et al., 2017).
Because of evidence described previously that even the same theory-based
intervention applied to different clinical scenarios may produce disparate results
(Presseau et al., 2014), analyses of factors underlying the success or failure of E-HRs and
of theory-based interventions should ideally measure and control for disease state, patient
characteristics, and task. For example, Presseau et al. (2016) attributed the failure of their
theory-based intervention on thiazide prescriptions to overwhelming intention to
prescribe thiazides (5.93 on a 7-point scale) prior to the intervention. In addition to
controlling for nonmodifiable clinical scenarios, as suggested by Presseau et al. (2014),
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such research could experimentally manipulate modifiable intervention features, such as
the content of communications, as in a study of opioid-death notifications by Doctor et al.
(2018); use of a peer-physician clinical “champion” to accompany an educational
intervention, as in a study by Liebschutz et al. (2017); or implementation-intention
training, as in a study by Saddawi-Konefka, Schumacher, Baker, Charnin, and Gollwitzer
(2016). Additionally, fidelity to the underlying theory should be measured, as some
purportedly theory-based work has employed techniques inconsistent with theoretical
constructs (Prestwich et al., 2015). Challenges encountered in translating constructs to
specific design features, such as when evidence from theory-based research conflicts with
the needs or perceptions of participants, may help to explain these inconsistencies and
should, ideally, be addressed during intervention design (see Witteman et al., 2017).
Research Methodology
The field of psychology could contribute research expertise to studies of E-HRs in
several ways, consistent with the objective of assessing the effects of health system-level
interventions on individual experiences and behavior (see Bandura, 2003; Marks et al.,
2015). Many of these derive from human factors psychology, a subspecialty focused on
human-machine-environment interaction (Savage et al., 2017). However, because humanfactors research is a diverse field, encompassing not only cognitive psychology but also
informatics and industrial engineering (Holden, 2011; Lyell & Coiera, 2017; Ratwani et
al., 2019), the interprofessional distinctions described in this section may be imprecise.
Validated system-assessment tools. One area where psychology could make an
important contribution is the continued assessment of E-HR systems using validated
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tools, such as the Instrument for Evaluating Human-Factors Principles in MedicationRelated Decision Support Alerts (I-Me-DeSA; see Zachariah et al., 2011) or other
human-factors standards, such as clarity, prioritization of clinical information presented
on screen, and provision of actionable information (see Phansalkar et al., 2014). Not only
the devices, but also the processes used to develop them, can be the subject of such
human-factors assessment. Metrics for accepted design-process standards, which could
become research questions in a qualitative or quantitative study, include whether users
(e.g., physicians) were included in the design process, whether interfaces were evaluated
against accepted graphical-display principles (e.g., for font, color, and layout), and
whether formal usability testing was required prior to product launch (see Savage et al.,
2017). A recommended process for health care settings is assessment of practiceenvironment requirements prior to the initial design phase, using observation, interviews,
and analyses of task-related cognitive needs (Ray et al., 2019), ideal tasks for health
psychologists trained in qualitative research techniques.
Automation-bias assessment. Although originating in fields other than health
care (e.g., luggage screening and air traffic control; Lyell & Coiera, 2017), automationbias assessment has been applied to study the potential hazards of incorrect guidance
delivered by CDS, which may encourage users to switch from an original, correct
decision to an incorrect choice recommended by the system (Goddard, Roudsari, &
Wyatt, 2014; Lyell et al., 2017). For example, Lyell et al. (2017) assessed performance
on electronic-prescribing tasks in a sample of 120 medical students and found that correct
CDS guidance reduced errors by 59%, but incorrect guidance increased errors by 87%. A
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gap in the automation-bias literature is that most studies have used experimental designs
(see Lyell & Coiera, 2017), suggesting a need for naturalistic fieldwork to provide
information about the conditions under which this problem is likely to occur (see
Goddard, Roudari, & Wyatt, 2012). Environmental and psychological mediators that
should be incorporated into these assessments include trust in the CDS system,
complexity of verification tasks (i.e., determining whether a warning represents a true
threat), workload, time constraints, and intrinsic task complexity (see Goddard et al.,
2012), factors that may affect cognitive load (see Lyell & Coiera, 2017).
Physiological and psychological assessments of cognitive load. Studies
assessing cognitive load during task performance, using either subjective scales or
physiologic measures, could provide valuable information about psychological and
biologic plausibility when assessing associations of E-HR features with medical
decisions. Scales used in studies of mental workload associated with Web browsing
(Jimenez-Molina, Retamal, & Lira, 2018) and learning activities (Skulmowski & Rey,
2017) include the NASA Task Load Index (NASA-TLX), which assesses mental and
physical demands, effort, performance, and frustration, and cognitive-load surveys
designed to distinguish intrinsic versus extraneous load types. A disadvantage of scales is
that they are administered after task completion and do not allow for real-time assessment
of task-related load, which is better assessed using physiologic techniques (JiminezMolina et al., 2018). These include pupillography (measures of changes in pupil
diameter), which indicates sympathetic and parasympathetic nervous system responses;
fixed (focused) versus saccadic (rapid) eye movements; electroencephalography, which
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provides measures of mental alertness and task difficulty; and skin conductivity. These
measures can be combined and assessed in multifactorial experiments under various
conditions. For example, Mazur et al. (2016) assessed the performance of 29 medical
trainees on three clinical tasks using two different E-HRs, measuring subjective demand
using NASA-TLX, task demands using time to task completion and number of clicks,
and cognitive load using pupillary changes and electroencephalography. Results of that
study suggested that E-HR type and clinical task interact in producing task demand,
without a significant association between the physiologic measures and task performance.
Validated opinion scale. A standardized scale of physician opinions about EHRs, developed and tested using accepted psychometric procedures (see DeVellis, 2017),
would likely contribute a great deal to the understanding of how physicians perceive and
experience electronic technologies. Of the survey studies of physician opinions about
meaningful use, none included reliability or validity testing of questions about the
program (Emani et al., 2014; Shanafelt et al., 2016; Weeks et al., 2014), and only one
included a pilot test, which was conducted only on the principal investigators (Emani et
al., 2014). Given findings of the current study and previous research suggesting
autonomy as a core issue, the addition of a validated measure of autonomous motivation
to such a survey might also provide helpful information about psychological factors
underlying responses to E-HR implementation (see Emani et al., 2017).
Theory-informed, system-wide evaluations. Finally, to inform public policy
consistent with APA (2014) objectives, health psychologists may wish to consider, where
feasible, more theory-based analyses of the effects of population-level interventions on
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medical decisions. Studies of individual characteristics alone, common in health
psychology, do not address the effects of environmental factors (Kelder et al., 2015;
Sallis & Owen, 2015), such as the health-system structures that Bandura (2004)
implicated as important influences on individual health. An easily scalable analysis
would apply the theoretical framework and data set used in this study to other disease
states and drugs, preferably with a sample size sufficient for study of the interaction
effects of ownership and health-system interventions described previously in this section.
Implications
Positive Social Change
Potentially unsafe prescribing of ADHD medications affects a small minority of
adults, estimated in this study at 8.3% in the Scenario A analysis of adults treated for
ADHD and 1.5% in the Scenario B analysis of adults with either CVD or SUD. Similarly,
the study by Fairman et al. (2018) identified one-year prevalence rates of 2% for serious
CVD and 11–19% for SUD among adults newly treated for ADHD with medications.
Despite these relatively low prevalence rates, the prescribing problem measured in the
current study has potentially important implications for two targets of health psychologyinformed interventions intended to produce positive change (see Bandura, 2004):
population health (see APA, 2014) and systemic interventions on medical decisions (see
Glanz et al., 2015). Each target is discussed below.
Population health. Several trends and recent research findings suggest growing
recognition of potentially unsafe prescribing of ADHD medications. These include recent
FDA (2019) guidance on stimulants, which recommends assessment of heart rate and
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blood pressure in the drug-development process; a report that from 2006–2016 in the
United States, the 150% rate of increase in use of prescribed amphetamines far outpaced
the 8% population growth (Piper et al., 2018); and the expansion of CDC drug
surveillance efforts to include prescribed and nonprescribed stimulants (Kariisa et al.,
2019). The risks of these trends were underscored by a recently reported 37% rate of
increase from 2016–2017 in U.S. overdose deaths from psychostimulants with abuse
potential, excluding cocaine but including prescribed stimulants and a few illicit drugs
(Kariisa et al., 2019). In that regard, it is concerning that in the current study, having a
black-box warning was, unexpectedly, positively associated with potentially unsafe
prescribing despite the availability of atomoxetine and its recommended use for patients
with SUD (Bolea-Alamañac et al., 2014; Post & Kurlansik, 2012). These findings suggest
that effective health-system interventions to promote evidence-based practice in ADHDmedication prescribing may produce positive changes in population health, consistent
with APA (2014) objectives.
Systemic interventions on medical decisions. Closely related to population
health is the narrower concern of how interventions to promote evidence-based medicine
affect physicians. Physicians commonly attribute occupational dissatisfaction and
professional burnout to the increased clerical burden and diminished patient-engagement
opportunities associated with E-HRs (Friedberg et al., 2013; Shanafelt et al., 2016;
Wright & Katz, 2018). The HITECH Act is certainly not the only source of professional
dissatisfaction for physicians; other sources include difficult relationships with payers
(e.g., insurance companies, Medicare, Medicaid), patient nonadherence to medical
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advice, reductions in time allotted for visits, and managerial decisions perceived to
diminish quality of care (Colligan et al., 2016; Friedberg et al., 2013). Nonetheless, the
role of meaningful use as a large systemic intervention should not be overlooked because
of its potential effects on the health of individual patients. These effects arise from two
sources: medical errors caused or facilitated by technology (see Amato et al., 2017;
Brown et al., 2017) and the health consequences that may result when physicians either
cut back on practice hours or leave medicine altogether because of burnout (see Olson,
2017; Wright & Katz, 2018).
For example, in a 2014 survey of U.S. physicians regarding their plans for the
coming 12 months, 20% reported an intention to reduce work hours and 2% a planned
career change, and odds of making either change were multiplied by 1.81 (95% CI [1.49,
2.19]) for physicians evidencing burnout and by 1.44 (95% CI [1.16, 1.80) for those
dissatisfied with their E-HR (Sinsky et al., 2017). Olson (2017) has suggested that these
trends represent a “proverbial canary in the coal mine” (p. 1610) by highlighting the way
that systemic dysfunction can damage the well-being and productivity of individual
physicians, with unintended consequences that may include a reduction in the already
tenuous supply of doctors available to care for patients. Recognizing environmental
influences on health as Bandura (2001) did, Olson and others (see Card, 2018) have
called for interventions to improve the wellness of health systems, not just the emotional
resilience of individual physicians who must respond to systemic dysfunction. How
health psychology might contribute to those efforts is discussed next.
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Implications for Practice
If confirmed by additional research, this study’s findings may facilitate the design
and evaluation of interventions that effectively increase evidence-based decisions with
fewer unintended consequences than those currently experienced in medicine. These
interventions, like the problems they are intended to address, represent complex
interactions of medical practice environment with individual physician behaviors,
consistent with the social cognitive theoretical framework for this research (see Bandura,
1989). Four strategies are discussed in this section: physician empowerment, balancing
clinical relevance and uniformity, physician-patient relationships, and training delivered
in interdisciplinary team contexts.
Physician empowerment. To the extent that autonomy is a core issue for
physicians, greater physician empowerment in efforts to improve evidence-based
practice, including E-HR system design, might improve not only the systems but also
physician response to them by increasing perceived autonomy, as self-determination
theory (see Deci & Ryan, 2008a) and the corporate study by Deci et al. (1989) suggest. A
small body of evidence supports this strategy. For example, Gawande (2018) described
the positive results achieved in one health system when a neurosurgical team met
regularly to modify its commercial E-HR by removing clinically unimportant functions
and adding useful ones. Although this story was reported only in the popular press, the
strategy is supported by a summary of the literature on best practices for successful E-HR
design, which recommended patient care-centered development by an interdisciplinary
team including human factors psychology specialists, with extensive input and testing by
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physicians and patients (see Ray et al., 2019), consistent with the human-factors
standards described previously. The strategy is also supported by the “cranky comments”
study described in Chapter 2, which showed that physician complaints accurately
identified dysfunctional CDS features (Aaron et al., 2018).
Generally, local physician participation in the design of systems to promote
evidence-based care may be associated with acceptance of these systems and with
positive outcomes for them (Milos, Westerlund, Midlöv, & Strandberg, 2014; Robbins et
al., 2012), whereas replacing locally developed systems with large, commercial platforms
can increase overrides of recommended actions (Wright et al., 2018). The positive
outcomes of participatory approaches may be attributable, in part, to their implicit
recognition of the biomedical expertise of physicians, a commonly expressed determinant
of occupational satisfaction (see Friedberg et al., 2013). This effect is likely attributable
to the training physicians receive, which shapes their occupational and personal identity
(see Bandura, 2001) as autonomous, biomedical experts devoted to patient care
(Berkhout et al., 2018; Cooke et al., 2006). Interventions that implicitly acknowledge this
aspect of physicians’ identity may be better received than those that remove opportunities
for engagement with clinically important, biomedically challenging problems (see
Colligan et al., 2016).
Balancing clinical relevance and uniformity. Apart from autonomy, but also
suggesting value in local customization, is a need to address a common complaint about
E-HRs and CDS: they may report metrics irrelevant to the clinical circumstance or
patient (see Gawande, 2018; Schiff et al., 2016). This issue may help to explain the
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relative successes of locally developed systems. Still, balanced against the human factors
standard of end-user involvement (see Savage et al., 2017) and the widely recognized
need for customization of E-HR functions to match the specific tasks and culture of a
unique medical practice environment (see Ray et al., 2019) is the need for uniformity.
Standardization of systems may promote evidence-based decisions, consistent with the
original goal of CDS (see Bates et al., 2003), and facilitate the interoperability among
systems necessary for care coordination (see Samal et al., 2016).
An emerging solution to this challenge is modular E-HR and CDS applications
based on common knowledge bases, using software compatible with multiple E-HR
system platforms (Haug, Narus, Bledsoe, & Huff, 2018; Samal, Amore, Bates, & Wright,
2017). Using this approach, provided by initiatives like the Substitutable Medical Apps
Reusable Technologies project, an individual physician can choose individual “apps”
suitable for the specialty and practice, providing a measure of autonomy over system
design while ensuring that each app meets uniform standards (see Rosenbloom, Carroll,
Warner, Matheny, & Denny, 2017). Examples include a pediatric growth chart app that
began as a browser-based system at one children’s hospital and is currently available on
two major E-HR platforms (Haug et al., 2018), and a risk assessment tool for chronic
kidney disease, developed by one hospital using a fully interoperable knowledge base and
software (Samal et al., 2017). Health psychologists could serve on interdisciplinary teams
that choose or redesign such apps, providing expertise on cognitive principles and
facilitating discussions of the local needs that should, ideally, be the primary determinant
of system configuration (see Ray et al., 2019).
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Physician-patient relationships. A focus on physician-patient relationships, a
commonality between the disciplinary interests of medicine and health psychology, may
also be helpful. From the medical perspective, interventions that increase time spent in
patient interaction, such as using medical assistants as E-HR “scribes” to reduce clerical
burden, have been associated with improved job satisfaction (Sinsky et al., 2013).
Moreover, the needs and opportunities for shared physician-patient decision-making are
garnering increased attention in the medical literature (see Elwyn, Frosch, & Kobrin,
2016). From the health psychologist perspective, interpersonal communication in the
medical encounter is recognized as an important determinant of high-quality medical
decision-making (Duggan & Street, 2015). Thus, both disciplines should have an interest
in studies or initiatives that measure or foster good physician-patient relationships, which
physicians not only value (see Colligan et al., 2016; Tak et al., 2017), but also view as
integral to high-quality patient care (see Friedberg et al., 2013). A unique contribution of
health psychology to this endeavor is its multilevel focus, which enables an
understanding of the effects of macrolevel trends on microlevel processes and outcomes
(Bandura, 2004). A health psychologist can interpret physician-patient communication
and decision-making in the context of broader social influences affecting both parties,
such as consumerism in medicine (see J. Shapiro et al., 2011) or direct-to-consumer
advertising of medications and laboratory tests (see Schwartz & Woloshin, 2019).
Training in an interdisciplinary team context. Although results for CDS were
generally favorable in this study, the literature review suggested an unmet need for
training that better reflects cognitive psychological principles by providing specific
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guidance on use of CDS in expert decision-making, the primary goal of medical
education (Berkhout et al., 2018). Specifically, the understanding that learning is
facilitated by hands-on practice in relevant environmental contexts, which was derived
from cognitive psychology (Cooke et al., 2006), underlies core medical training protocols
(Berkhout et al., 2018) including clinical rotation experiences during medical school and
extensive opportunities for supervised decision-making in real-world clinical settings
throughout training (see Mowery, 2015). However, that context-specific training process
typically does not account for CDS (Hersh et al., 2014; Pageler et al., 2013). For
example, recently drafted milestones (competency benchmarks) for family practice
trainees mention use of health information technology, specifically “documentation
required for billing and coding,” and suggest that a highest-level trainee may improve EHR functionality (Anim et al., 2019, p. 10). However, these standards do not reference
specific skills needed for a physician to apply CDS appropriately to an individual patient
(Pageler et al., 2013). Such skills include critical evaluation of the guidance provided,
ability to formulate questions that can be answered by CDS, use of CDS to identify and
address limitations in the trainee’s medical knowledge, and balancing E-HR-delivered
information with the individual patient’s history and physical examination results.
This gap between the training received by physicians and the environmental
context in which they operate after graduation, which is highly likely to include CDS
according to the results of this and previous research (see Hsiao & Hing, 2014), may help
to explain the frustration that physicians express about using E-HRs for patient care
activities, particularly when using sophisticated systems (see Emani et al., 2017). If so,

167
specific guidance to physicians on using E-HRs to facilitate, rather than supplant, their
own clinical judgment may be helpful. Health psychologists, trained in principles of
cognition and learning, might be ideal choices to design and deliver this education.
Such interventions could be carried out as part of a comprehensive strategy for
interdisciplinary care teamwork, with collaboration of human factors psychologists to
provide guidance on the cognitive effects of human-machine-environment interaction
(Holden, 2011) and on cognitively appropriate system-development strategies described
previously in this chapter (see Ray et al., 2019; Savage et al., 2017), informatics
specialists in analysis of electronic health records to provide evidence-based suggestions
for clinical priorities, and physicians as medical experts (see Holden et al., 2018). This
approach would recognize both the inevitability and the value of electronic health data,
while giving full weight to the biomedical expertise of physicians in making decisions
about the care of their patients.
Conclusion
In October 2019, a qualitative study, described by its authors as the first to use
cognitive assessment techniques to improve E-HR inbox messaging, was published in
JAMA Network Open (D. R. Murphy, Giardina, Satterly, Sittig, & Singh, 2019). Nearly 2
years earlier, a commentary in the New England Journal of Medicine had described an
urgent need to “restore meaning and sanity for physicians,” implicating E-HRs and
meaningful use requirements as major contributors to physician burnout and its
consequences: medical errors, mental health or substance abuse problems, and premature
retirements (Wright & Katz, 2018, p. 310). That the 2019 study was published a decade
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after HITECH Act passage illustrates the slow rate of adoption of psychology-informed
scholarship in the efforts to promote evidence-based decisions. That both studies were
published in prominent medical journals highlights the import of these issues for
physicians.
In interpreting these trends, it is notable that both CDS and the HITECH Act were
intended to act on psychological phenomena, cognition and motivation, respectively; yet,
paradoxically, neither was based on any psychological theory. In this research, I explored
the possibility that using theoretical frameworks in designing and testing health system
interventions on physician behavior might result in improved medical decisions, with
fewer unintended consequences. Results, although providing modest support for theorybased approaches, identified promising areas for future investigations in health
psychology and highlighted autonomy as a theme that may tie together multiple threads
of research on medical decision-making, including the current study. For physicians—
and, ultimately, for the patients they treat—the greatest need in promotion of evidencebased medicine may be for approaches that acknowledge and rely on their expertise,
supporting them with high-quality analytics and education on using electronic tools in
health care delivery, while returning to them the measure of control over medical
decision-making warranted by their training.
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Appendix A: National Center for Health Statistics Assessments of Nonresponse Bias to
the 2012 National Ambulatory Medical Care Survey and Current Weighting Method
Characteristic
Age group
Sex
Census division (office location)
Metropolitan status (office location)
Type of doctor
Specialty

Specialty category
Practice type
Annual visit volume quartile
State (office location)

Analyses before weighting for nonresponse
Comparison of physician respondents versus
nonrespondents to the induction interview
(based on data provided by the AMA and
AOA)

Comparison of physicians providing > 1 visit
versus those providing no visits (based on
data provided by the AMA and AOA and, for
the visit quartiles, on physician induction
interview or statistical estimates of
physician’s visit volume)

Indicators used for nonresponse bias estimate (Hing et al., 2016)
Less than 50 years, 50 years or older
Male, female
New England, Middle Atlantic, East North Central, West North Central, South
Atlantic, East South Central, West South Central, Mountain, Pacific
MSA, not MSA
Medicine, osteopathy
General or family practice, internal medicine, pediatrics, general surgery,
obstetrics and gynecology, orthopedic surgery, cardiovascular diseases,
dermatology, urology, psychiatry, neurology, ophthalmology, otolaryngology,
oncology, allergy, pulmonology, other specialties
Primary care, surgical, medical
Solo, two physicians, group or HMO, medical school or government, other,
unclassified
0–25, 26–50, 51–75, 76–100
Connecticut, Massachusetts, other New England, New Jersey, New York,
Pennsylvania, Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas,
Minnesota, Missouri, other West North Central, Florida, Georgia, Maryland,
North Carolina, South Carolina, Virginia, other South Atlantic, Alabama,
Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, Texas,
Arizona, Colorado, Utah, other Mountain, California, Oregon, Washington, other
Pacific
Statistically significant results (Hing et al., 2016)a
Characteristics (%) of respondents vs. nonrespondents, respectively:
New England 5.3% vs. 7.5%
East North Central 14.2% vs. 11.3%
East South Central 6.2% vs. 5.1%
General or family practice 18.4% vs. 15.2%
Pediatrics 12.1% vs. 7.7%
Orthopedic surgery 4.1% vs. 5.2%
Cardiovascular disease 3.1% vs. 4.4%
Oncology 1.6% vs. 2.3%
Primary care 48.8% vs. 43.6%
Surgery 19.1% vs. 23.2%
Solo practitioner 25.1% vs. 21.7%
Of 39 state comparisons, 13 significantly differed; all by < 1.5 percentage points
Characteristics (%) for those providing visit data vs. no visit data, respectively:
New England 5.3% vs. 6.8%
East South Central 6.6% vs. 5.2%
MSA 90.7% vs. 92.4%
Non-MSA 9.3% vs. 7.6%
General or family practice 19.7% vs. 15.6%
Pediatrics 13.0% vs. 8.6%
Cardiovascular disease 3.0% vs. 4.0%
Oncology 1.5% vs. 2.1%
Primary care 50.8% vs. 44.2%
Surgical 18.7% vs. 22.0%
Solo practitioner 26.2% vs. 22.2%
Annual visit volume
Quartile 1 32.3% vs. 20.5%
Quartile 2 19.8% vs. 28.5%
Quartile 3 17.7% vs. 29.2%
Quartile 4 30.2% vs. 21.8%
Of 39 state comparisons, 10 significantly differed; all by < 1.5 percentage points
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Analyses after weighting for nonresponse
Comparison of U.S. in-scope sample physicians
with induction interview respondent physicians
(based on data provided by the AMA and AOA)

Statistically significant results (Hing et al., 2016)a
Characteristics (%) of in-scope sample vs. respondents, respectively:
MSA 91.7% vs. 92.7%
Non-MSA 8.3% vs. 7.3%
Potential bias (absolute value of difference between in-scope sample and
respondents)
0 (zero) bias for 62 estimates
< 1.0 percentage points for 18 estimates
2 estimates with bias > 1.0 percentage points:
-Solo practitioner 1.7 percentage points (23.7% vs. 25.4%)
-Group or HMO 1.3 percentage points (59.4% vs. 58.1%)

Comparison of U.S. in-scope sample physicians
with physicians providing > 1 visit (based on data
provided by the AMA and AOA and, for the visit
quartiles, on physician induction interview or
statistical estimates of physician’s visit volume)

Characteristics (%) of in-scope sample vs. those providing > 1 visit,
respectively:
Solo practitioner 23.7% vs. 26.7%
Group or HMO 59.4% vs. 56.6%
Annual visit volume
Quartile 1 25.0% vs. 33.2%
Quartile 2 25.2% vs. 20.1%
Quartile 3 24.8% vs. 17.9%
Quartile 4 25.0% vs. 28.8%
Of 39 state comparisons, 4 significantly differed; all differences < 1.5
percentage points
Potential bias (absolute value of difference between in-scope sample and
respondents)
0 (zero) bias for 37 estimates
< 1.0 percentage points for 39 estimates
> 1.0–< 2.0 percentage points for 4 estimates
> 2.0 percentage points for 6 estimates:
-Solo practitioner 3.0 percentage points
-Group or HMO 2.8 percentage points
-Annual visit volume (quartile 1: 8.2 percentage points; quartile 2: 5.1
percentage points; quartile 3: 6.9 percentage points; quartile 4: 3.8 percentage
points)

Comparison of estimated in-scope sample visits
with NAMCS sampled visits (based on data
provided by the AMA and AOA and, for the visit
quartiles, on physician induction interview or
statistical estimates of physician’s visit volume)

Characteristics (%) of visits, comparing estimated in-scope sample with
NAMCS sample, respectively:
MSA 91.1% vs. 89.5%
Non-MSA 8.9% vs. 10.5%
Oncology 1.8% vs. 1.4%
Annual visit volume
Quartile 1: 9.9% vs. 18.3%
Quartile 3: 27.2% vs. 21.3%
Of 39 state comparisons, 2 significantly differed, both < 0.5 percentage point
Potential bias (absolute value of difference between in-scope sample visits
and NAMCS sampled visits)
< 0.5 percentage points for 66 estimates
> 0.5– < 1.0 percentage points for 8 estimates
> 1.0– < 2.0 percentage points for 5 estimates
> 2.0 percentage points for 2 estimates:
-Annual visit volume (quartile 1: 8.4 percentage points; quartile 3: 5.9
percentage points)
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Summary of weight calculation procedures, 2014–2016 (CDC, 2017, 2018, 2019b)
Step 1: Calculate sample-selection weights based on multiplicative inverses (reciprocals) of sampling probabilities for (a) selecting
physician from each stratum and (b) selecting a visit from the sampled physician, annualized based on a count of weeks in which
physician saw patients. Sampling strata were defined as follows:
2014—Primary versus nonprimary care type, 25 geographic areas (nine Census divisions, 17 most populous states) = up to 50
strata
2015—Fourteen physician specialties, 20 geographic areas (four Census regions, 16 most populous states) = up to 280 strata
2016—Fourteen physician specialties, four Census regions = up to 56 strata
Because a stratum could contain no visits (e.g., if no visits were made by sampled adults to a particular specialist in a particular
state), actual number of strata for the current study sample was unknown until data were accessed. The logistic regression models
contained 301 physicians and 101 strata in Scenario A, and 1,659 physicians and 130 strata in Scenario B.
Step 2: Adjust for nonresponse, accounting for seasonality, number of weeks practiced during year, and number of visits during a
typical week of practice. Weights accounted for nonresponse within the following strata:
2014—Fourteen physician specialties, 25 geographic areas, MSA status = up to 700 strata
2015—Fourteen physician specialties, 20 geographic areas, MSA status = up to 560 strata
2016—Three practice types and four regions = up to 12 strata; physicians who submitted E-HRs were treated as nonrespondents
because their submissions could not be used
Step 3: Apply ratio adjustment to correct for differences in the sampling frame between time of sample selection and time of data
collection, calculated for each physician specialty group and geographic area.
Step 4: Apply a weight-smoothing adjustment that corrects for outlier weights. Numerator and denominator, respectively, are total
visit count in each group before and after trimming largest weights, for each physician group as defined in Step 2 above.

Note. Only statistically significant results (differences in percentages) are shown in the table. Comparisons on indicators not shown in
the table were not statistically significant. For factors with multiple categories where χ2 test was performed for the variable overall
(e.g., Census, specialty), table presents only indicators where response rate significantly differed from national rate. Note that
significant results for surgical specialties are described but not relevant because visits to surgeons were excluded from the current
study sample. AMA = American Medical Association; AOA = American Osteopathic Association; E-HR = electronic health record;
HMO = health maintenance organization; MSA = metropolitan statistical area; NAMCS = National Ambulatory Medical Care Survey;
CDC = U.S. Centers for Disease Control and Prevention.
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Appendix B: Antidiabetic and Antihypertensive Drug Names

Antidiabetic
Sources
Drug Names
CDC
Acarbose
(2017); J. Albiglutide
W. M.
Alogliptin
Cheng,
Bromocriptine
Badreldin, Canagliflozin
Patel, and Colesevelam
Bhatt
Dapagliflozin
(2017)
Dulaglutide
Empagliflozin
Ertugliflozin
Exenatide
Gliclazide
Glimepiride
Glipizide
Glyburide
Insulin
Linagliptin
Liraglutide
Lixisenatide
Metformin
Miglitol
Nateglinide
Pioglitazone
Pramlintide
Repaglinide
Rosiglitazone
Saxagliptin
Semaglutide
Sitagliptin
Tolbutamide

Antihypertensive
Sources Drug Names, A to L Drug Names, M to Z
CDC
Acebutolol
Mecamylamine
(2017);
Aliskiren
Metolazone
Fairman, Amiloride
Metoprolol
Romanet, Amlodipine
Methylclothiazide
Early,
Atenolol
Methyldopa
and
Azilsartan
Minoxidil
Goodlet
Benazepril
(nontopical)
(2019)
Betaxolol
Moexipril
Bisoprolol
Nadolol
Candesartan
Nebivolol
Captopril
Nicardipine
Carvedilol
Nifedipine
Chlorothiazide
Nisoldipine
Chlorthalidone
Olmesartan
Clonidine
Penbutolol
Diltiazem
Perindopril
Doxazosin
Pindolol
Enalapril
Prazosin
Eplerenone
Propranolol
Eprosartan
Quinapril
Felodipine
Ramipril
Fosinopril
Reserpine
Furosemide
Spironolactone
Guanabenz
Telmisartan
Guanfacine
Terazosin
Hydralazine
Timolol
Hydrochlorothiazide Torsemide
Indapamide
Trandolapril
Irbesartan
Treprostinil
Isradipine
Triamterene
Labetalol
Valsartan
Lisinopril
Verapamil
Losartan
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Appendix C: International Classification of Diseases Drug Codes
Diagnosis

ICD-9 Codes

ICD-10 Codes

Angina
Anxiety

413 Angina pectoris
300 Anxiety, dissociative and somatoform
disorders

I20
F40
F41
F42
F44
F45

Arrhythmias

426 Conduction disorders
427 Cardiac dysrhythmias
V45.0 Cardiac device in situ; unspecified,
pacemaker, automatic implantable defibrillator, or
other

Attention-deficit
hyperactivity
disorder

314 Hyperkinetic syndrome of childhood

Bradycardia (slow
heartbeat)

427.89 Other specified cardiac dysrhythmias
426.0 Atrioventricular block, complete
426.1 Atrioventricular block other and unspecified
426.2 Left bundle branch hemiblock
426.3 Other left bundle branch block
426.5 Bundle branch block other and unspecified

R00.l
I44.0
I44.1
I44.2
I44.3
I44.4
I44.5
I44.6
I44.7

Cancer, metastatic

196 Secondary and unspecified malignant
neoplasm of lymph nodes
197 Secondary malignant neoplasm of respiratory
and digestive systems
198 Secondary malignant neoplasm of other
specified sites
199.0 Disseminated malignant neoplasm without
specification of site
199.1 Other malignant neoplasm without
specification of site

C77
C78
C79
C7B

Cardiac anomalies

745 Bulbus cordis anomalies and anomalies of
cardiac septal closure
746 Other congenital anomalies of heart
747 Other congenital anomalies of circulatory
system

Q20
Q21
Q22
Q23
Q24
Q25
Q26
Q27
Q28

Cardiomegaly
Cardiomyopathy

429.3 Cardiomegaly
425 Cardiomyopathy

I51.7
I42
I43

I44
I45
I48
I49
Z95.0
Z95.81
F90

(appendix continues)
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Diagnosis

ICD-9 Codes

ICD-10 Codes

Connective
tissue/rheumatic
disordera

517.1 Rheumatic pneumonia
710.0 Systemic lupus erythematosus
710.1 Systemic sclerosis
710.4 Polymyositis
714.0 Rheumatoid arthritis
714.1 Felty’s syndrome
714.2 Other rheumatoid arthritis with visceral
or systemic involvement
714.81 Rheumatoid lung
725 Polymyalgia rheumatica

M05
M06
M32
M33.2
M34
M35.3

Dementia (codes
used for verification
of the indicator)a,b
Diabetes
complicationsa

290 Dementias
331 Other cerebral degenerations

HIV (codes used for
verification of the
indicator)a

042 Human immunodeficiency virus [HIV]
disease

B20

Hypertensive heart
disease

402 Hypertensive heart disease
404 Hypertensive heart and chronic kidney
disease

I11
I13

Hypotension

458 Hypotension

I95

Liver disease, mild

571.2 Alcoholic cirrhosis of liver
571.4 Chronic hepatitis
571.5 Cirrhosis of liver without mention of
alcohol
571.6 Biliary cirrhosis
and not severe

250.4 Diabetes with renal manifestations
250.5 Diabetes with ophthalmic
manifestations
250.6 Diabetes with neurological
manifestations

F03
G30
E10.2
E11.2
E13.2
E14.2
E10.3
E11.3
E13.3
E14.3
E10.4
E11.4
E13.4
E14.4

K70.2
K70.3
K71.7
K73
K74.0
K74.2
K74.3
K74.4
K74.5
K74.6

(appendix continues)
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ICD-9 Codes

ICD-10 Codes

Liver disease,
severe

572.2 Hepatic encephalopathy
572.3 Portal hypertension
572.4 Hepatorenal syndrome
572.8 Other sequelae of chronic liver disease

K72.1
K72.9
K76.6
K76.7

Myocardial
infarction
(heart attack)
historya

410 Acute myocardial infarction
412 Old myocardial infarction

I21
I22
I23
I25.2

Paraplegiaa

342 Hemiplegia and hemiparesis
344.1 Paraplegia

G04.1
G81
G82.2

Peptic ulcera

531 Gastric ulcer
532 Duodenal ulcer
533 Peptic ulcer site unspecified
534 Gastrojejunal ulcer

K25
K26
K27
K28

Peripheral
arterial disease

443.9 Peripheral vascular disease, unspecified
V43.4 Blood vessel replaced by other means

Renal disease
(codes used for
verification of
the indicator)

585 Chronic kidney disease (ckd)
586 Renal failure, unspecified

N18
N19

Pulmonary
diseasesa

490 Bronchitis, not specified as acute or chronic
491 Chronic bronchitis
492 Emphysema
493 Asthma
494 Bronchiectasis
495 Extrinsic allergic alveolitis
496 Chronic airway obstruction, not elsewhere
classified
500 Coal workers’ pneumoconiosis
501 Asbestosis
502 Pneumoconiosis due to other silica or silicates
503 Pneumoconiosis due to other inorganic dust
504 Pneumonopathy due to inhalation of other dust
505 Pneumoconiosis, unspecified
or condition code for asthma or COPD

J40
J41
J42
J43
J44
J45
J46
J47
J60
J61
J62
J63
J64
J65
J66
J67

I73.9
Z95.8
Z95.9

(appendix continues)
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Substance use
disorder (codes
used for
verification of
the indicators)

ICD-9 Codes
291 Alcohol-induced mental disorders
292 Drug-induced mental disorders
303.xx Alcohol dependence syndrome
304.xx Drug dependence
305.xx Nondependent abuse of drugs
965.0 Poisoning by opiates and related narcotics
967 Poisoning by sedatives and hypnotics
969.1 Poisoning by phenothiazine-based
tranquilizers
969.2 Poisoning by butyrophenone-based
tranquilizers
969.4 Poisoning by benzodiazepine-based
tranquilizers
969.5 Poisoning by other tranquilizers
969.6 Poisoning by psychodysleptics
(hallucinogens)
969.7 Poisoning by tranquilizers, hallucinogens, or
psychostimulants
970 Poisoning by central nervous system stimulants

ICD-10 Codes
F10
F11
F12
F13
F14
F15
F16
F18
F19
T40
T42.3x, T42.4x, T42.6x, T42.7x
T43.6x

Substance use
disorder,
alcoholic
effects on liver

571.0 Alcoholic fatty liver
571.1 Alcoholic hepatitis
571.2 Alcoholic cirrhosis
571.3 Alcoholic liver damage

K70

Valvular
disorders,
aortic
Valvular
disorder, mitral

424.1 Aortic valve disorders
746.3 Congenital stenosis of aortic valve

I35
I06

424.0 Mitral valve disorders
394 Diseases of mitral valve
396 Diseases of mitral and aortic valves
424.3 Pulmonary valve disorders

I34
I05

Valve disorder,
tricuspid

424.2 Tricuspid valve disorders, specified as
nonrheumatic
397.0 Diseases of tricuspid valve

I36
I07

Valve disorder,
other

424.9 Endocarditis, valve unspecified

I38
I39
I08

Valvular
disorder,
pulmonary

I37

Notes. Codes and descriptions were obtained from icd9data.com and icd10data.com. ICD-9 codes (U.S. Department of Health and
Human Services, 1997) and a map from ICD-9-CM (clinical modification for U.S. health care) to ICD-10-CM (U.S. Department of
Health and Human Services, 2015) are in the public domain. Although ICD-10-CM code files are publicly available for download
from the CMS (2018a) website, the ICD-10, which was the basis for ICD-10-CM, is promulgated by the World Health Organization
(CMS, 2018b). For this reason, the right-hand column does not contain verbatim descriptions of each code.
a
Used in Charlson Comorbidity Index (Quan et al., 2011). bA dementia indicator was added to the survey in 2014 (CDC, 2018).
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Appendix D: Assessments of Sample Size Adequacy, Scenario A
n
All patients
Sex
Female
Male
Age group (years)
17–25
26–49
50 or older
Race and ethnicity
White, non-Hispanic
Black, non-Hispanic
Hispanic
Other
Primary payment source
Private
Medicaid
Medicare
Other
Office location
Urban
Nonurban
Physician specialty
Cardiology
Psychiatry
Neither of these
Black-box diagnosis
Yes
No
Charlson comorbidities
None
One
Two
Three or more
Psychiatric comorbidities
Depression, no
Depression, yes
Anxiety, no
Anxiety, yes
Relationship with patient
New
Established, not PCP
PCP
Environmental features
CDS, no
CDS, yes
Meaningful use, no
Meaningful use, yes
Patient revenue, no
Patient revenue, yes
Prescription typec
New
Continued

81

Potentially unsafe medication
%a
95% CI
Relative CI
width
width (%)
100.0
NA
NA

Safer medication or psychotherapy
%a
95% CI
Relative CI
width
width (%)
729
100.0
NA
NA
n

31
50

39.0
61.0

27.0
27.0

69.2
44.3

392
337

54.7
45.3

11.1
11.1

20.3
24.5

18
52
11

23.4
61.6
15.0b

28.4
29.6
20.0

121.4
48.1
133.3

233
349
147

31.7
46.5
21.8

10.4
12.8
9.3

32.8
27.5
42.7

73
4
2
2

94.9
3.1b
1.7b
0.3b

9.4
8.1
6.3
2.2

9.9
261.3
370.6
733.3

635
30
41
23

85.5
4.8
6.0
3.6

8.1
5.5
4.3
3.8

9.5
114.6
71.7
105.6

36
12
4
25

44.0b
9.3b
3.6b
43.1b

36.5
15.7
9.9
39.7

83.0
168.8
275.0
92.1

403
83
42
164

58.2
13.5
5.8
22.4

20.5
12.3
6.0
22.8

35.2
91.1
103.4
101.8

73
8

89.9
10.1b

22.9
22.9

25.5
226.7

683
46

92.1
7.9b

18.2
18.2

19.8
230.4

42
38

64.1b
34.5b

32.1
31.7

Not assessed; total number of visits = 3
50.1
451
60.3
19.9
91.9
276
39.6
20.0

33.0
50.5

72
9

93.9
6.1b

10.6
10.6

33b
696

5.4
5.4

135.0
5.6

74
6

91.6
7.4b

16.6
16.3

5.2
4.4

5.5
107.3

50
31
65
16

62.2b
37.8b
81.7
18.3

31.5
31.5
21.5
21.5

50.6
83.3
26.3
117.5

453
276
530
199

65.1
34.9
70.4
29.6

13.7
13.7
13.8
13.8

21.0
39.3
19.6
46.6

6
47
25

6.2b
72.7
21.1

14.6
27.2
25.6

235.5
37.4
121.3

60
456
195

9.7
64.1
26.1

7.5
15.5
14.8

77.3
24.2
56.7

24
56
25
56
11
70

30.5b
69.5b
27.8b
72.2b
17.9b
82.1

34.2
34.2
30.7
30.7
28.2
28.2

112.1
49.2
110.4
42.5
157.5
34.3

298
413
311
418
67
662

35.3
64.7
40.1
59.9
7.1
92.9

23.3
23.3
23.6
23.6
9.0
9.0

66.0
36.0
58.9
39.4
126.8
9.7

15
66

21.7
78.3

22.9
22.9

105.5
29.2

116
505

17.5
82.5

9.8
9.8

56.0
11.9

112.9
173.8

4.0
96

18.1
693
94.3
220.3
29
4.1
Not assessed; total number of visits = 6
Not assessed; total number of visits = 2

Notes. CDS = computerized decision support; CI = confidence interval; NA = not applicable; NCHS = National Center for Health
Statistics; PCP=primary care provider; SE = standard error.
a
Percentages are based on weighted counts, not on the unweighted counts shown in the table. No estimates met the statistical reliability
standard of design effect-adjusted denominator > 30 (Parker et al., 2017).bEstimate does not meet statistical reliability standard for
confidence interval width. cLimited to patients prescribed > 1 medication.
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Appendix E: Assessments of Sample Size Adequacy, Scenario B
Potentially unsafe medication
%a
95% CI
Relative CI
width
width (%)
143
100.0
NA
NA

8,958

58
85

34.3
65.7

21.4
21.4

62.4
32.6

4,134
4,824

46.3
53.7

3.8
3.8

8.2
7.1

26
75
42

16.9
44.9
38.2

18.3
24.1
25.6

108.3
53.7
67.0

233
1,251
7,474

2.8
14.8
82.5

1.5
4.4
4.9

53.6
29.7
5.9

131
5
4
3

93.9
3.4b
1.4b
1.3b

9.3
8.9
3.5
6.1

9.9
261.8
250.0
469.2

7,372
730
567
289

77.2
9.5
9.4
3.9

5.7
2.9
4.5
1.9

7.4
30.5
47.9
48.7

65
15
17
36

47.3
7.8b
8.0
37.0b

29.4
11.3
10.1
32.4

62.2
144.9
126.3
87.6

2,605
648
4,708
404

31.5
7.6
54.9
5.9

4.6
3.2
5.3
3.8

14.6
42.1
9.7
64.4

133
10

92.5
7.5b

14.0
14.0

15.1
186.7

7,987
971

90.0
10.0

5.9
5.9

6.6
59.0

9
57
77

5.0b
48.4b
46.7

9.7
30.6
29.7

194.0
63.2
63.6

2,873
435
5,650

25.5
4.7
69.9

9.6
2.6
9.5

37.6
55.3
13.6

113
30

75.6
24.4

26.0
26.0

34.4
106.6

2,130
6,828

27.0
73.0

7.0
7.0

25.9
9.6

118
16
5
4

79.3
9.6
6.3b
4.7b

23.5
11.3
26.3
15.6

29.6
117.7
417.5
331.9

5,139
1,905
1,145
769

56.4
21.3
12.9
9.5

6.6
3.9
3.0
5.5

11.7
18.3
23.3
57.9

88
55
120
23

62.8
37.2
85.2
14.8

24.7
24.7
17.4
17.4

39.3
66.4
20.4
117.6

7,570
1,388
8,479
479

84.1
15.9
94.0
6.0

3.5
3.5
3.2
3.2

4.2
22.0
3.4
53.3

15
80
43

5.6b
66.1
28.3

8.6
25.0
24.6

153.6
37.8
86.9

1,118
4,530
3,104

10.8
43.9
45.3

2.9
9.2
8.7

26.9
21.0
19.2

37
104
33
110
21
122

30.0
70.0
19.6
80.4
13.0b
87.0

30.2
30.2
20.8
20.8
21.3
21.3

100.7
43.1
106.1
25.9
163.8
24.5

951
7,797
1,032
7,926
1,645
7,313

10.1
89.9
12.1
87.9
14.3
85.7

5.6
5.6
6.2
6.2
6.1
6.1

55.4
6.2
51.2
7.1
42.7
7.1

n

All patients
Sex
Female
Male
Age group (years)
17–25
26–49
50 or older
Race and ethnicity
White, non-Hispanic
Black, non-Hispanic
Hispanic
Other
Primary payment source
Private
Medicaid
Medicare
Other
Office location
Urban
Nonurban
Physician specialty
Cardiology
Psychiatry
Neither of these
Black-box diagnosis
Yes
No
Charlson comorbidities
None
One
Two
Three or more
Psychiatric comorbidities
Depression, no
Depression, yes
Anxiety, no
Anxiety, yes
Relationship with patient
New
Established, not PCP
PCP
Environmental features
CDS, no
CDS, yes
Meaningful use, no
Meaningful use, yes
Patient revenue, no
Patient revenue, yes

n

Safer medication or psychotherapy
%a
95% CI
Relative CI
width
width (%)
100.0
NA
NA

Note. Estimates for the variable indicating new versus continuing prescription could not be computed because only 1 visit included the
prescribing of a medication that was both new and safer. CDS = computerized decision support; CI = confidence interval; NA = not
applicable; NCHS = National Center for Health Statistics; PCP = primary care provider; SE = standard error.
a
Percentages are based on weighted counts, not on the unweighted counts shown in the table. No estimates in the “safer” column met
the statistical reliability standard of design effect-adjusted denominator > 30 (Parker et al., 2017). Design effect-adjusted denominator
for potentially unsafe prescriptions = 41. bEstimate does not meet statistical reliability standard for confidence interval width.
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Appendix F: Multicollinearity Assessments, Atheoretical and Theory-Based Models
Tolerance
Atheoretical model
Male sex
Age group 26 to 49 years
Age group 50 years or older
White or Hispanic race
Medicaid insurance
Urban MSA
Depression
Anxiety
Cardiology
Psychiatry
Black-box warning
Comorbidity index >1
Interval-scale age
CDS
CDS × BBW
Meaningful use
Theory-based model
Male sex
Age group 26 to 49 years
Age group 50 years or older
White or Hispanic race
Medicaid insurance
Urban MSA
Depression
Anxiety
Cardiology
Psychiatry
Black-box warning
Comorbidity index > 1
Interval-scale age
CDS
Meaningful use
Patient-derived revenue
PCP, > 4 visits
PCP, < 3 visits
Continuing prescription

Scenario A
Variance
inflation factor

.925
1.081
.347
2.882
.131
7.646
.969
1.032
.905
1.105
.825
1.212
.809
1.236
.823
1.215
Not included in model; n = 3
.627
1.596
Not included in model; n = 72 of
81 potentially unsafe prescriptions
.922
1.084
.173a
5.767
.419
2.389
Not included in model
.380
2.635

.912
1.096
.347
2.878
.128
7.787
.960
1.042
.890
1.124
.751
1.332
.804
1.244
.823
1.216
Not included in model; n = 3
.330
3.029
Not included in model; n = 72 of
81 potentially unsafe prescriptions
.909
1.100
.169c
5.914
.414
2.416
.360
2.774
.910
1.099
.599
1.670
.510
1.961
.928
1.078

Scenario B
Tolerance
Variance
inflation factor
.968
.179
.113
.967
.949
.977
.863
.865
.858
.766
.106

1.033
5.586
8.867
1.034
1.054
1.024
1.158
1.157
1.165
1.306
9.391

.879
.307b
.406
.121
.574

1.137
3.260
2.465
8.260
1.741

.967
.182
.114
.963
.944
.954
.860
.865
.680
.716
.598

1.034
5.488
8.745
1.039
1.059
1.048
1.163
1.156
1.471
1.396
1.671

.875
1.142
.306d
3.270
.572
1.750
.574
1.742
.983
1.017
.689
1.451
.736
1.359
Not included in model; n = 11 of 12
safer prescriptions

Note. Derived using method recommended by Midi et al. (2010). Tolerance for each predictor is 1 minus R2 for the regression of the
predictor on all other predictors (Warner, 2013). Variance inflation factor is the reciprocal of tolerance. BBW = black-box warning;
CCI = Charlson comorbidity index; CDS = computerized decision support; CVD = cardiovascular disease; MSA = metropolitan
statistical area; PCP = primary care provider.
a
After removal of the categorical age indicators, tolerance improved to .913, with variance inflation factor of 1.096. bAfter removal of
the categorical age indicators, tolerance improved to .629, with variance inflation factor of 1.589. cAfter removal of the categorical age
indicators, tolerance improved to .899, with variance inflation factor of 1.112. dAfter removal of the categorical age indicators,
tolerance improved to .625, with variance inflation factor of 1.600.
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Appendix G: Assessments of Sample External Validity Using National or Large-Sample
Benchmarks
Measure and source

Use of E-HR (ONC, 2019)

Physicians
Time period and unit
of analysis
2014–2015

Benchmark percentage

82.8 in 2014
86.9 in 2015

Patients with cardiovascular disease
Demographic and clinical characteristicsa (Xian et
Time period and unit
Benchmark percentage
al., 2019)
of analysis
Female
White
Black
Hispanic
Private insurance
Hypertension
Diabetes

2015, 133 practices
throughout the
United States, % of
patients

36.2
87.3
10.4
6.8
56.5
85.2
39.8

Adults with attention-deficit hyperactivity disorder
Comorbidities (Kooij et al., 2019)
Time period and unit
Benchmark percentage
of analysis
Anxiety
Substance use disorder

Review article; time
34
period not specified
11
Adult patients with attention-deficit hyperactivity disorder treated with medication
Demographic and clinical characteristics (Fairman et Time period and unit
Benchmark percentage
al., 2018)
of analysis

Female
Age group (years)
25–34
35–44
45–54
55–64
Serious CVD
Substance use disorder
Diabetes
Hyperlipidemia
Hypertension
Percentage reporting
stimulant use
(Compton et al., 2018)
Alcohol use disorder
Cannabis use disorder
Opioid use disorder

2014–2015, privately
insured enrollees
aged 18–64 years
treated for ADHD
with medicationb

51.1

25.8
21.2
14.0
5.7
2.0
11.7–18.8c
3.1
11.5
11.5
Adult U.S. residents with substance use disorder
Time period and unit of
Benchmark percentage
analysis
Household surveys,
U.S. residents aged >
18 years

18.3%
29.1%
25.8%

Study sample % of
visits
2014–2015
89.1

Study sample % of
visits
2014–2016
46.3
76.8
9.8
9.3
49.0
74.0
31.8
Study sample % of
visits
2014–2016
28.7
11.4
Study sample, % of
visits
2014–2016
53.3
41.6
19.1
23.3
16.0
0.6
10.0
1.8
4.8
8.3
Study sample
% of visits
2014–2016
4.1

Note. ADHD = attention-deficit hyperactivity disorder; CVD = cardiovascular disease; E -HR = electronic health record; NAMCS =
National Ambulatory Medical Care Survey; ONC = Office of the National Coordinator for Health Information Technology.
a
Patient characteristics for sample overall were calculated from the published article as weighted averages of characteristics reported
separately for patients with cerebrovascular disease only, coronary artery disease only, or both. Statistical test comparisons with present
sample were not performed for insurance coverage or race because of differences in definitions. Pearson χ2 tests: diabetes χ2[1] =
62.92, p < .001; hypertension χ2[1] = 158.3, p < .001; percentage female χ2[1] = 90.55, p < .001 bExcluding lisdexamfetamine.
Statistical significance test comparisons with present sample were not performed because N in the study by Fairman et al. (2018) was
91,588. cRate shown for the study by Fairman et al. (2018) includes all patients in sample, not just the patients treated with stimulants.
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Appendix H: Initial Assessments of Statistical Reliability of Logistic Regression
Coefficients
Cases in model (n)
Predictor
Reference
group
Male
Age (years)
White or
Hispanic
race
Medicaid
Urban
Depression
Anxiety
Cardiology
Psychiatry

Female
Black or
other race
Other or no
insurance
Nonurban
No
depression

Neither
cardiology
nor
psychiatry
CCI of > 1
CCI = 0
CDS
No CDS
BBW
No BBW
BBW ×
No
CDS
interaction
Meaningful No
use
meaningful
use
Theory–based terms, first
stage of theory–based
modeling
PCP, > 4
Not PCP
visits
PCP, < 3
Not PCP
visits
Patient
No patient
revenue
revenue
Continued
New
prescription prescription

Scenario A: patients with ADHD
669a
β
SE of Number potentially
β
unsafe
Dummy Reference
0.487
.305
48
29
–0.006 .010
Not applicable
1.100
.626
72
5

Scenario B: patients with CVD or SUD
8,685a
β
SE of Number potentially
β
unsafe
Dummy Reference
0.370
.253
83
54
–0.040 .009
Not applicable
1.022
.532
130
7

–0.539

.587

12

65

–0.627

.365

16

121

–0.722
0.560

.707
.383

69
30

8
47

–0.075
0.251

.439
.302

127
54

10
83

–1.003 .419
16
61
Not included in model; n = 3
1.231
.431
41
36

–0.686
–0.765
1.904

.326
.567
.364

23
9
56

114
128
81

0.041
.614
6
71
–0.607 .741
53
24
Removed in sample size adequacy test
Removed in sample size adequacy test

–0.011
–1.409
–0.225
0.605

.398
.776
.729
.770

24
100
107
76

113
37
30
61

1.619

.772

52

25

1.053

.418

104

33

0.040

.607

13

64

–0.436

.518

20

117

–0.264

.635

12

65

0.488

.453

23

114

–0.968

.454

67

10

0.133

.372

118

19

–0.258

.287

64

13

Removed in sample size adequacy test

Note. ADHD = attention-deficit hyperactivity disorder; BBW = black-box warning; CCI = Charlson comorbidity index; CDS =
computerized decision support; CVD = cardiovascular disease; PCP = primary care provider; SE = standard error; SUD = substance
use disorder.
a
Excludes cases with missing values on any predictor in either the theory-based or atheoretical models. In Scenario A, this exclusion
criterion includes 108 visits in which no medication was prescribed, because the theory-based model includes a predictor of whether
the medication was new or continued.

240
Appendix I: Atheoretical Models, Scenarios A and B, Complex Samples Logistic
Regression Analyses of U.S. Office-Based Physician Visits Made by Adults, 2014–2016

Unweighted number of visits
Number of physicians (strata)
“c” (concordance) Statistic
Nagelkerke R2
Model χ2 (critical χ2, α = .05;
df), p
Predictor
Reference
group
Male
Female
Age (years)
White or
Black or
Hispanic
other race
race
Medicaid
Any other
payment
source
Urban
Nonurban
Depression
Anxiety
Cardiology
Psychiatry

BBW
CDS
BBW × CDS
Meaningful
use

No
depression
Neither
cardiology
nor
psychiatry
No BBW
No CDS
No
interaction
No
meaningful
use

Scenario A: patients with ADHD
Potentially unsafe prescription versus any other
treatment (safer medication or psychotherapy)
669
301 (101)
.572
.099
31.03 (16.92; df = 9), p < .001
β

Scenario B: patients with CVD or SUD
Potentially unsafe prescription versus no
potentially unsafe prescription
8,685
1,659 (130)
.870
.243
306.59 (21.03; df = 12), p < .001
β

SE

OR

0.371
–0.040
1.028

.253
.009
.534

1.449
0.961
2.794

[0.882, 2.380]
[0.945, 0.977]
[0.981, 7.960]

Not included in model; removed in statistical
reliability assessment

–0.619

.366

0.539

[0.262, 1.105]

–0.582

.713

0.559

[0.137, 2.277]

0.551

.407

1.735

[0.777, 3.871]

Not included in model; removed in statistical
reliability assessment
0.250
.299
1.284
[0.714, 2.307]

0.511
–0.003
1.121

SE

OR

.301
.009
.632

1.667
0.997
3.068

–0.960
.413
0.383
Not included in model; n = 3
1.214
.424
3.367

95% CI
[0.921, 3.017]
[0.978, 1.015]
[0.883, 10.661]

[0.169, 0.865]
[1.459, 7.771]

Not included in model; removed in sample size
adequacy test
–0.620
.733
0.538
[0.127, 2.284]
Not included in model; removed in sample size
adequacy test
1.602
.753
4.961
[1.124, 21.898]

95% CI

–0.685
–0.768
1.900

.328
.564
.357

0.504
0.464
6.688

[0.265, 0.959]
[0.153, 1.403]
[3.321, 13.468]

–0.224

.726

0.800

[0.192, 3.324]

–1.406
0.608

.782
.777

0.245
1.836

[0.053, 1.137]
[0.400, 8.428]

1.053

.417

2.865

[1.265, 6.488]

Note. Bold text denotes a statistically significant predictor. Sampling-design degrees of freedom were 200 for Scenario A and 1,529
for Scenario B. ADHD = attention-deficit hyperactivity disorder; BBW = black-box warning; CDS = computerized decision support;
CI = confidence interval; CVD = cardiovascular disease; df = degrees of freedom; LL = log likelihood; NA=not applicable; OR =
odds ratio (exponentiated β); SE = standard error; SUD = substance use disorder.
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Appendix J: Theory-Based Models, Scenarios A and B, Logistic Regression Analyses of
U.S. Office-Based Physician Visits Made by Adults, 2014–2016
Binary Outcome

Unweighted number of visits
Number of physicians (strata)
“c” (concordance) Statistic
Nagelkerke R2
Model χ2 (critical χ2, α = .05;
df), p
Predictor
Reference
group
Male
Female
Age (years)
White or
Black or
Hispanic race
other race
Medicaid
Any other
payment
source
Urban
Nonurban
Depression
Anxiety
Cardiology

Psychiatry

BBW
CDS
Meaningful use

Patient-derived
revenue
PCP
Continuing
prescription

No
depression
No anxiety
Neither
cardiology
nor
psychiatry
Neither
cardiology
nor
psychiatry
No BBW
No CDS
No
meaningful
use
No revenue
on this
basis
Physician is
not the PCP
New
prescription

Scenario A: patients with ADHD
Potentially unsafe prescription versus another
treatment (safer medication or
psychotherapy)
669
301 (101)
.587
.116
36.41 (21.03; df = 12), p < .001

Scenario B: patients with CVD or SUD
Potentially unsafe prescription versus no
potentially unsafe prescription

β

SE

OR

β

SE

OR

0.501
–0.001
1.163

.293
.010
.647

1.650
0.999
3.199

[0.925, 2.941]
[0.979, 1.018]
[0.893, 11.466]

0.361
–0.040
1.020

.264
.009
.536

1.435
0.961
2.774

[0.855, 2.407]
[0.945, 0.977]
[0.970, 7.937]

Not included in model; removed in statistical
reliability assessment

–0.599

.375

0.549

[0.263, 1.146]

–0.630

.699

0.533

[0.134, 2.113]

0.596

.393

1.814

[0.837, 3.935]

Not included in model; removed in statistical
reliability assessment
0.238
.303
1.269
[0.701, 2.299]

95% CI

8,685
1,659 (130)
.871
.243
305.68 (22.36; df = 13), p < .001
95% CI

–0.958
.393
0.384
[0.177, 0.832]
Not included in model; n = 3

–0.684
–0.743

.323
.657

0.505
0.476

[0.268, 0.951]
[0.131, 1.724]

1.163

1.936

.415

6.928

[3.069, 15.639]

Not included in model; removed in sample
size adequacy test
–0.563
.756
0.570
[0.128, 2.531]
1.398
.807
4.046
[0.823, 19.884]

0.287

.452

1.333

[0.549, 3.236]

–0.913
1.072

.410
.423

0.402
2.922

[0.180, 0.898]
[1.275, 6.698]

–0.941

.465

0.390

[0.156, 0.976]

0.113

.374

1.119

[0.538, 2.330]

–0.136

.564

0.873

[0.287, 2.656]

0.085

.423

1.088

[0.475, 2.495]

–0.257

.289

0.773

[0.438, 1.366]

Not included in model; removed in sample
size adequacy test

.549

3.200

[1.085, 9.441]

Note. Bold text denotes a statistically significant predictor. Sampling-design degrees of freedom were 200 for Scenario A and 1,529
for Scenario B. ADHD = attention-deficit hyperactivity disorder; BBW = black-box warning; CDS = computerized decision support;
CI = confidence interval; CVD = cardiovascular disease; df = degrees of freedom; LL = log likelihood; OR = odds ratio
(exponentiated β); PCP = primary care provider; SE = standard error; SUD = substance use disorder.

